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Abstract 
For centuries, chronic pain was denied as being real by physicians, mainly because there was no 
evidence of tissue damage. More recently, the lack of understanding of the neural mechanisms 
underlying chronic pain, particular that arising from nervous system damage, has hindered treatment 
development which has led to the over-prescription of opioids even though they are generally 
ineffective and have serious side-effects including addiction. Chronic pain of neuropathic origin is 
exceptionally difficult to treat, with this inability largely due to our lack of understanding of the 
underlying mechanisms.   
Whilst the brain circuitry responsible for the perception of acute painful stimuli have been mapped in 
both animal studies and studies using brain imaging in awake humans, the circuitry responsible for 
the initiation and maintenance of chronic pain remain unknown. Over the past few decades, many 
human brain imaging investigations have reported regional changes in brain anatomy and function in 
individuals with chronic pain. Surprisingly, these studies have shown that chronic neuropathic pain is 
not simply on-going acute pain, or at least chronic pain is not associated with constant activation of 
acute pain circuits. They have shown that neuropathic pain is associated with altered brain rhythms 
and in particular thalamocortical dysrhythmia. In addition, animal studies have shown that 
neuropathic pain is associated with altered non-neural function including microglial and astrocyte 
activation at the level of the primary afferent synapse. These results have led to theories that non-
neuronal cells may be crucial for the initiation and maintenance of chronic pain, particularly chronic 
neuropathic pain.  
It has been a long held view that astrocytes mainly play the role of neural support in the central 
nervous system, however, these cells are also capable of controlling neural function. In fact, astrocytes 
have access to every neural synapse and animal models of chronic neuropathic pain have shown that 
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targeting astrocytes can control pain intensity. As such, the focus of this thesis is to identify the role 
of astrocytes in modulating neural function in chronic neuropathic pain and to determine whether 
reducing astrocyte activity can reduce pain intensity.  
The first investigation (Chapter two) describes an experimental procedure whereby on-going patterns 
of neural activity were assessed in patients with orofacial neuropathic pain using resting state 
functional magnetic resonance imaging. Chronic orofacial neuropathic pain was associated with an 
increase in on-going infra-slow oscillatory activity (ISO, <0.1Hz) in regions of the ascending pain 
pathway, i.e. primary afferent synapse, the somatosensory thalamus and the somatosensory cortex. 
Interestingly, astrocytes display calcium wave oscillations at similar frequencies, and these calcium 
oscillations can lead to oscillatory release of neurotransmitters. Therefore, in this research series, it is 
speculated that the increase in ISOs in patients with chronic neuropathic pain are due to an increase 
in astrocyte activity causing the oscillatory release of neurotransmitters which modulate neural 
activity.   
While the results from Chapter two strongly suggest that the changes in neural activity in patients 
with chronic neuropathic pain are a result of increases in astrocyte activity, chapter three of this thesis, 
attempts to measure an anatomical marker of astrocyte activation. T2 relaxation time is dependent 
upon the tissue make-up and an increase in astrocyte activity will have an effect on T2 relaxation time. 
Indeed, post-mortem investigations have shown that an increase in astrocyte activity causes a 
decrease in T2 relaxation time. Using this indirect, non-invasive measure of astrocyte activation, there 
are decreases in T2 relaxation times, indicative of astrocyte activation in specific regions of the pain 
pathway in patients with chronic neuropathic pain, that is, in the primary afferent synapse and the 
primary somatosensory cortex.  
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Finally, if chronic neuropathic pain is caused, at least in part, by increases in astrocyte activity, then 
reducing astrocyte activation should reduce the intensity of pain. Chapter four describes an 
experimental procedure whereby patients with orofacial neuropathic pain were administered an 
astrocyte modulator, palmitoylethanolamide (PEA) and neural activity was compared before and after 
treatment. The results showed that PEA decreased pain intensity in over half of these patients (73%), 
and decreased ISO in regions of the primary afferent synapse and the somatosensory thalamus, that 
is, the same areas that showed increases in ISOs in these patients when compared to healthy controls 
in Chapter two. Chapter four indicates that decreases in ISOs due to PEA were correlated to decreases 
in pain intensity at the regions of primary afferent synapse. Importantly, a decrease in the circuitry 
strength between regions of the primary afferent synapse and the somatosensory thalamus is 
essential for the decrease in pain intensity.  
Overall, this thesis provides an increased understanding of the role of astrocytes in chronic 
neuropathic pain. More importantly, it describes the effect of an astrocyte modulator in neural activity 
and pain intensity in patients with chronic neuropathic pain. Unlike other drugs, PEA has no side-
effects and can be used to treat chronic neuropathic pain in the future.  
x 
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CHAPTER ONE 
INTRODUCTION 
1
Pain is a biologically important process in life as it serves to protect from potentially harmful 
surroundings and alerts to tissue damage. It is the most common reason individuals seek medical help, 
and the likelihood of experiencing pain increases with age for both males and females (Australian 
Bureau of statistics, 2011). Pain usually resolves with tissue healing or with the removal of harmful 
surroundings, however, there are cases where the pain continues for longer than 3 months with no 
biological advantage, and this is called chronic pain (Merskey et al., 1994).  
1. Chronic pain
Chronic pain affects 67% of the Australian population aged 15 years and over, and costs 34.3 billion 
dollars annually, which includes $11 billion in productivity and $7 billion in direct health care costs. 
(ABS, 2011). While acute pain resolves within three months of initial tissue damage whether tissue 
damage is has resolved or not, and serves to protect by eliciting a change in behaviour to avoid harm 
or is a by-product of the healing process, chronic pain lasts longer than three months, can be 
accompanied by tissue damage (such as cancer), appears to serve no biological function (Sessle, 1987), 
and is recognised as a disease state rather than a symptom of injury (IASP 1986). Although 
understanding the pathways and mechanisms involved in acute pain is interesting, the central 
representation of chronic pain appears to be very different (Farrell et al., 2005); Gustin et al., 2014; 
Youssef et al., 2014). For example, brain imaging studies have revealed that acute experimental pain 
evokes increases in blood flow to pain-specific brain regions (Farrell et al., 2005), chronic pain is 
actually associated with very little change in these areas and indeed in the thalamus it is associated 
with blood flow decreases (Gustin et al., 2014b; Youssef et al., 2014). Given these differences, chronic-
specific pain studies are needed to better understand the underlying mechanisms responsible for 
chronic pain which could lead to the development of better treatment and prevention regimens. 
2
Why the neural mechanism underlying acute and chronic pain are different is yet to be determined, it 
is interesting that psychological distress has been shown to be a secondary factor or predictor of 
chronic pain development (Andersson, 1999). Indeed, there are a number of psychological factors that 
can contribute to the development  of chronic pain, such as catastrophizing (Turner et al., 2002). Pain 
catastrophizing is an individual’s view that their pain state as worse than it actually is and greater 
catastrophizing levels are associated with greater intensity of on-going pain (Turner et al., 2002). 
Similarly, pain anxiety, i.e., the feeling of nervousness about pain and whether it will end, can affect 
the ability of an individual to cope with their chronic pain and this can alter the pain intensity and 
overall experience (McCracken and Gross, 1993). Depression, the feeling of severe dejection, has also 
been associated with the presence of chronic pain and it has been suggested that depression can be 
a predictor of chronic pain intensity and development, although there is debate whether depression 
predisposes an individual to chronic pain or that chronic pain predisposes and individual to developing 
depression (Fishbain et al., 1997). While addressing the psychological aspect of chronic pain can be 
important in regulating the pain intensity and its effect on social behaviour (Morley et al., 1999), 
eliminating these factors rarely eliminates or prevents the development of  chronic pain itself. 
One of the major unresolved issues surrounding chronic pain is exactly what causes acute pain to 
become chronic in some individuals and not in others. Whilst the precise mechanisms underlying the 
development and/or maintenance of chronic pain remains largely unknown, some investigations point 
to a peripheral starting point, whereby changes in the chemical composition in the periphery lead to 
chronic pain (Voscopoulos and Lema, 2010). Whilst this is likely the case in some individuals, 
peripheral changes are not necessary for the development of chronic pain as evidenced by the 
development of chronic pain following strokes encompassing the somatosensory pathways in the 
brainstem and thalamus (Klit et al., 2009a). Whilst changes in the periphery and central nervous 
system are likely involved in the development of chronic pain, our lack of understanding is limiting our 
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ability to develop effective chronic pain treatments. Current pharmacological treatments used to 
effectively treat acute pain are ineffective in treating patients suffering with chronic pain (Dworkin et 
al., 2003; Finnerup et al., 2005). This attributes to the long-term suffering and physical and economic 
disadvantages and hence, more research into the mechanisms underlying chronic pain is necessary.   
 
1.1 Chronic neuropathic pain 
Whilst there are various forms of chronic pain, the focus of this thesis is to explore the mechanisms 
underlying chronic neuropathic pain. Neuropathic pain arises due to damage or presumed damage to 
the nervous system such as that resulting from mechanical trauma, metabolic disease, neurotoxic 
chemicals, infection or tumour invasion (Campbell and Meyer, 2006). In the United Kingdom, 48% of 
the population suffer from a chronic pain condition and 8% of those are neuropathic in nature 
(Torrance et al., 2006). A review of surveys conducted around the world found that 1 in 14 adults has 
neuropathic pain and that chronic pain is more common in women and the elderly (Andrew et al., 
2014). Considering that chronic neuropathic pain impedes daily activities and reduces the quality of 
life, there is a calling for a better understanding and treatment of the condition (Andrew et al., 2014; 
Barrett et al., 2007; Tölle et al.).  
 
1.2 Trigeminal neuropathic pain 
1.2.1 Background and presentation 
Whilst chronic neuropathic pain can occur as a consequence of a brain stroke, diabetic neuropathy, or 
nerve impingement, to name a few, the focus of this thesis is on neuropathic pain localized to the 
orofacial region. The reason for this is that orofacial afferents terminate in the caudal brainstem, an 
area whose structure and function can be explored using modern human brain imaging techniques. 
Thus a considerable advantage of using this population of neuropathic pain subjects is that it is 
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possible to explore changes along the entire extent of the ascending pain pathway from the primary 
afferent synapse to the cerebral cortex.  
More specifically, this thesis explores individuals with post-traumatic trigeminal neuropathy which is 
characterized by mostly constant, unilateral face pain within one or more divisions of the trigeminal 
nerve (Burchiel, 1993). It can be caused by physical insult from operative procedures such as root canal 
treatment, traumatic accidents or disease. Patients usually present with sharp or dull continuous pain, 
often fluctuating throughout the day with shooting pain superimposed (Burchiel, 1993; Gustin et al., 
2011). The pain is often associated with allodynia (pain to a normally non-noxious stimulus), 
hyperalgesia (an increased response to a noxious stimulus) and sensory loss (Nurmikko and Eldridge, 
2001). 
1.2.2 Incidence and prognosis 
Unlike trigeminal neuralgia, which often results from nerve compression and is often episodic in 
nature (Love and Coakham, 2001), post-traumatic trigeminal neuropathy cannot be diagnosed using 
magnetic resonance imaging or other brain imaging techniques. Trigeminal neuropathy has been 
reported to develop in up to approximately 12% of patients that undergo  standard root canal 
treatment (Polycarpou et al., 2005). Furthermore, since it is usually the result of nerve damage from 
such endodontic procedures, dentists recommend a clean-up of the wound, antibiotics for infections 
and possibly performing the procedure again (Yoldas et al.). Essentially, when this does not alleviate 
the pain and the pain lasts for over 3 months, it is diagnosed as chronic trigeminal neuropathic pain 
(Burchiel, 1993; Merskey, 1986).  
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1.2.3 Treatments 
Similar to general chronic pain conditions, much of the treatment for trigeminal neuropathic pain has 
been ineffective due to our limited understanding of the mechanisms underlying the condition. The 
most common treatments prescribed to neuropathic pain patients, including trigeminal neuropathy, 
are, but not limited to, tricyclic antidepressants, carbamazepine, gabapentin and tramadol (Sindrup 
and Jensen, 1999). These treatments, may reduce the intensity of pain in some patients but they 
usually prove ineffective and have grave short and long term side effects (Bennett and Simpson, 2004; 
Killian and Fromm, 1968).  
1.3 Models of chronic neuropathic pain 
1.3.1 Central sensitization 
Over the past few decades, a number of animal models have been developed so that the mechanism 
response for neuropathic pain can be investigated in experimental animals. Indeed, investigations 
exploring central sensitization began from the observation that allodynic responses could not be 
explained by changes in peripheral nociceptor function in animal models of pain. As early as the 1960s, 
Iggo (Brown and Iggo, 1967; Iggo, 1960) and Perl (Bessou and Perl, 1969; Burgess and Perl, 1967; Perl, 
1968) reported that sensory neurons which respond only to noxious stimuli  (Woolf and Ma, 2007) 
become sensitized after exposure to inflammatory mediators (injury), i.e., their threshold to pain and 
heat stimuli was reduced (Bishop et al., 2010; Campbell et al., 1988; Kocher et al., 1987). They 
suggested that whilst peripheral sensitization accounted for pain hypersensitivity following injury, it 
could not account for dynamic allodynia (pain due to tangential movement across skin), temporal 
summation of pain or secondary allodynia. This led to studies to determine whether neural receptor 
sensitization can occur in the central nervous system as well. In 1965, Mendall and Wall found that a 
repeated low frequency stimulation of a nerve led to a progressive increase in action potentials in the 
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dorsal horn (Mendell and Wall, 1965), and this effect was found to last for multiple hours (Cook et al., 
1986). This effect was termed central sensitization. 
It is now well-established that in neuropathic pain conditions, central sensitization occurs. For 
example, patients with carpal tunnel syndrome in one wrist showed hypersensitivity to cold and heat 
in the non-affected wrist (De La Llave-Rincón et al., 2009; Fernandez-de-las-Penas et al., 2009). 
Furthermore, in a group of patients with chronic neuropathic pain, the increase in pain intensity was 
concurrent with an increase in pain sensations from an innocuous stimulus (Koltzenburg et al., 1994). 
This data suggests that central sensitization is evident in some chronic neuropathic pain conditions 
and may be important in the development and/or maintenance of pain following nerve injury.  
1.3.2 Pain matrix 
Numerous investigations have reported functional and anatomical changes in numerous brain regions 
in multiple chronic pain conditions. For the main part, these changes occur in areas that have been 
shown to be activated during acute painful stimuli in normally pain-free individuals, a network called 
the pain matrix. It has been hypothetised that the “flow and integration of information” in this 
network results in the emergence of pain (Tracey, 2005). This term was adapted from neuromatrix 
which was proposed by Ronald Melzack, who ironically, proposed this term due to their inability to 
identify a group of brain regions that were devoted to the processing of pain (Melzack, 1989).  
The pain matrix poses a problem when it is viewed as a solid piece of evidence, that is, the areas that 
make up the pain matrix are specific to pain. Yet, the majority of the regions that make up the pain 
matrix are also involved in other types of processing such as emotional or motivational processing 
(Tracey and Johns, 2010). Electrophysiological studies have identified nociceptive specific neurons in 
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regions of the pain matrix but also sparsely distributed throughout the brain (Kenshalo Jr and Isensee, 
1983; Whitsel et al., 1969; Yamamura et al., 1996).  Nonetheless, the pain matrix can be useful in 
imaging studies to identify regions that may be involved in pain processing, and include such areas as 
the primary somatosensory cortex, thalamus and regions of the cortex encompassing the insula, 
cingulate and prefrontal cortices (Apkarian et al., 2005; Jones et al., 2003; Lorenz and Casey, 2005; 
Schweinhardt and Bushnell, 2010). 
A number of investigations throughout the years indicate that painful stimuli activates the cortical 
regions that make up the pain matrix such as the somatosensory cortices, the insular cortex and the 
anterior cingulate cortex (Bushnell and Apkarian, 2006; Garcia-Larrea et al., 2003). Furthermore, there 
are strong correlations between the magnitude of the pain matrix response and the intensity of pain 
(Coghill et al., 1999; Derbyshire et al., 1997; Iannetti et al., 2005; Tölle et al., 1999). Therefore, the 
pain matrix is widely used as a loose guide for the areas that are likely involved in the processing of 
pain, with the understanding that these regions may also be involved in other processes. 
1.3.3 Thalamocortical dysrhythmia 
Two regions of the brain, the thalamus and the cortex,  are separately involved in processing pain and 
are in a constant and synchronous loop (Jones, 2001). Recent investigations have demonstrated that 
whole brain activity changes arise from changes of the connections between these two regions and 
include changes to overall brain rhythm. Indeed changes in this thalamo-cortical circuitry can alter 
processing in recurrent circuits resulting in thalamocortical dysrhythmia (Pinault, 2004). There is now 
considerable evidence that chronic neuropathic pain is characterized by altered thalamocortical 
rhythm which likely arises from altered function in the thalamus or its cortical targets (Sarnthein et 
al., 2006; Walton and Llinas, 2010). That is, it is likely that the thalamus can modulate higher cortical 
regions by setting patterns of activity through ongoing thalamocortical loop.  It has been proposed 
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that this altered brain activity pattern may underlie the constant perception of pain, although how 
this occurs is unknown. 
A number of recent human electrophysiological investigations are consistent with this idea that 
neuropathic pain is associated with altered thalamocortical processing. For example, one study 
compared baseline brain activity in patients with neuropathic pain and healthy controls. Within 
specific frequency ranges, there was an increase in power of brain activity in the insula, anterior 
cingulate, prefrontal and somatosensory cortices. The authors proposed that these increases in power 
were a result of thalamocortical dysrhythmia, that is, changes in the firing activity of one or more 
regions within thalamocortical loop (Stern et al., 2006). More recently, an investigation reported 
altered thalamocortical rhythm, from electrophysiological recordings in patients with type 1 complex 
regional pain syndrome. This condition was associated with increased spectral power in specific 
frequency ranges, which were also localized in brain regions including the somatosensory cortex 
(Walton and Llinas, 2010). This evidence suggests that changes to the activity to one or more of regions 
of the thalamocortical circuitry may lead to thalamocortical dysrhythmia which is associated with 
chronic neuropathic pain. 
1.4 Nervous system 
1.4.1 Pain Pathways 
Whilst there are reported changes in thalamo-cortical loops in individual with chronic pain, what about 
other regions of the “pain matrix” that also respond to acute painful stimuli? As mentioned above, the 
pathways that are responsible for acute pain perception have been explored extensively. A number 
of human and animal investigations have revealed that the sensory and discriminative components of 
pain originating from the body travel through the spinothalamic tract, and the sensory and 
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discriminative components of pain from the face travel through the trigeminothalamic tract  (Nash et 
al., 2010; Simone et al., 1991). Neurons within these ascending tracts receive inputs from primary 
afferent neurons in the periphery and they themselves project to a number of brainstem and higher 
brain areas. Experimental models have established that the spinothalamic tract neurons project to the 
ventroposterior lateral (VPL) nuclei of the contralateral somatosensory thalamus and 
trigeminothalamic tract neurons project to the ventroposterior medial (VPM) nuclei of the 
contralateral somatosensory thalamus (Graziano and Jones, 2004).  
While these ascending pathways were mapped using experimental animal models, recent 
advancement in technology, such as functional magnetic resonance imaging and positron emission 
tomography, have allowed for the mapping of these pathways in awake humans. The following section 
will briefly outline what is currently known from experimental animal and human imaging studies with 
respect to changes within the ascending pain pathway associated with the presence of chronic 
neuropathic pain.  
1.5 Central Nervous System 
1.5.1 Dorsal horn 
The centre of the spinal cord is composed of gray matter (neuronal cell bodies and axon terminals) 
and the outer region comprises of white matter (axons). The gray matter has a dorsal section 
(posterior), in which sensory information, particularly nociception, first terminates as it enters the 
central nervous system from the periphery  (Brown, 1982) (Figure 1.5.1).  
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Figure 1.5.1: Illustration of the spinal cord showing the inner gray matter and the outer white matter. 
The dorsal horn is the posterior section of the gray matter. Adapted from Todd (Todd, 2010).   
Damage to the peripheral nerves can result in significant and pronounced changes in the dorsal horn 
(McLachlan et al., 1993). For example, animal models of neuropathic pain which involve injury to a 
peripheral nerve, are associated with neural death at the dorsal horn (Scholz et al., 2005; Sugimoto et 
al., 1990; Whiteside and Munglani, 2001). Spared nerve injury, chronic constriction injury and spinal 
nerve ligation models of neuropathic pain are all associated with neural loss in the dorsal horn. 
Furthermore, these neural changes are associated with the development of allodynia and hyperalgesia 
which were prevented when this neural loss was prevented by reducing caspase activity (Scholz et al., 
2005) or treatment with a NMDA receptor antagonist, which reduced the extent of cell death 
(Whiteside and Munglani, 2001).  
In addition to neural loss in the dorsal horn, animal studies have reported evidence of chemical 
changes associated with the development of neuropathic pain. For example, following a peripheral 
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nerve injury there is an increase in calcitonin gene-related peptide in the dorsal horn, which has an 
excitatory effect on postsynaptic neurons (Miki et al., 1997). Furthermore, spared peripheral nerve 
injury and chronic constriction injury models of neuropathic pain are associated with decreases in 
presynaptic GABA release in the dorsal horn and a decrease in GABA synthesizing enzymes (Ibuki et 
al., 1996; Meisner et al., 2010; Moore et al., 2002). In the chronic constriction injury model of 
neuropathic pain, significant increases in Ca2+ in the dorsal horn occur and these changes are 
associated with the development of thermal and mechanical hyperalgesia (Kawamata and Omote, 
1996). In addition to these chemical changes, other animal neuropathic pain models have reported 
astrocytic changes in the dorsal horn; these changes will be discussed in detail in a later section. 
1.5.1.1 Spinal trigeminal nucleus 
Whilst nociceptor afferents innervating the body enter the spinal cord and synapse in the dorsal horn, 
those innervating the head and oral cavity enter the central nervous system via the trigeminal nerve. 
The trigeminal nerve enters the brainstem at the level of the pons and fibres carrying nociceptive 
information descend in the dorsolateral medulla to synapse onto the spinal trigeminal nucleus on the 
ipsilateral side (Paxinos et al., 2012). Second order neurons then decussate in the medulla and travel 
to the thalamus, terminating in the ventral posterior nucleus. The trigeminothalamic projection 
involved in pain processing, from the subnucleus caudalis of the spinal trigeminal nucleus is well 
understood. Specifically, neurons in the marginal layer (lamina I) of the subnucelus caudalis project to 
the ventral posteromedial thalamus and the posterior thalamic nucleus (Shigenaga et al., 1979). 
Although the sub nuclei interpolaris and oralis are also involved in processing orofacial pain, their 
ascending thalamic projects remain less clear (Ralston, 2005; Sessle, 2000) (Figure 1.5.1.1) 
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.Figure 1.5.1.1: Trigeminothalamic pathway for nociception arising from the peripheral trigeminal 
nerve in the face. Noxious afferents synapse at the spinal nucleus of the trigeminal complex, where 
fibres ascend the brain stem to synapse at the ventroposterior medial nucleus of the thalamus, in which 
they continue to the primary somatosensory cortex. Adapted from Purves (Purves, 2004) .  
Investigations have revealed that the spinal trigeminal nucleus is divided into three sub nuclei; the 
caudalis, interpolaris and the oralis (Olszewski, 1950; Sessle, 2000). The sub nuclei caudalis is the most 
caudal of the three and lies within the closed medulla. It is generally considered to be the primary 
relay for orofacial nociceptive information originating in cutaneous and mucosal tissues (Sessle, 2000).  
Directly rostral to the sub nuclei caudalis lies the sub nuclei interpolaris which also receives noxious 
information originating from the orofacial region and in particular from jaw muscles. Finally, the spinal 
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trigeminal sub nucleus oralis lies in the rostral medulla (Dessem et al., 2007). While it is believed that 
this sub nuclei is involved in the processing of the noxious stimuli from the oral cavity, it has been 
shown that its lesion does not resolve oral cavity pain perception (Duale et al., 1996; Luccarini et al., 
1998). However, it is suggested that noxious stimuli to the face are processed by both the spinal 
trigeminal sub nucleus oralis and the sub nucleus interpolaris (Nash et al., 2009).  
As the spinal trigeminal nucleus plays a key role in the processing of trigeminal neuropathic pain, 
this series of investigations will analyse changes in its neural activity in patients compared to 
controls, its anatomical changes compared to controls and whether these changes can be reversed 
with therapy. The spinal trigeminal nucleus shows increases in infra-slow oscillatory activity 
compared to healthy controls (Chapter 2), changes in anatomy (Chapter 3) and a reduction in infra-
slow oscillatory activity after PEA (Chapter 4). 
1.5.2 Thalamus 
Second order neurons originating in SpV project to the ventral posterior (VP) region of the thalamus 
amongst other thalamic and brainstem targets. The thalamus plays an important role in the processing 
of chronic neuropathic pain, even in the absence of peripheral nerve injury. This is evidenced by the 
results from brain stroke studies which have revealed that between 11-55% of patients develop 
neuropathic pain following a stroke that encompasses the thalamus (Klit et al., 2009b). Since the first 
description of central post-stroke pain (CPSP) in 1906, research suggests that the development of pain 
is contingent on the stroke damaging the ascending somatosensory pathway from the medulla to the 
thalamus or cortex (Leijon et al., 1989). Whilst CPSP can occur after a cerebrovascular lesion at any 
level of the ascending somatosensory pathway, lesions in the thalamus result in a relatively high 
occurrence of PSP (17%) (Klit et al., 2009b). Recently, a clinical report described a series of patients 
with unilateral CPSP following lesions to the ventral posterior lateral/medial thalamus contralateral to 
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their painful side and with no other brain lesions. The authors suggested that for the onset of CPSP, 
lesions affecting normal synaptic connections to/from the somatosensory thalamus are crucial (Kim 
et al., 2007). Interestingly, these patients showed clinical characteristics of this CPSP in the thalamus 
that closely resembled those of other central and peripheral neuropathies (Henry et al., 2008; Klit et 
al., 2009b).  
It is evident that the thalamus plays an important role in the processing of neuropathic pain, and so 
understanding what role the thalamus plays in generating and/or maintaining pain following nerve 
injury is important. Numerous human brain imaging investigations have revealed that the thalamus 
displays altered anatomy in individuals with neuropathic pain. For example, An investigation by 
Apkarian and colleagues found decreases in gray matter volume in the thalamus in patients with lower 
back pain compared to healthy controls (Apkarian et al., 2004). Similarly, in individuals with chronic 
orofacial neuropathic pain, gray matter volume has shown to be significantly reduced in the ventral 
posterior thalamus as well as the insula, putamen, somatosensory cortex and the nucleus accumbens 
(Gustin et al., 2011; Henderson et al., 2013). Furthermore, chronic pain that occurs following spinal 
cord injury is associated with significant reductions in mean diffusivity, a marker of anatomical change 
derived from changes in the motion of free water, in the ventral posterior thalamus (Gustin et al., 
2014b). 
As well as structural changes, there are also reports of significant biochemical changes in the thalamus 
in individuals with chronic neuropathic pain. One investigation found that the concentration of N-
acetyl in the thalamus was lower in neuropathic pain patients compared to healthy controls (Pattany 
et al., 2002). Moreover, the thalamus also had a significant reduction in N-acetyl/creatine ratio in 
patients with neuropathic pain (Gustin et al., 2011). A reduction in the N-acetyl/creatine ratio is 
indicative of neural viability (Gustin et al., 2011) and therefore, it appears that the thalamic anatomical 
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changes characterized by altered grey matter volume and mean diffusivity may reflect changes in 
neural functioning, although changes in other types of cells cannot be ignored. In addition to 
anatomical and biochemical changes, there is evidence of blood flow changes in the thalamus. One 
study showed decreased blood flow in the thalamus in patients with central pain compared to healthy 
controls (Fukui et al., 2002). Similarly, patients with complex regional pain syndrome (sometimes 
categorized as chronic neuropathic pain) also have decreased blood flow to the thalamus when 
compared to healthy controls (Hsu and Chang, 2013).  Indeed, it has been suggested that the most 
common resting activity change observed in individuals with various forms of neuropathic pain is that 
of a decrease in the thalamus (Gustin et al., 2014a; Yen and Lu, 2013). 
A number of electrophysiological recordings in individuals with neuropathic pain have revealed that 
the properties of neurons within the thalamus and thalamic circuitry are altered. Intraoperative 
studies suggest somatotopic rearrangement, abnormal responsiveness to peripheral stimuli and 
abnormal spontaneous discharge patterns in thalamic neurons of patients with CPSP (Lenz et al., 1998; 
Lenz et al., 1989). These zones have shown changes in neural activity and stimulation causes pain 
sensations at higher frequency than normally expected (Lenz et al., 1998). Furthermore, lesions to 
these regions in the medial thalamus have been shown to successfully relieve CPSP (Jeanmonod et al., 
1993).  
A number of non-invasive measures in neuropathic pain suggest altered neural activity in the thalamus 
and in regions of the cortex in which it projects to. Positron emission tomography and functional 
magnetic resonance imaging studies show that allodynic pain increases activity in the thalamus 
(Peyron et al., 1998; Schweinhardt et al., 2006). Whereas, spontaneous pain (at rest) decreases neural 
activity (Hsieh et al., 1995). Moreover, patients with neuropathic pain revealed thalamic spontaneous 
activity compared to healthy controls (Sarnthein et al., 2006) and recently altered thalamocortical 
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rhythm is evident in individuals with chronic orofacial neuropathic pain (Di Pietro et al, 2018). These 
results indicate that, in patients with chronic neuropathic pain, there is a possible change in the 
pattern of firing in the neurons of the thalamus.  
Further to human investigations, experimental animal studies have also demonstrated thalamic 
activity changes in neuropathic pain models. The spinal cord injury model of neuropathic pain is 
associated with changes in burst firing within the thalamus in rats that develop neuropathic pain 
compared to pain-free controls (Hains et al., 2006). Similarly, Gerke and colleagues reported increased 
burst and oscillatory firing in the thalamus associated with the development of pain following spinal 
cord injury (Gerke et al., 2003). There is also evidence of functional changes in neurons within the 
thalamus following lesions within the spinal cord causing neuropathic pain. The investigation showed 
increases in spontaneous activity and responses that are induced by cutaneous stimuli, and larger 
receptive field sizes than neurons in the thalamus of primates with intact spinal cords (Weng et al., 
2000). Based on this evidence, neuropathic pain is associated with altered firing in both humans and 
experimental animal models, which may be transferred to and from other regions of the pain pathway. 
Investigations have demonstrated that chronic neuropathic pain is associated with anatomical and 
biochemical changes in the thalamus as well as changes in the pattern of activity. This series of 
investigations will analyse changes in the neural activity and anatomical changes in the thalamus 
in patients with orofacial neuropathic pain, compared to controls, and analyse whether these 
changes can be reversed with treatment. 
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1.5.2.1 Thalamic reticular nucleus 
It is well known that an area of the thalamus, the thalamic reticular nucleus (TRN), regulates all sensory 
information passing through the thalamus and so it is likely that changes in thalamic activity associated 
with neuropathic pain are likely regulated by this thalamic region. The thalamic reticular nucleus (TRN) 
is a layer of cells that insheathes much of the rostral and lateral surfaces of the dorsal thalamus and is 
bordered laterally by the internal capsule (Jones, 1975). Essentially, all information travelling between 
the thalamus and the cerebral cortex is modulated by the TRN, and evidence from over four decades 
ago showed that the cerebral cortex (Carman et al., 1964; Jones, 1975) and thalamic relay nuclei 
(Jones, 1975) provide extensive input to the TRN, and the main output of the TRN is to thalamic relay 
nuclei. The study showed that fibres from a specific nucleus within the thalamus and intended for a 
particular area of the cortex, are either associated with a particular set of axons that terminate in a 
specified region of the TRN or give rise to collaterals (Jones, 1975). Furthermore, corticothalamic fibres 
originating from a specific area of the cerebral cortex passing to a specific thalamic nucleus will also 
send collaterals to the same portion of the TRN which receives axons from that specific thalamic 
nucleus. The TRN can be divided into sectors that process specific sensory modalities as there is very 
little communication between the somatosensory TRN and TRN regions not involved in 
somatosensation (Beck et al., 1996; Crabtree, 1992; Pinault, 2004). Figure 1.5.2.1 illustrates this 
circuitry.   
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Figure 1.5.2.1: General organization of the three principal projection neurons. Note that the ascending 
afferents (green) synapse on ventroposterior (VP) thalamic relay cells (blue), where VP axons pass 
through the thalamic reticular nucleus (TRN) to synapse in the primary somatosensory cortex. 
Corticothalamic neurons (orange) are in layer 6 of the cortex, where they send feedback to both TRN 
inhibitory neurons (red) and VP neurons. Copied from Guillery and colleagues (Guillery et al., 1998).  
The TRN is considered an inhibitory cell of the thalamus as it is the main GABA-producing nucleus 
(Spreafico et al., 1994), and any change to the level of GABA in the thalamus is likely a measure of the 
change in activity of neurons in the TRN. Indeed, magnetic resonance imaging based spectroscopy 
analysis of GABA levels in the thalamus is likely reflective of TRN activity. As such, Henderson and 
colleagues found decreased TRN activity in patients with chronic neuropathic pain which was 
attributed to a decrease in GABA levels in the thalamus. Furthermore, the study also measured resting 
cerebral blood flow, an indirect measure of neural activity, and found that these patients showed a 
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decrease in neural activity in the TRN (Henderson et al., 2013). These data suggest that the changes 
in the TRN activity are associated with chronic neuropathic pain through their GABAergic action on 
the somatosensory thalamus. Through this GABAergic action, the TRN is capable of modulating the 
thalamocortical circuitry. This process alters thalamocortical dysrhythmia which is associated with 
chronic neuropathic pain. The phenomenon, thalamocortical dysrhythmia, was discussed earlier.  
The thalamus shows changes in pattern of activity in patients compared to healthy controls (Chapter 
2) and a reversal with treatment (Chapter 4).
1.5.3 Primary somatosensory cortex 
Whilst the role of the dorsal horn/SpV and thalamus have begun to be investigated in greater detail 
in recent years, there is a also a considerable number of studies that have investigated the role of the 
primary somatosensory cortex in pain processing. Third order neurons within the thalamus project to 
the primary somatosensory cortex which is located in the postcentral gyrus of the parietal lobe. This 
region is composed of Brodmann areas 1, 2, 3a and 3b (Garey, 2006; Nelson and Chen, 2008) and  
animal and human investigations have revealed that cutaneous input is predominantly received by 
Brodmann areas 1 and 3b (Nelson and Chen, 2008; Sur et al., 1980). In the early 20th century, a group 
of investigators stimulated various parts of the somatosensory cortex and found that according to the 
region of stimulation, sensations were experienced in particular regions on the contralateral side of 
the body (Penfield and Rasmussen, 1950). Since then, the somatosensory cortex has become 
extensively mapped with the leg represented medially in the paracentral lobule and the hand and face 
represented more laterally. This somatotopic map is often referred to as the sensory homunculus.  
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 1.5.3.1 Role in neuropathic pain 
Although the function of the somatosensory cortex has been studied extensively, its role in the 
processing of pain remains unclear. While it is not always activated in experimental pain studies 
(Bushnell et al., 1999 199), lesions within the somatosensory cortex increased pain intensity, with only 
some reporting temporary loss of painful sensations (Head and Holmes, 1911; Holmes, 1927). This has 
led to the idea that the somatosensory cortex may not be involved in coding painful sensations but it 
is more likely to code tactile sensibility and localization (Holmes, 1927).  Moreover, a study in 1937 
demonstrated that deep brain stimulations in the primary somatosensory cortex caused a ‘pins and 
needles’ sensation rather than a painful sensation (Penfield and Boldrey, 1937). The role of the 
somatosensory cortex in the processing of pain is also supported in a rat model where painful 
sensations were recorded after blocking the primary somatosensory cortex(Uhelski et al., 2012). 
Whilst these reports do not rule out the prospect that the primary somatosensory cortex is involved 
in pain processing; indeed, it is generally accepted that it is responsible for the sensory qualities of 
pain, they do raise the prospect that other brain regions also code these specific aspects of the pain 
experience. 
 
Whilst it remains unclear what role the primary somatosensory cortex plays in the coding of chronic 
neuropathic pain, there is emerging evidence that the primary somatosensory cortex displays 
functional reorganization in individuals with chronic pain states (Elbert et al., 1994; Pleger et al., 2004; 
Wrigley et al., 2009). For example, one study measured cortical reorganisation using functional 
magnetic resonance imaging. An innocuous stimulus was applied to the lip, thumb and little finger to 
activate their respective cortical representations, and distances from these regions to an anatomical 
marker were calculated as a measure of cortical organization. All three regions showed changes in 
cortical organization compared to healthy controls, and in the little finger, the change in the distance 
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was positively correlated to pain intensity (Wrigley et al., 2009). By using a similar technique to 
determine reorganisation of the primary somatosensory cortex in patients with complex regional pain 
syndrome, the ulnar nerve and median nerve were stimulated and their cortical representations were 
mapped. The findings indicate that in these patients, the representation of the arm is smaller than 
that of healthy controls (Pleger et al., 2004). Furthermore, hand and arm amputees with phantom 
limb sensations have reorganization of the primary somatosensory cortex in regions that represented 
the amputated hand/arm (Elbert et al., 1994). Interestingly, some studies show that these cortical 
reorganisations can be reversed (Maihofner et al., 2004; Pleger et al., 2005).  
The primary somatosensory cortex shows changes in neural activity in patients compared to healthy 
controls in Chapter 2.  
1.6 Astrocytes in neuropathic pain 
1.6.1 Anatomy and function of astrocytes 
Whilst above is a description of studies that have focussed primarily on the impulse-conducting cells 
of the brain, recent evidence suggests that non-neural cells also play a role in regulating neural activity 
and maybe a critical role in the development and maintenance of chronic pain. Traditionally, 
astrocytes were thought to almost exclusively play a role in supporting neural function; however, more 
recently, astrocytes have been shown to have a more significant role in the central nervous system 
including the modulation of neural activity (Pekny and Nilsson, 2005; Sofroniew, 2009b). There are 
two types of astrocytes; astrocytes in gray matter called protoplasmic and astrocytes in white matter 
called fibrous (Miller and Raff, 1984). Both types of astrocytes make direct contact with blood vessels, 
form gap junctions with neighbouring astrocytes, and protoplasmic astrocytic processes contact 
Nodes of Ranvier and envelop synapses (Butt et al., 1994; Hildebrand, 1971a, b). These contacts 
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suggest that astrocytes may also play a role in modulating neural activity. Indeed, studies indicate that 
astrocytes can produce and release mediators that control blood vessel diameter and flow in a 
coordinated matter (Attwell et al., 2010; Zonta et al., 2002). Therefore, an increase in blood flow due 
to an increase in neural activity (and vice versa) is largely dependent on astrocyte activity. 
Furthermore, astrocytes envelop synapses and are responsible for maintaining the fluid (Attwell et al., 
2010; Zonta et al., 2002), ion (O'connor and Kimelberg, 1993; Walz, 1989), pH (Chesler, 2005) and 
transmitter (Anderson and Swanson, 2000) homeostasis through their foot processes, which are rich 
in aquaporin and potassium transporters (Newman, 1986; Papadopoulos et al., 2004). These 
processes also express high levels of transporters for neurotransmitters such as glutamate, GABA and 
glycine (Auld and Robitaille, 2003; Schousboe et al., 2004). Astrocytes clear neurotransmitters from 
the neural synapse and release them in response to neural activity, which in turn regulates neural 
activity. 
Although astrocytes express sodium and potassium channels and exhibit an inward current, they do 
not ‘fire’ like neurons, rather, they exhibit a regulated increase in intracellular calcium which can occur 
in waves (Pasti et al., 1997). Such astrocytic intracellular calcium waves have functional significance in 
astrocyte-astrocyte and astrocyte-neuron communication (Pasti et al., 1997). The increase in calcium 
can occur from internal stores and are triggered by a number of neurotransmitters  (Dani et al., 1992). 
The calcium waves can themselves elicit the release of neurotransmitters from astrocytes (e.g. 
glutamate) into the extracellular space and these calcium waves and the subsequent release of 
gliotransmitters can propagate to neighbouring astrocytes through gap junctions (Kozlov et al., 2006; 
Tian et al., 2005).  
In mild to moderate astrogliosis (increase in astrocyte activity – usually a result of nerve damage), 
there is an increase in cell body and process size, namely hypertrophy. However, this occurs within 
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the domain of the individual astrocyte, as, at this stage, astrocytes do not overlap, rather, they tile the 
entire central nervous system (Sofroniew, 2009a; Sofroniew and Vinters, 2010b). There is also an 
upregulation of glial fibrillary acidic protein (GFAP), which can give the false impression of proliferation 
(Sofroniew and Vinters, 2010b). Mild to moderate astrogliosis can be associated with acute single 
events, such as nerve damage, and has potential to resolve.  
1.6.2 Role of astrocytes in neuropathic pain 
Following peripheral nerve injury, such as nerve damage due to root canal treatment, astrocytes can 
become chronically activated (astrogliosis), a process that is currently not entirely understood. 
Nonetheless, in a number of investigations, astrocytes play an important role in the initiation and/or 
maintenance of neuropathic pain. For example, GFAP (a marker of astrocyte activation) knockout mice 
showed slower wound healing than wild type, illustrating the importance of astrocytes in the healing 
process following injury (Pekny et al., 1999). Furthermore, following spinal nerve ligation in rats, there 
is an immediate activation of both microglia and astrocytes in the dorsal horn. However, on day 21, 
there is predominant activation of astrocytes, which is associated with persistent allodynia. 
Interestingly, blocking astrocyte activity in the dorsal horn reverses allodynia (Zhuang et al., 2005; 
Zhuang et al., 2006). Furthermore, hyperactive astrocytes in the dorsal horn increase allodynia 
responses in rats and blocking this astrocyte activation reverses the allodynic response (Miyoshi et al., 
2008b). In a trigeminal neuropathic pain model, there is an increase in astrocyte activation in the spinal 
trigeminal nucleus which is associated with hyperalgesia. Inhibition of astrocyte activity prevented 
hyperalgesia and inflammation in orofacial region of the face (Guo et al., 2007).  
Behavioural hyperalgesia correlates with astrocyte activation in a neuropathic pain model. Colburn et 
al. (1999) measured the effects of different types of nerve injuries on astrocyte activity in the spinal 
cord. Glial activity and mechanical allodynia were associated with spinal nerve or dorsal root injury. 
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Interestingly, injury to the dorsal root almost exclusively increases astrocyte activity, i.e. no increases 
in microglial activity (Colburn et al., 1999). Moreover, after nerve injury, astrocyte activity persisted 
longer than microglial activity. Astrocyte activity can last more than 150 days after nerve injury and 
although in most cases astrocyte activation follows microglial reaction (Miyoshi et al., 2008a), one 
investigation showed that bone cancer increased astrocyte activation in the absence of microglia (Hald 
et al., 2009).  
Nerve damage also increases gap junctions between astrocytes which are important for astrocyte-
astrocyte communication and the propagation of calcium waves. Following chronic constriction injury 
of the infra-orbital nerve, there was an increase in gap junction protein (connexion 43) in the 
trigeminal ganglion cells (Ohara et al., 2008). Moreover, inflammation in the masseter muscle 
increased astrocytic connexion 43 in the spinal trigeminal nucleus in the rat model (Guo et al., 2007). 
These data suggest that astrocytes play an important role in neuropathic pain through processes such 
as gap junctions and inflammation.  
Astrocytes are increasingly being explored for their role in the maintenance of neuropathic pain. In 
Chapter 2, astrocytes are speculated to be the key player in the changes in neural activity in the 
ascending pain pathway.  
1.6.2.1 Targeting astrocytes for treatment of neuropathic pain 
It is becoming clear that astrocytes play a crucial role in neuropathic pain and therefore modulating 
astrocyte activity may assist in reducing or preventing neuropathic pain. Indeed, one supplement that 
has been shown to modulate astrocyte activity, namely, palmitolyethanolamide (PEA), has been used 
extensively in Europe to reduce neuropathic pain in multiple conditions (Hesselink and Hekker, 2012). 
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PEA is a naturally occurring fatty acid amide that can be found in foods such as meat, eggs, soybeans 
and peanuts. It belongs to the family of N-acetylethanolamines, which act on cannabinoid receptors 
and interact with inflammatory cells in the nervous system. It has a neuroprotective, anti-
inflammatory, anti-nociceptive and anti-convulsant properties (Calignano et al., 1998; Lambert et al., 
2001; Lo Verme et al., 2005; Skaper et al., 1996). Further, under pathological conditions, such as brain 
ischemia (Franklin et al., 2003) and neuroinflammation (Darmani et al., 2005), the levels of PEA 
significantly increase, which suggests neuroprotective activity. However, in chronic conditions, 
endogenous PEA levels decrease (Petrosino et al., 2007), suggesting that there is an interaction with 
the chronicity of a disease state and endogenous PEA levels. 
Whilst the precise mechanism remains unclear, it is thought that the main target of PEA is the 
peroxisome proliferator-activated receptor alpha (PPAR-α) (D'Agostino et al., 2009; D'Agostino et al., 
2007; Lo Verme et al., 2005; LoVerme et al., 2006; Raso et al., 2011). PPAR-α is an isotope of the PPARs 
that can affect the transcription of a number of genes (Brown and Plutzky, 2007; Duval et al., 2007) 
and is expressed by astrocytes. These astrocytes play a role in the antinociceptive effects of PEA 
through their PPAR-α pathway (Raso et al., 2011). It is not yet well understood how PEA functions in 
neuropathic pain, however a number of clinical trials have proven its ability to reduce the pain 
intensity in a number of neuropathic conditions such as sciatic pain, diabetic neuropathic pain, lower 
back pain and post-stroke pain (M Keppel Hesselink, 2012). There has also been no documentation of 
any side effects to the drugs or any drug-drug interactions.  
The effects on PEA on neural activity is explored in Chapter 4, where PEA was administered to 
patients with neuropathic pain and ISOs were measured before and after treatment. Results show 
that infra-slow oscillations were decreased with PEA in the ascending pain pathway.  
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1.7 Neuroimaging: Magnetic resonance imaging 
The overall aim of this thesis is to explore functional and anatomical changes in individuals with 
trigeminal neuropathic pain with particular focus on the spinal trigeminal nucleus, thalamus and 
somatosensory cortex. So is it possible to measure changes in brain activity and anatomy in living 
humans? Magnetic resonance imaging (MRI) is a scanning technique that implements strong magnets, 
and radiofrequency signals to generate structural and continuous images of the body’s internal organs 
to measure changes in structure and activity, respectively.   
1.7.1 Functional magnetic resonance imaging 
One sequence of imaging that can be collected using an MRI that provides an index of neural activity 
is blood oxygenation level dependent (BOLD) functional magnetic resonance imaging (fMRI). The 
physiological basis of BOLD fMRI relies on the increase in energy required for neurons to fire when 
activated. This increase in energy increases in blood flow to that area of neurons and an increase in 
the ratio of oxygenated to deoxygenated haemoglobin in the tissue. Thus, there is a difference in the 
magnetic properties of oxygenated and deoxygenated haemoglobin, which is what the fMRI measures 
(Peyron et al., 2000). FMRI can be used to measure neural activity in response to tasks or resting 
activity which can then be used to analyse oscillatory and functional network changes between 
groups.   
1.7.1.1 Arterial spin labelling 
In chronic neuropathic pain conditions, the pain cannot be switched on and off and hence BOLD 
cannot be used for investigating blood flow changes in these conditions  as it cannot be directly used 
to compared blood flow levels between groups (Wasan et al., 2011). While, positron emission 
tomography allows for the measurement of blood flow changes, this technique is invasive and has a 
poor spatial resolution. Consequently, arterial spin labelling (ASL), pseudo-continuous ASL (pCASL) in 
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particular, which has a higher signal to noise ratio than previous ASL techniques, can be used to 
measure regional on-going blood flow as an index of on-going levels of neural activity in individuals 
with chronic neuropathic pain conditions. It allows for the absolute quantification of regional cerebral 
blood flow by use of magnetically labelled water, similar to the principles of positron emission 
tomography (Wu et al., 2007).  
1.7.1.2 Low frequency oscillations 
In addition to measuring evoked or on-going activity levels using fMRI or ASL, the pattern of on-going 
neural activity can be explored using resting state fMRI. Using a resting state fMRI time series, one can 
break the signal into its individual component frequencies using Fast Fourier transforms and the 
power at each frequency can be measured. These low frequency oscillations suggest some 
connectivity between functionally related regions at rest (Biswal et al., 1995) and it has been shown 
that infra-slow oscillations (<0.1Hz) are fundamental to cerebral and thalamic function (Hughes et al., 
2011; Lőrincz et al., 2009). Furthermore, as mentioned above, changes in thalamic bursting activity 
have been shown in chronic neuropathic pain models and as such, this method allows for 
measurement of low frequency oscillatory activity in regions of the somatosensory pathway between 
patients and healthy controls. 
1.7.2 T2 relaxometry 
Whilst it is not possible to measure astrocyte activation directly in a living human, there is evidence 
that a specific anatomical imaging technique - T2 relaxation time – can be used as an indicator of 
astrocytic activity (Jackson et al., 1994; Schwarz et al., 1996; Wagner et al., 2012). T2 relaxation times 
are influenced by the chemical characteristics of the tissue such as static dipolar fields, which increase 
as the size of structures increase (such as the increase in GFAP levels in astrocyte activity) (Goldman 
and Shen, 1966; Solomon, 1955). Therefore, an increase in astrocytic release of GFAP (an intermediate 
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filament composed of a variety of proteins), increases the static dipolar field, and reduces the T2 
relaxation time (Sofroniew, 2009b; Sofroniew and Vinters, 2010a; Stewart, 1993).  
1.8 Overarching aims of the thesis 
To investigate altered neural activity in chronic orofacial neuropathic pain and the effects of PEA on 
neural activity. 
1.8.1 Specific aims of the thesis 
Investigate infra-slow oscillatory activity using fMRI in patients with orofacial neuropathic pain. 
This work is presented in Chapter 2, and was published as Chronic Neuropathic Pain: It’s about 
the Rhythm, The Journal of Neuroscience, 2016: 36 (3), p. 1008-1018. 
Investigate whether previously identified infra-slow oscillations in orofacial neuropathic pain result 
from astrogliosis using T2 relaxometry. 
This work is presented in Chapter 3, and was published as Altered regional brain T2 relaxation 
times in individuals with chronic orofacial neuropathic pain, NeuroImage: Clinical, 2018: 19, 
p. 167-173.
To investigate whether an astrocyte modulator can reduce orofacial neuropathic pain and to 
investigate its effects on infra-slow oscillatory activity and cerebral blood flow.  
This work is presented in Chapter 4, and was submitted to Nature Medicine as Effects of the 
glial modulator, palmitoylethanolamide, on chronic pain intensity and brain function.  
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Chronic Neuropathic Pain: It’s about the Rhythm
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The neural mechanisms underlying the development and maintenance of chronic neuropathic pain remain unclear. Evidence from
human investigations suggests that neuropathic pain is associated with altered thalamic burst firing and thalamocortical dysrhythmia.
Additionally, experimental animal investigations show that neuropathic pain is associated with altered infra-slow (0.1 Hz) frequency
oscillations within the dorsal horn and somatosensory thalamus. The aim of this investigation was to determine whether, in humans,
neuropathic pain was also associated with altered infra-slow oscillations within the ascending “pain” pathway. Using resting-state
functional magnetic resonance imaging, we found that individuals with orofacial neuropathic pain have increased infra-slow oscillatory
activity throughout the ascending pain pathway, including within the spinal trigeminal nucleus, somatosensory thalamus, thalamic
reticular nucleus, and primary somatosensory cortex. Furthermore, these infra-slow oscillations were temporally coupled across these
multiple sites and occurred at frequencies similar to calciumwaves in activated astrocytes. The region encompassing the spinal trigem-
inal nucleus also displayed increased regional homogeneity, consistent with a local spread of neural activity by astrocyte activation. In
contrast, no increase in oscillatory behavior within the ascending pain pathway occurred during acute noxious stimuli in healthy
individuals. These data reveal increased oscillatory activity within the ascending pain pathway that likely underpins increased thalamo-
cortical oscillatory activity, a self-sustaining thalamocortical dysrhythmia, and the constant perception of pain.
Key words: astrocytes; infra-slow oscillations; orofacial pain; regional homogeneity; spinal trigeminal nucleus; thalamocortical rhythm
Introduction
Neuropathic pain (NP) is a disease state with an enormous
socioeconomic burden and with unmet needs for the popula-
tion. In the United States alone, it is estimated to afflict10%
of the population, costing on average $17,000 per patient
yearly (Wang et al., 2009a,c). Additionally, there are frequent
clinical misdiagnoses as a result of the lack of quantitative and
validated tests, and current treatment regimens are ineffective
in a significant number of individuals. Hindering our ability to
improve diagnoses and treatment is our poor understanding
of the neural mechanisms responsible for the development
and maintenance of chronic NP. Surprisingly, although acute
noxious stimuli evoke robust signal increases in a well-
described set of neural structures (Farrell et al., 2005) and
individuals with chronic pain display increased activation
during acute noxious stimuli in these same regions (Gracely et
al., 2002; Giesecke et al., 2004), multiple human brain imaging
investigations have not found robust increases in ongoing
blood flow in these same regions in individuals with chronic
pain, particularly NP. Indeed, the most consistent differe-
nce is a thalamic blood flow decrease (Hsieh et al., 1995; Iada-
rola et al., 1995; Moisset and Bouhassira, 2007; Youssef et al.,
2014).
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Significance Statement
Chronic neuropathic pain is associated with altered thalamic firing and thalamocortical dysrhythmia. The mechanisms respon-
sible for these changes remain unknown. In this study,we report in individualswith neuropathic pain increased oscillatory neural
activity within the ascending pain pathway with evidence that these changes result from altered neural–astrocyte coupling. We
propose a series of neural and glial events after nerve injury that result in the generation of altered thalamocortical activity and a
persistent neuropathic pain state. Defining the underlying mechanisms responsible for neuropathic pain is critical if we are to
develop more effective treatment regimens.
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Despite the apparent lack of ongoing blood flow increases in
most of the ascending pain pathway, NP is associatedwith altered
thalamic firing, including increased burst firing in the somato-
sensory thalamus without an overall increase in activity (Lenz et
al., 1989). Experimental animal investigations confirm that in-
creased somatosensory thalamus burst firing is associated with
NP and furthermore have revealed that this altered firing occurs
in a rhythmic manner, with burst intensity oscillating at infra-
slow frequencies (Gerke et al., 2003; Iwata et al., 2011). It is
thought that this altered thalamic firing underpins the thalamo-
cortical dysrhythmia that occurs in individuals with NP and that
results in the constant perception of pain (Sarnthein et al., 2006;
Walton and Llina´s, 2010). Coincidently, thalamic astrocytes dis-
play calcium wave oscillations that modulate neurotransmitter
release from adjacent neurons, at approximately the same infra-
slow frequency range as the thalamic neuronal oscillations re-
ported in animal models of NP (Crunelli et al., 2002), and it has
been shown that NP is associated with astrocyte activation within
the ascending pain pathway (Okada-Ogawa et al., 2009; Shi et al.,
2012; Ji et al., 2013). Thus, it is conceivable that, in individuals
with NP, an increase in oscillatory astrocyte activity within the dor-
sal horn and/or somatosensory thalamus results in an increase
thalamocortical oscillatory activity, a self-sustaining thalamocortical
dysrhythmia, and the constant perception of pain.
We investigated whether individuals with NP displayed in-
creased infra-slow oscillatory activity in ascending pain path-
ways, including the level of the primary afferent synapse and
whether this activity dominates information flow throughout the
brain. Because we propose that pathological processes including
chronic astrocyte activation play a critical role in generating
infra-slow oscillations, we hypothesized that, in healthy individ-
uals, activation of the ascending pain pathway by an acute nox-
ious stimulus does not increase infra-slow oscillatory activity.
Materials andMethods
Subjects. Seventeen subjects with chronic orofacial NP (14 females;
mean SEMage, 50.6 2.8 years) and 44 pain-free controls (33 females;
mean age, 45.9  2.0 years) were recruited for the study. There was no
significant difference in age (t test, p 0.05) or gender composition ( 2
test, p  0.05) between the two subject groups. NP subjects were diag-
nosed using the Liverpool criteria as having posttraumatic neuropathy
(Nurmikko and Eldridge, 2001).
During the 7 d before the MRI session, each subject kept a pain diary
recording the intensity of their ongoing pain, three times a day. Subjects
rated the intensity of their pain using a 10 cm horizontal visual analog
scale (VAS), with 0 indicating “no pain” and 10 indicating “the most
intense imaginable pain.” These pain intensity scores were then averaged
over the 7 d period to create ameanpain intensity score.On the day of the
MRI scanning, each NP subject outlined the location of their ongoing
pain on a standard drawing of the head and completed a McGill Pain
Questionnaire, the Beck’s Depression Inventory (BDI; Beck et al., 1961),
and the Pain Catastrophizing Scale (PCS; Sullivan et al., 1995). Table 1
shows NP subject characteristics, including pain duration, pain location,
7 d pain intensity, medication, depression, and pain catastrophizing
scores. Informedwritten consent was obtained for all procedures accord-
ing to the Declaration of Helsinki, and the study was approved by our
local Institutional Human Research Ethics Committees. Data from 13 of
the 17 NP subjects were used in previous investigations (Gustin et al.,
2011; Henderson et al., 2013; Wilcox et al., 2015).
MRI acquisition.All NP and control subjects lay supine on the bed of a
3 tesla MRI scanner (Achieva; Philips) with their head immobilized in a
tight-fitting head coil. With each subject relaxed and at rest, a series of
180 gradient echo echo-planar functional MRI (fMRI) image volumes
using blood oxygen level-dependent contrast were collected. Each image
volume contained 35 axial slices covering the entire brain (field of view,
240  240 mm; matrix size, 80  78; slice thickness, 4 mm; repetition
time, 2000 ms; echo time, 30 ms; flip angle, 90°). In each subject, a
high-resolution 3D T1-weighted anatomical image set covering the en-
tire brain was collected (turbo field echo; field of view, 250  250 mm;
matrix size, 288  288; slice thickness, 0.87 mm; repetition time, 5600
ms; echo time, 2.5 ms; flip angle, 8°).
In addition, in 15 of the control subjects, a catheter connected to a
syringe filled with hypertonic saline (5%) was placed into the right mas-
seter muscle midway between its upper and lower borders. The catheter
was connected to an infusion pump with a 10 ml syringe placed outside
the scanner room.An infusion of hypertonic saline (4ml/h) into the right
masseter muscle was then started, and the subject indicated by pushing a
buzzer when the pain intensity reached a score of 5 of 10 on a numerical
11 point VAS. While in pain, a series of 180 fMRI image volumes were
then collected using the same parameters as described above. Each sub-
ject was instructed to push a buzzer once if the pain fell below 5 and twice
if it increased above 5, and the infusion rate was adjusted accordingly to
maintain the pain intensity at 5 of 10. After the scan, each subject was
asked to rate the average pain during the scan on a 10 cmhorizontal VAS.
Each NP and control subject was scanned only once, and all data were
used for additional analysis. Furthermore, to reduce the potential effects
of software upgrades and other factors that can alter signal-to-noise ra-
tios, we collected the control and NP subject data randomly throughout
a 3.5 year period during which this investigation was conducted.
MRI analysis. Using SPM12 (Friston et al., 1995), all functional
magnetic resonance images were motion corrected, and global signal
drifts were removed using the detrending method described byMacey et
al. (2004), spatially normalized to the Montreal Neurological Institute
(MNI) template, and spatially smoothed (6 mm full-width half-max-
imum Gaussian filter). In no subject was there significant movement
(0.5 mm in any direction). In those NP subjects with pain restricted to
the left side of the face (n 9), resting fMRI scans were reflected across
the midline so that, in all NP subjects, the right side was ipsilateral to
ongoing pain. Given this, the individual analyzing the data was not
blinded to the subject groups. To assess thalamic oscillatory activity, we
placed a cuboid over the left (contralateral) thalamus, covering 18, 24,
and 15 mm in the x, y, and z directions, respectively. This cube was then
divided into 240 individual volumes of interest (VOIs) that were 3 3
Table 1. PTN subject characteristics
Subject
Age
(years) Gender
Pain
duration
(years)
Pain
intensity
(VAS) Location Analgesic medication BDI PCS
1 51 Male 3.5 2.1 Right None 6 10
2 47 Female 5 1.1 Left None 24 47
3 52 Female 1.5 6.9 Bilateral Oxycodone hydrochloride,
paracetamol
18 29
4 55 Female 2 5.2 Left Docusate sodium; sennosides,
amitriptyline, gabapentin,
oxycodone, paracetamol
21 25
5 42 Female 11 4.8 Right Carbamazepine 34 36
6 54 Female 6.5 1.6 Right Amitriptyline 9 20
7 44 Female 2 6.4 Left None 11 15
8 41 Female 3.5 4.0 Left None 6 11
9 67 Female 14 8.4 Left None 4 29
10 43 Male 16 5.8 Left Desvenlafaxine 5 9
11 44 Female 1.5 1.2 Right Ibuprofen, codeine
phosphate, paracetamol
19 25
12 65 Female 7 2.5 Left Amitriptyline, paracetamol 6 11
13 50 Female 7 0.5 Right None 6 2
14 67 Female 20 4.2 Right Thyroxine sodium, rosuvastatin,
venlafaxine, pregabalin,
phenylethylamine,
ergotamine
32 18
15 67 Female 3 8.4 Left None 6 5
16 43 Male 9 5.8 Left Desvenlafaxine 30 29
17 44 Female 7.5 1.2 Right None 5 35
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3mmeach (Fig. 1a). The individual resting fMRI signal intensity changes
in each of these 240VOIswere then derived for each of the 44 control and
17 NP subjects from the nonspatially smoothed fMRI image sets. Power
spectra based on fast Fourier transforms were calculated usingMATLAB
software (MathWorks) for each individual subject’s resting fMRI signal.
Power values were then averaged over each VOI for the control and NP
groups, and significant differences between power spectra were deter-
mined at 0.002 Hz intervals from 0.006 to 0.25 Hz (two-sample t tests,
p  0.05). Significant differences between control and NP groups were
color coded for significance, and the percentage of significantly different
VOIs at each frequency were plotted. This analysis revealed that the
frequency band with the greatest number of significantly different VOIs
was 0.03–0.06 Hz, and this band was used for subsequent analyses.
Low-frequency amplitude analysis.Using the SPM toolbox REST (Song
et al., 2011), we calculated the sum of amplitudes of low-frequency fluc-
tuations (ALFFs) between 0.03 and 0.06 Hz for each voxel in control and
NP subjects using the spatially smoothed fMRI image sets. In addition,
we divided these ALFF values by total power over the entire frequency
range to obtain fractional ALFF (fALFF) values for each voxel. Both
ALFFs and fALFFs have been shown to have high test–retest reliability,
particularly in gray matter, and reliability is reportedly greater in ALFFs
than fALFFs (Zuo et al., 2010). Furthermore, parcellation-based reliabil-
ity analyses demonstrate highly consistent and reliable rank ordering of
infra-slow oscillatory power across the brain. These findings are consis-
tent with ALFFs and fALFFs reflecting neuronal activity. Significant dif-
ferences between groups were then determined using a two-sample
random-effects procedure with age and gender as nuisance variables for
both ALFF and fALFF values (p  0.05, false discovery rate corrected,
minimum cluster size of 10 voxels). For each significant cluster, power
spectra were calculated from resting percentage change fMRI signals, and
the power at each frequency was calculated. We then plotted the mean
power between 0.03 and 0.06 Hz for control and NP subjects.
To determine the potential effects of head movement, for each move-
ment parameter (x, y, z, pitch, roll, yaw), power spectra were calculated,
Figure 1. Infra-slow oscillations within the thalamus. a, A cuboid 18 24 15 mm consisting of 240 individual VOIs was placed over the left (contralateral to highest pain) thalamus in 44
controls and 16 subjects with orofacial NP. Slice locations are indicated by the horizontal lines on the coronal section and the numbers to the top right of each axial slice in MNI space. At each
rostrocaudal level of the thalamus, 48 VOIs were assessed for significant power differences. b, Each gray band beside an axial image consists of a row for each VOI in that slice, with spectral power
differences between control and NP subjects (controls NP or controls NP) at frequencies between 0.006 and 0.25 Hz color coded for significance ( p value). Gray represents no significant
difference. c, A plot of the percentage of significantly different voxels over the entire frequency spectrum revealed that the frequency band 0.03–0.06 Hz had the highest percentage of significa-
ntly different VOIs. This frequency band was used for all subsequent analysis.
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and themean power between 0.03 and 0.06 Hz in control and NP groups
were compared (p  0.05, two-tailed, two-sample t test). The effects of
BDI and PCSwere determined by assessing their relationships with 0.03–
0.06Hz power in significant clusters inNP subjects (p 0.05). The effect
of medication on infra-slow oscillations was determined by comparing
0.03–0.06 Hz power in each significant cluster in NP subjects taking
analgesic medications (n 9) with those not taking medication (n 8;
p 0.05, two-tailed, two-sample t test). In addition, the effects of later-
ality were tested by reflecting each significant cluster across the midline
and comparing mean power between 0.03–0.06 Hz in control and NP
groups (p  0.05, two-tailed, two-sample t test). Finally, to determine
whether changes in low-frequency oscillations were temporally coupled
between the resulting significant clusters, cross-correlations were per-
formed between resting fMRI signal intensity changes in each significant
cluster in control and NP subjects (5 volume moving average applied to
each cross-correlation curve).
Degree centrality analysis. To assess the influence of infra-slow fre-
quency oscillations on local network connectivity, we measured degree
centrality. Using the DPARSF toolbox (Chao-Gan and Yu-Feng, 2010),
the preprocessed images were bandpass filtered (0.03–0.06 Hz), and
voxel-based graphs were generated for each individual. Correlations be-
tween fMRI time series of each voxel with every other voxel in the brain
were computed, resulting in a correlation matrix (minimum correlation
r value of 0.25). A binary, undirected adjacency matrix was then ob-
tained, and degree centrality was calculated by counting the number of
significant correlations between each voxel and all other voxels. For NP
subjects, voxels with the greatest degree centrality were determined using
a one-sample t test (p  0.05, false discovery rate corrected, minimum
cluster size of 10 voxels). To determine whether the resulting significant
clusters differed between NP and control subjects, degree centrality val-
ues were extracted from each cluster in all subjects and compared using
two-sample t tests (two-tailed, two-sample t test, p 0.05).
Local homogeneity analysis.To determine the role of factors such as the
influence of astrocyte activation on neural function (albeit indirect evi-
dence), wemeasured Kendall’s coefficient of concordance (KCC), which
evaluates the similarity of the time series within each voxel and its nearest
neighbors. Using the DPARSF toolbox (Chao-Gan and Yu-Feng, 2010),
the preprocessed images were bandpass filtered (0.03–0.06 Hz), and
voxel-based graphs were generated for each individual subject. For each
voxel, the KCC was computed from the time course of that voxel and its
19 neighboring voxels. Significant differences in regional homogeneity
between NP and controls subjects were then determined using a two-
sample random-effects procedure (p  0.05, false discovery rate cor-
rected, minimum cluster size of 10 voxels).
Acute pain analysis. Finally, we determined changes in infra-slow fre-
quency oscillations (0.03–0.06 Hz) in 15 subjects during acute noxious
Figure 2. NP is associatedwith increased infra-slow oscillation power in the ascending pain pathway. Brain regions inwhich NP subjects had significantly increased (hot color) or decreased (cool
color) ALFFs (a) and fALFFs (b; random effects, p 0.05, false discovery rate corrected, minimum cluster size of 10 voxels). Location of each axial slice inMNI space is indicated at the top right. The
green shading indicates the thalamic region activated during innocuous brushing of the right lip, i.e., the orofacial somatosensory thalamus. NP is associated with increased infra-slow oscillations
in the region of the primary afferent synapse (spinal trigeminal nucleus), as well as other parts of the ascending pain pathway. dlPFC, Dorsolateral prefrontal cortex. c, Power spectrum plots of four
clusters in which power in the 0.03–0.06 Hz range was significantly increased in NP subjects (red) compared with controls (black). Plots of the mean SEM power between 0.03 and 0.06 Hz are
shown for controls and NP subjects. Note that, at frequencies above 0.06 Hz, power was remarkably similar in both control and NP subjects. cont, Controls; ipsi, ipsilateral.
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stimulus (masseter muscle pain) compared with all 44 controls. We cal-
culated ALFF and fALFF maps using the spatially smoothed fMRI image
sets, and significant differences between controls and acute pain were
determined for both ALFF and fALFF values using a two-sample
random-effects procedure with age and gender as nuisance variables
(p  0.05, false discovery rate corrected, minimum cluster size of 10
voxels). Furthermore, for those clusters that displayed a significant in-
crease in infra-slow frequency oscillations in NP subjects during the first
analysis, signal intensity changes were extracted for each of the subjects
during acute pain and in controls. For each cluster, power spectra were
calculated, and significant differences between acute pain and no pain sub-
jects were determined in the same process described above (two-sample t
test, p  0.05). The anatomical locations of each significant cluster were
confirmed using the Atlas of the Human Brainstem and Cerebellum (Duver-
noy, 1995) and the Atlas of the Human Brain (Mai et al., 2007).
Results
Altered infra-slow oscillations in ascending pain pathways
Power spectra based on fast Fourier transforms of resting fMRI
signal intensity fluctuations within the left thalamus (contralat-
eral to highest ongoing pain) revealed that the greatest number of
voxels in which power was significantly different in NP subjects
compared with controls occurred within the frequency band
0.03–0.06 Hz (Fig. 1b). Using this restricted frequency range
(0.03–0.06 Hz), a voxel-by-voxel analysis revealed a pattern of
difference that closely overlapped the ascending pain pathway
(Fig. 2a,b). That is, NP subjects had a significantly increased
infra-slow oscillation power in the dorsolateral medulla in the
region of the ipsilateral (right) spinal trigeminal nucleus subnu-
cleus caudalis/interpolaris (SpV; mean  SEM, 0.03–0.06 Hz
power; controls, 2.2 0.4; NP, 9.5 3.6; p 0.0007), contralat-
eral medial thalamus encompassing the mediodorsal, centrolat-
eral, and orofacial somatosensory nuclei (controls, 1.1 0.1; NP,
2.3 0.5; p 0.0004), contralateral lateral thalamus encompass-
ing the region of the thalamic reticular nucleus (TRN; controls,
0.9 0.1; NP, 1.7 0.3; p 0.002), and the orofacial represen-
tation of contralateral primary somatosensory cortex (S1; con-
trols, 3.2  0.4; NP, 7.0  1.2; p  0.0001; Fig. 2c; Table 2,
Amplitudes of low-frequency oscillations and fractional ampli-
tudes of low-frequency oscillations). The location of the con-
tralateral somatosensory thalamus was defined by overlaying the
change in low-frequency powerwith functional activation during
repeated innocuous brushing of the right side of the mouth as
reported previously (Henderson et al., 2013). The location of all
other clusters were derived from our previous investigations and
human brain atlases (Duvernoy, 1995; Paxinos andHuang, 1995;
Mai et al., 2007), and we are confident that the changes reported
encompass the nuclei described. We confirmed that these infra-
slow oscillations were restricted to the frequency range of 0.03–
0.06 Hz by extracting and plotting the entire frequency range
(0–0.25Hz; Fig. 2c), andwe are confident thatmovement did not
have a significant effect on these results because there was no
significant difference in movement-related power between con-
trols and NP subjects in any of the six directions (x, p 0.13; y,
p 0.30; z, 0.35; pitch, p 0.57; roll, p 0.43; yaw, p 0.59).
In NP subjects, we found no significant relationship between
mean 0.03–0.06 Hz power in any of these ascending pain path-
way clusters identified above with either BDI (ipsilateral SpV, r
0.35, p 0.19; contralateral medial thalamus, r 0.06, p 0.82;
contralateral TRN, r  0.06, p  0.82; contralateral S1, r 
0.11, p  0.67) or PCS (ipsilateral SpV, r  0.33, p  0.21;
contralateral medial thalamus, r0.03, p 0.92; contralateral
TRN, r0.09, p 0.72; contralateral S1, r 0.32, p 0.23).
There were also no significant differences inmean power in these
clusters in NP subjects on medications compared with those not
on medications (mean  SEM power; ipsilateral SpV: medica-
tions, 10.2 6.2; no medications, 8.8 4.0, p 0.43; contralat-
eral medial thalamus: medications, 2.4  0.7; no medications,
2.2 0.8, p 0.41; contralateral TRN:medications, 1.8 0.5; no
medications, 1.5 0.4, p 0.329; contralateral S1: medications,
7.1 2.1; no medications, 6.9 1.3, p 0.46). There were also
no significant correlations between pain intensity or pain dura-
tion andmean 0.03–0.06Hz power in any of these ascending pain
pathway clusters (pain intensity: ipsilateral SpV, r  0.05, p 
0.86; contralateral medial thalamus, r  0.18, p  0.51; con-
tralateral TRN, r0.09, p 0.74; contralateral S1, r0.09,
p  0.74; pain duration: ipsilateral SpV, r  0.07, p  0.81;
contralateral medial thalamus, r0.41, p 0.11; contralateral
TRN, r0.50, p 0.06; contralateral S1, r0.45, p 0.08).
Furthermore, reflecting these clusters across themidline revealed
no significant differences in mean power between controls and
NP subjects in the ipsilateral SpV (mean SEM power; controls,
8.1  4.7; NP subjects, 8.9  3.7, p  0.45), contralateral TRN
(controls, 0.9  0.1; NP subjects, 1.6  0.5, p  0.08), or con-
tralateral S1 (controls, 4.2  0.6; NP subjects, 4.3  1.1, p 
0.47), although there was a significant increase in NP subjects in
the contralateral medial thalamus (controls, 0.9  0.1; NP sub-
jects, 2.4 0.5, p 0.003).
To determine whether infra-slow oscillation power increases in
the ascendingpainpathwaywere temporally coupled,weperformed
Table 2. MNI coordinates, cluster size, and t score for regions of significant
difference between control and NP patients
Brain region
MNI coordinate
Cluster size t scorex y z
Amplitudes of low-frequency oscillations
Controls NP
Right dorsolateral prefrontal cortex 8 30 20 50 4.41
NP controls
Ipsilateral spinal trigeminal nucleus 6 40 50 31 4.33
Ipsilateral cerebellar cortex 24 66 26 114 4.09
Contralateral somatosensory thalamus 8 24 6 105 5.42
Contralateral dorsal posterior insula 40 16 20 558 3.62
Contralateral S1 64 18 18 5 4.98
Fractional amplitudes of low-frequency oscillations
NP controls
Contralateral somatosensory thalamus 6 24 8 31 4.84
Contralateral TRN 12 10 6 28 4.40
Degree centrality
Ipsilateral spinal trigeminal nucleus 10 38 48 26 13.89
Contralateral dorsolateral pons 8 38 34 40 13.27
Ipsilateral cerebellar cortex 24 70 30 199 17.57
Contralateral cerebellar cortex 26 88 32 66 15.41
Ipsilateral insula 40 8 0 40 16.42
40 4 10 17 12.81
Contralateral medial thalamus 6 24 10 29 12.84
Contralateral TRN 12 8 4 23 15.18
Contralateral S1 60 12 34 31 13.05
50 16 46 53 10.21
Ipsilateral dorsolateral prefrontal cortex 38 38 8 25 17.25
38 2 34 61 15.10
28 22 48 16 13.14
Contralateral dorsolateral prefrontal cortex 28 20 42 70 14.15
Mid-cingulate cortex 2 12 28 33 13.19
Regional homogeneity
NP controls
Ipsilateral spinal trigeminal nucleus 6 40 48 14 5.97
Ipsilateral cerebellar cortex 20 52 18 21 5.03
Contralateral cingulate cortex 4 32 28 64 6.36
6 4 46 76 6.19
8 20 34 36 5.80
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cross-correlation analyses of resting fMRI
signal intensity changes between the SpV,
medial thalamus,TRN,andS1. Inbothcon-
trol and NP subjects, signal intensity cou-
pling occurred between the SpV andmedial
thalamus and between themedial thalamus
and TRN (Fig. 3). However, in NP subjects
only, additional correlation peaks occurred
at regular time lag intervals of 30 s (0.03
Hz), reflecting the presence of temporally
coupled increased infra-slow oscillations
within the ascending pain pathway.
Altered network connectivity in
ascending pain pathways
The influence of these low-frequency os-
cillatory differences within the ascending
pain pathway on local network connectiv-
ity was assessed by using degree centrality.
Network theory methodologies such as
degree centrality treat the brain as an in-
tegrated network with each voxel consid-
ered a node in a networkwith connections
between nodes defined by their resting
activity (Bullmore and Sporns, 2009).
Degree centrality identifies the most con-
nected nodes by counting the number of
other voxels that display similar signal
intensity fluctuations. It defines central
nodes with the highest number of connec-
tions and assumes that the importance of
a particular node is dictated by the num-
ber of other nodes with which it directly
interacts (Joyce et al., 2010). In a remark-
ably similar pattern to the infra-slow
oscillation changes, we found that, in NP
subjects, the ascending pain pathway dis-
played the greatest degree centrality (Fig.
4a). The number of direct connections
was significantly greater in NP subjects in
the ipsilateral SpV (mean  SEM  103
centrality score: controls, 18.7  1.1; NP
subjects, 22.2 1.7, p 0.02), contralat-
eral medial thalamus (controls, 28.0 
2.1; NP subjects, 33.6  2.3, p  0.006),
contralateral TRN (controls, 22.2  1.6;
NP subjects, 27.3 1.4, p 0.03), and the
orofacial representation of the contralat-
eral S1 (controls, 22.8 1.4; NP subjects,
29.7  2.0, p  0.004; Fig. 4b; Table 2,
Degree centrality). In addition, we found
high degree centrality in the cerebellar
cortex, contralateral dorsolateral pons, bi-
lateral dorsolateral prefrontal cortex, and
the mid-cingulate cortex.
Altered local homogeneity at the
primary afferent synapse
If increased infra-slow oscillation power
in NP subjects and the concurrent in-
crease in local network connectivity are
associated with increased synchronicity of
astrocyte activation and the subsequent
Figure 3. Signal intensity fluctuations in the ascending pain pathway are coupled temporally. Graph shows cross-correlations
of resting signal intensity changes within the ascending pain pathway in controls and NP subjects. Tight temporal coupling with
zero time lag occurred between the spinal trigeminal nucleus, somatosensory thalamus, and TRN. A lag of4 s occurred between
the somatosensory thalamus and cortex. Also note the, in only NP subjects, correlation peaks (indicated by red asterisks) occurred
at30 s apart, i.e., indicating ongoing increased infra-slow oscillations in the 0.03 Hz range.
Figure4. NP is associatedwith increased degree centrality in the ascending pain pathway and increased regional homogeneity
at theprimary afferent synapse.a, Brain regions inwhichNP subjects displayed thehighest (hot color) degree centrality ( p0.05,
falsediscovery rate corrected,minimumcluster size of 10voxels). Increaseddegree centrality implies agreater influenceof thepain
pathway in the overall flow of information through the brain. The location of each axial slice in MNI space is indicated at the top
right (z-direction inmillimeters). The green shading indicates the thalamic region activated during innocuous brushing of the right
lip, i.e., the orofacial somatosensory thalamus. b, Plots of mean SEM degree centrality in controls (black) and NP subjects (red)
in four regions of the ascending pain pathway. These plots show there is a significant increase in degree centrality in the ascending
pain pathway in NP subjects compared with controls. c, NP subjects also displayed greater regional homogeneity than controls,
although this increasewas restricted to the region of the ipsilateral spinal trigeminal nucleus, cerebellar cortex, andmid-cingulate
cortex ( p0.05, false discovery rate corrected,minimumcluster size of 10 voxels). Regional homogeneity evaluates the similarity
of the time series within each voxel and its nearest neighbors and could result from local astrocyte activation. dlPFC, Dorsolateral
prefrontal cortex; ipsi, ipsilateral; MCC, mid-cingulate cortex.
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recruitment of surrounding astrocytes and neurons, neighboring
voxels should display increased signal intensity synchronization.
To determine whether there was such an increase in regional
homogeneity, we measured KCC as an index to evaluate the sim-
ilarity of the time series within each voxel and its 19 nearest
neighbors. Remarkably, this analysis revealed that, within the
ascending pain pathway, regional homogeneity was increased
significantly in NP subjects compared with controls within the
ipsilateral SpV (Fig. 4c; Table 2, Regional homogeneity). In addi-
tion, increased local homogeneity occurred in the ipsilateral cer-
ebellar cortex and the contralateral mid-cingulate cortex.
No increase in infra-slow oscillations during acute pain
In a final series of experiments, we aimed to provide additional
evidence that the infra-slow oscillation power increases that oc-
cur in the ascending pain pathway in NP subjects reflected an
ongoing central pathological process and not constant peripheral
nociceptor activation. We found that acute orofacial pain
(mean SEM intensity, 4.8 0.3 of 10) did not evoke significant
increases in infra-slowoscillation power in any brain regionusing
either ALFF or fALFF analysis procedures. However, we did find
significant ALFF decreases during acute pain in the region of the
ventral striatum, posterior cingulate cortex, and precuneus (Fig.
5). Importantly, in contrast to individuals with chronicNP, acute
pain did not evoke any change in infra-slow oscillation power in
the ipsilateral SpV (controls, 2.2 0.4; acute pain, 1.9 0.5, p
0.36), contralateral medial thalamus (controls, 1.1  0.1; acute
pain, 1.3 0.3, p 0.22), contralateral TRN (controls, 0.9 0.1;
acute pain, 0.9  0.2, p  0.49), and contralateral S1 (controls,
3.2 0.4; acute pain, 2.5 0.5, p 0.15).
Discussion
We describe here a series of experimental findings that show that
NP is associated with increased infra-slow oscillatory activity
within the ascending pain pathway. These pain pathway changes
are also associated with altered whole-brain network connectiv-
ity, as well as local homogeneity changes at the primary afferent
synapse. Importantly, these oscillatory and network alterations
do not occur during acute noxious stimuli in healthy individuals.
The oscillatory and network changes that occur in individuals
with chronic NP are consistent with pathological processes that
involve astrocyte activation, synaptic modulation, and the devel-
opment of thalamocortical dysrhythmia.
Although individuals with NP display increased sensitivity in
ascending pain pathways (Gracely et al., 1992; Petrou et al.,
2012), human brain imaging studies report no increase in cere-
bral blood flow, an index of neural activity, in these same brain
regions (Hsieh et al., 1995; Iadarola et al., 1995; Moisset and
Bouhassira, 2007; Youssef et al., 2014). This is curious given that
direct neuronal recordings in the human somatosensory thala-
mus revealed increased burst firing (Lenz et al., 1989), and elec-
troencephalogram recordings report altered thalamocortical
rhythm in humans with NP (Sarnthein et al., 2006). Further-
more, thalamocortical dysrhythmia is thought to result from ab-
errant activity in recurrent thalamocortical loops that involve
collaterals to GABAergic neurons in the TRN (Pinault, 2004),
and we showed recently reduced TRN blood flow and reduced
thalamic GABAergic content in individuals with NP (Henderson
et al., 2013; Gustin et al., 2014). Our results show that, in individ-
uals with NP, the pattern of neural activity is indeed altered at
multiple levels of the ascending pain pathway.
Infra-slow oscillatory activity is a fundamental property of
cerebral and thalamic function and is maintained by adenosine
receptor-mediated signaling (Lorincz et al., 2009; Hughes et al.,
2011). Adenosine is likely released by astrocytes because they can
display spontaneous intracellular infra-slow calcium oscillations
(Parri and Crunelli, 2001), are responsive to glutamate and ace-
Figure 5. Significant changes in infra-slow oscillation power during acute pain comparedwith pain-free condition in controls. Acute pain did not evoke increased infra-slow oscillation power in
any brain region, but did evoke decreased power (cool color scale) in the contralateral ventral striatum, bilateral posterior cingulate cortex (PCC) andprecuneus. Power spectrumplots of four clusters
within the ascending pain pathway derived from the analysis between controls and NP subjects are shown in the lower panel. The four clusters chosen were those which in NP subjects displayed
increased infra-slow oscillations (red shading). The power spectrumplots aswell as plots ofmean (SEM) power between 0.03–0.06Hz in controls during acute pain (black) and in controls during
no pain (green) show that powerwas not significantly increased in the ascending pain pathway during acute pain (two-tailed, two-sample t test, p 0.05). Location of each axial slice inMNI space
is indicated at the top right. cont, Controls; ipsi, ipsilateral.
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tylcholine, and a link between adenosine and infra-slow oscilla-
tory activity has been demonstrated in the cortex (Cunningham
et al., 2006). Coincidently, thalamic astrocytes display calcium
wave oscillations at approximately the same infra-slow frequency
range as the signal oscillations in our NP subjects (Crunelli et al.,
2002), and these infra-slow astrocyte calcium waves can propa-
gate among surrounding astrocytes and can elicit large and long-
lasting NMDA-mediated currents in thalamocortical neurons
(Crunelli et al., 2002). Indeed, synchronous burst firing has been
linked to astrocyte calcium signaling and associated glutamate
release (Tian et al., 2005), and, in pathological situations, greater
numbers of astrocytes may display enhanced calcium wave syn-
chrony and amplitude and enhanced NMDA receptor function
(Parri and Crunelli, 2001; Halassa et al., 2007). Increased infra-
slow oscillations are associated with the development of 
rhythms into paroxysmal events (Hughes
et al., 2011) and are coupled to high-
frequency power fluctuations in the cor-
tex (Vanhatalo et al., 2004; Mantini et al.,
2007). These data are consistent with the
idea that altered astrocyte function in in-
dividuals withNP results in increased tha-
lamic infra-slow oscillation power, which
in turn evokes increased high-frequency
power and the perception of pain (Sarn-
thein et al., 2006). Although there are well
documented microglial changes within
ascending pain pathways in humans
with NP (Banati, 2002; Loggia et al.,
2015), there is no evidence to suggest
that they play a role producing the infra-
slow oscillations.
Although infra-slow oscillations in
individuals with NP might be generated
independently at multiple sites, evi-
dence suggests that they originate in the
primary afferent synapse: (1) there is
tight temporal coupling of infra-slow
oscillations between regions of the as-
cending pain pathway; (2) in experi-
mental animal models and human
postmortem tissue, NP is associated
with astrocyte activation in the dorsal
horn/spinal trigeminal nucleus (Garri-
son et al., 1991; Okada-Ogawa et al.,
2009; Shi et al., 2012); (3) trigeminal
neuropathy is associated with decreased
ipsilateral SpV mean diffusivity, which
is consistent with increased size of acti-
vated astrocytes (Wilcox et al., 2015);
(4) inhibiting astrocyte activation atten-
uates and even reverses nerve injury-
induced mechanical allodynia (Zhuang
et al., 2006; Churi et al., 2008; Ji et al.,
2009, 2013; Morgenweck et al., 2013);
(5) despite no current evidence of a di-
rect relationship between regional
homogeneity and astrocytic activation,
we speculate that increased regional ho-
mogeneity in SpV is consistent with
infra-slow frequency calciumwaves prop-
agation among neighboring astrocytes;
and (6) in an experimental animal model
of NP, infra-slow oscillatory activity in somatosensory thalamus
was eliminated by severing the connection between the primary
afferent synapse and the thalamus (Iwata et al., 2011).
A critical role for astrocyte activation in NP maintenance is
consistent with the finding that NP medications, such as val-
proate, phenytoin, and gabapentin, reduce astrocyte calcium sig-
naling (Tian et al., 2005). Furthermore, inhibition of neural
activity or astrocyte activation reverses themechanical allodynia-
induced nerve injury in experimental animals (Wang et al.,
2009b). Although some of our NP subjects were taking anticon-
vulsantmedications, they showed similar elevations in infra-slow
oscillations as those not taking medications. We cannot deter-
mine whether these levels were reduced compared with before
medication use and may indeed underlie the fact that we did not
find significant relationships between pain intensity andduration
Figure 6. Proposed series of events that result in the maintenance of chronic NP. After nerve injury, excess activity within
primaryafferentneurons results in excessiveneurotransmitter releaseat theprimaryafferent synapse. This release results inneural
death and elicits astrocyte activation,which results inmore regular and increasedmagnitude calciumwaves resulting in increased
regional homogeneity (RH). This in turn results in oscillatory gliotransmitter release and increased infra-slow neural oscillations,
which are subsequently transferred to the somatosensory thalamus. Additional neural loss in the somatosensory thalamus results
in reduced blood flow in the TRN and a subsequent reduction in GABAergic release back onto the somatosensory thalamus. This
reduced inhibition combined with increased infra-slow oscillations and the recurrent nature of thalamocortical circuits results in
altered thalamocortical connectivity, increased dominance of the ascending pain pathway in overall brain function represented by
increased degree centrality (DC), altered thalamocortical loop dynamics, a self-sustaining thalamocortical dysrhythmia, and the
constant perception of pain.
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and infra-slow oscillatory changes in NP subjects. In addition to
central changes, it has also been reported that ectopic peripheral
afferent discharges contribute to the maintenance of NP (Devor
and Seltzer, 1999; Liu et al., 2000). Although these investigations
report increased oscillatory firing well above infra-slow levels
(40 Hz), oscillatory input may maintain glial activation and
infra-slow oscillatory activity.
We propose that, after nerve injury, increased activity within
primary afferent neurons results in excessive neurotransmitter
release, likely glutamatergic. This results in neural death, which
likely involves local interneurons because of the following: (1) in
animal models of NP, GABAergic interneuron loss occurs in the
dorsal horn, which is closely related to glutamate receptor activa-
tion (deNovellis et al., 2004; Scholz et al., 2005); and (2) orofacial
NP is associated with reduced gray matter volume and mean
diffusivity within SpV (Wilcox et al., 2015). Excess neural dis-
charge also elicits astrocyte activation, spreading oscillating cal-
cium waves, oscillatory gliotransmitter release characterized by
increased regional homogeneity, and increased infra-slow neural
oscillations throughout the ascending pain pathway. Addition-
ally, local interneuron loss within the somatosensory thalamus
resulting from a similar mechanism to that which occurs in SpV
results in reduced TRN activity, reduced GABAergic output onto
the somatosensory thalamus (Henderson et al., 2013) and, in
combinationwith increased infra-slowoscillatory activity, results
in altered thalamocortical connectivity, increased dominance of
the ascending pain pathway characterized by increased degree
centrality, a self-sustaining thalamocortical dysrhythmia, and the
constant perception of pain (Fig. 6).
Although this model points to a critical role for the primary
afferent synapse in maintaining NP but does not exclude the
possibility that, in different individuals and in different NP con-
ditions, other sites along the ascending pain pathway play a role
in pain maintenance. Furthermore, it is possible that increased
infra-slow oscillations in regions other than the SpV, thalamus,
and S1 are involved in the maintenance of NP. For example, we
found altered infra-slow oscillatory power, degree centrality,
and/or regional homogeneity in the cerebellar, dorsolateral pre-
frontal, mid-cingulate, and insular cortices in NP subjects. In
animal models of NP, astrocyte activation occurs in the cingulate
cortex, and a recent study suggests that this activation may be
related to sleep disturbances (Kuzumaki et al., 2007; Yamashita et
al., 2014). Furthermore, increased gene expression indicative of
astrocyte activation occurs in the prefrontal cortex of mice with
NP that is likely related to pain comorbidities, such as mood
disorders (Alvarado et al., 2013). Although the focus of this in-
vestigation was on the ascending somatosensory pathway, it is
likely that changes in other brain regions, such as association
cortices, are involved inmaintaining the emotional and cognitive
aspects of NP. It is also possible that the changes in infra-slow
oscillatory power reported here do not result from astrocyte–
neural interactions and may result simply from purely neural
processes, although we suggest this is less likely.
Finally, there are a number of limitations that need to be rec-
ognized. First, given the relatively low spatial resolution of fMRI,
it is difficult to accurately localize each cluster to a particular
brain nucleus or region. Although we are confident that the clus-
ter locations described in this study include the regions labeled,
they also spread into other nuclei. Second, there is a potential bias
of circularity introduced by first performing an analysis to deter-
mine the frequency bandwithin the thalamus and then using this
band to perform voxel-by-voxel analyses (Kriegeskorte et al.,
2009; Vul et al., 2009). Unfortunately, we were not able to reduce
this circularity bias by performing the analysis on separate groups
of subjects because the recruitment of patients with post-
endodontic chronic pain is challenging and a split analysis would
have significantly reduced subject numbers in each group and
thus our statistical power. Furthermore, ALFF and fALFF mea-
surements are not independent because they are derived from the
same data, although it is recommended that both values are pre-
sented because they provide slightly different measures (Zuo et
al., 2010). Third, because we were interested in determining
changes within the ascending pain pathway, it was necessary to
reflect the images of some NP subjects across the midline. Our
result suggest that increased infra-slow oscillation patterns are
consistent with the contralateral projection of these pain path-
ways because we did not find a significant difference in power
when clusters were reflected across the midline, although there
remains a potential issue of lateralized function. Despite these
limitations, the discrete changes in infra-slow oscillations in pri-
marily pain-related brain regions make us confident that the
changes reported in this investigation are important in the main-
tenance of NP.
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A B S T R A C T
The neural mechanisms underlying the development and maintenance of chronic pain following nerve injury
remain unclear. There is growing evidence that chronic neuropathic pain is associated with altered thalamic
ﬁring patterns, thalamocortical dysrhythmia and altered infra-slow oscillations in ascending pain pathways.
Preclinical and post-mortem human studies have revealed that neuropathic pain is associated with prolonged
astrocyte activation in the dorsal horn and we have suggested that this may result in altered gliotransmission,
which results in altered resting neural rhythm in the ascending pain pathway. Evidence of astrocyte activation
above the level of the dorsal horn in living humans is lacking and direct measurement of astrocyte activation in
living humans is not possible, however, there is evidence that regional alterations in T2 relaxation times are
indicative of astrogliosis. The aim of this study was to use T2 relaxometry to explore regional brain anatomy of
the ascending pain pathway in individuals with chronic orofacial neuropathic pain. We found that in individuals
with trigeminal neuropathic pain, decreases in T2 relaxation times occurred in the region of the spinal trigeminal
nucleus and primary somatosensory cortex, as well as in higher order processing regions such as the dorsolateral
prefrontal, cingulate and hippocampal/parahippocampal cortices. We speculate that these regional changes in
T2 relaxation times reﬂect prolonged astrocyte activation, which results in altered brain rhythm and ultimately
the constant perception of pain. Blocking prolonged astrocyte activation may be eﬀective in preventing and even
reversing the development of chronic pain following neural injury.
1. Introduction
Chronic neuropathic pain is a complex disease resulting from actual
or presumed damage to the somatosensory nervous system. The con-
stant perception of pain that characterizes neuropathic pain is asso-
ciated with increased thalamic bursting activity (Gerke et al., 2003;
Iwata et al., 2011; Lenz et al., 1989), reduced thalamic blood ﬂow
(Hsieh et al., 1995; Iadarola et al., 1995; Moisset and Bouhassira, 2007;
Youssef et al., 2014) and increased cortical power, often termed tha-
lamocortical dysrhythmia (Di Pietro et al., 2018; Sarnthein et al., 2006;
Walton and Llinás, 2010). The increase in cortical power is associated
with an altered relationship with thalamic GABAergic content (Di
Pietro et al., 2018) and we have proposed that the thalamocortical
dysrhythmia that occurs in chronic neuropathic pain results from al-
tered interactions between the ventrocaudal thalamus, thalamic re-
ticular nucleus and the cerebral cortex (Henderson and Di Pietro,
2016).
In addition to cortical resting activity changes, as read with
electroencephalography (> 2Hz) we have previously shown that
chronic neuropathic pain is associated with increased infra-slow fre-
quency (< 0.1 Hz) oscillatory activity throughout the ascending pain
pathway, including the region of the primary aﬀerent synapse, ven-
trocaudal thalamus, thalamic reticular nucleus and primary somato-
sensory cortex (Alshelh et al., 2016). Interestingly, these infra-slow
oscillation increases occurred at approximately the same frequency
range as reported calcium waves in astrocytes, i.e. 0.03–0.06 Hz
(Crunelli et al., 2002). Astrocytes are known to modulate synaptic ac-
tivity by the release of gliotransmitters and it is well-documented in
preclinical animal models that neuropathic pain is associated with
prolonged astrocyte activation in the dorsal horn/spinal trigeminal
nucleus (Garrison et al., 1991; Okada-Ogawa et al., 2009). Given these
data, we have speculated that following nerve injury, prolonged as-
trocyte activation results in increased infra-slow oscillations in the as-
cending pain pathway which in turn is associated with thalamocortical
dysrhythmia and the constant perception of pain (Henderson and Di
Pietro, 2016).
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Whilst it is clear from preclinical animal models that neuropathic
pain is associated with astrocyte activation in the dorsal horn and
brainstem (Hsieh et al., 1995; Okada-Ogawa et al., 2009), robust evi-
dence is lacking in humans. There is, however, evidence from a post-
mortem study which revealed prolonged astrocyte activation, but no
microglial activation, in the dorsal horn of individuals with neuropathic
pain associated with HIV (Shi et al., 2012). Indirect measurements of
glial activation using Positron Emission Tomography (PET) have also
revealed chronic glial activation in humans with neuropathic pain.
Banati and colleagues (Banati et al., 2001) reported increases in binding
of [11C](R)-PK11195 (a sensitive in vivo marker of glial cell activation)
in the contralateral (to injury) thalamus of patients with phantom limb
pain. Similarly, Loggia and colleagues recently used the same technique
to show increased glial activation in the thalamus and primary soma-
tosensory cortex, contralateral to pain, of individuals with chronic low
back pain (Loggia et al., 2015). Whilst these brain imaging studies are
important and suggest chronic glial activation in the thalamus and
above, technical limitations mean that they cannot explore changes at
the level of the brainstem or, more importantly, the primary aﬀerent
synapse.
One non-invasive technique that has been used to measure glial
activation is T2 relaxometry (Jackson et al., 1994; Wagner et al., 2012),
a magnetic resonance imaging technique that can characterise changes
in the brainstem and above. There is immunohistochemical evidence
that decreased T2 relaxation times are associated with increased glial
activation (Schwarz et al., 1996) and in this investigation we hy-
pothesize that chronic orofacial neuropathic pain is associated with
signiﬁcantly reduced T2 relaxation time in the ascending pain pathway,
including the region of the spinal trigeminal nucleus, ventrocaudal (Vc)
thalamus, thalamic reticular nucleus and the orofacial region of the
primary somatosensory cortex.
2. Methods
2.1. Subjects
Thirty-seven subjects with chronic orofacial neuropathic pain (NP;
28 females, mean age 46.1 ± 2.5 years [± SEM]) and 40 healthy
controls without ongoing pain (24 females, mean age 40.6 ± 2.7
[± SEM]) were recruited for this study. All NP subjects were diagnosed
using the Liverpool criteria as having post-traumatic painful trigeminal
neuropathy (Nurmikko and Eldridge, 2001). Written informed consent
was obtained for all procedures and the study was approved by In-
stitutional Human Research Ethics Committees, University of Sydney.
For each NP subject, the intensity of their on-going pain was re-
corded on a 10 cm horizontal visual analogue scale (VAS) with 0 in-
dicating “no pain” and 10 indicating “worst imaginable pain”, three times
a day for the seven days prior to a magnetic resonance imaging (MRI)
session (Carlsson, 1983). These pain intensity scores were averaged
over the 7-day period to create a mean pain intensity score. On the day
of the MRI, all subjects were experiencing pain and were asked to draw
the distribution of their ongoing pain. Subjects were also asked to
complete a McGill Pain Questionnaire (Melzack, 1975), the Beck De-
pression Inventory (BDI) (Beck et al., 1961) and the Pain Catastro-
phizing Questionnaire (PCS) (Sullivan et al., 1995). A subset of the
control and NP subjects was used in a previous investigation (Alshelh
et al., 2016).
2.2. MRI acquisition
All subjects lay supine on the bed of a 3 Tesla MRI scanner (Philips
Achieva) with their head immobilized in a tight-ﬁtting 32-channel
SENSE head coil. With each subject relaxed and at rest, a high resolu-
tion T1-weighted anatomical image set covering the entire brain was
collected (turbo ﬁeld echo; ﬁeld of view 250×250 mm; matrix size
288×288; slice thickness 0.87mm; repetition time 5600ms; echo time
2.5 ms; ﬂip angle 8°; raw voxel size 0.87×0.87×0.87mm). Following
this, T2-weighted image sets covering the entire brain were collected
(ﬁeld of view 250×250 mm; matrix size 556× 556; slice thickness
5mm; repetition time 3000ms; echo times 20, 40, 60, 80, 100ms; raw
voxel size 0.4×0.4×5mm thick). Multiple echo times were used to
create multiple image sets for subsequent calculation of T2-relaxation
time maps.
2.3. MRI analysis
Using SPM12 (Friston et al., 1995) and custom software, the fol-
lowing equation was used to calculate T2 relaxation time brain maps:
T2= (TE2− TE1)/ln(SI1/SI2) where TE1 and TE2 are the echo times for
proton density and T2-weighted images, and SI1 and SI2 represent
proton density and T2-weighted image signal intensities, respectively. A
ceiling threshold of 500ms was applied to eliminate cerebrospinal
ﬂuid. In each subject, T2 relaxation maps were co-registered to each
individual's T1-weighted anatomical image set. The T1-weighted ana-
tomical image was then spatially normalized to a template in Montreal
Neurological Institute (MNI) space and the parameters applied to the T2
relaxation time maps. Finally, the T2 brain maps were spatially
smoothed using an 8mm full-width-at-half-maximum Gaussian ﬁlter. In
those NP subjects with pain restricted to the left side of the face
(n= 17), T2-weighted images were reﬂected across the midline so that
T2 diﬀerences could be assessed ipsilateral and contralateral to the side
of highest ongoing pain.
In addition to a wholebrain T2 relaxation analysis, we performed a
brainstem-speciﬁc analysis. The T2 relaxation maps were cropped to
include only the brainstem and cerebellum, and a mask of these regions
was created using the Spatial Unbiased Infratentorial Template (SUIT)
toolbox (Diedrichsen, 2006). These brainstem/cerebellum masks were
then manually adjusted to accurately encompass the brainstem and
cerebellum only. Using this mask, T2 relaxation brainstem images were
spatially normalized to the SUIT template in MNI space and spatially
smoothed using a 3mm full-width-at-half-maximum Gaussian ﬁlter.
Signiﬁcant diﬀerences in T2 relaxation time between controls and
NP subjects were determined using a voxel-by-voxel analysis of the
wholebrain and the brainstem only (p < 0.05, random eﬀects, false
discovery rate corrected for multiple comparisons, minimum cluster 10
voxels, age and gender as nuisance variables). A brain mask that ex-
cluded CSF as well as the brainstem was applied to the wholebrain
analysis. For both the wholebrain and brainstem only analyses, mean
(± SEM) T2 relaxation times of signiﬁcantly diﬀerent clusters were
extracted and plotted. Signiﬁcant correlations between T2 relaxation
times and pain intensity, BDI and PCS scores were also determined
(p < 0.05). In addition, to determine if medication use had a sig-
niﬁcant eﬀect on T2 relaxation times, for each cluster, T2 relaxation
times were compared between those NP subjects taking acute analgesic
medication alone (n= 5) or those taking prophylactic analgesic medi-
cation (n=11) with those not taking medication (n=21) (p < 0.05,
two-tailed, two-sample t-tests).
3. Results
3.1. Psychophysics
Individual NP subject characteristics are shown in Table 1, and
overall pain distributions and pain descriptors in Fig. 1. In 34 of the NP
patients, their on-going pain was unilateral (17 right, 17 left), and the
remaining 3 NP subjects reported bilateral pain. In all NP subjects, pain
was located in the 2nd and 3rd trigeminal nerve divisions, with 7
subjects also reporting pain in the 1st division. The mean (± SEM)
pain intensity over the 7 days prior to the MRI scanning session was
3.8 ± 0.4 out of 10 and the mean duration of pain was
4.1 ± 0.9 years. Using the McGill Pain Questionnaire, NP subjects most
frequently described their pain as “throbbing”, “tender” and
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Table 1
NP subject characteristics.
Subject Age (years) Gender Pain duration
(years)
Site Pain Intensity
(VAS)
Acute analgesic medication Prophylactic medication
1 27 M 3.4 Right 0.5 – Palmitoylethanolamide
2 21 F 12 Right 1.3 – Palmitoylethanolamide
3 35 M 8 Right 1.4 – Palmitoylethanolamide
4 45 M 14 Left 1.4 – Palmitoylethanolamide
5 33 F 7 Left 2.4 – –
6 53 F 2 Left 2.3 – –
7 21 M 0.3 Left 1.9 – Palmitoylethanolamide
8 64 F 17 Right 4.1 – –
9 76 F 25 Left 5.7 – –
10 67 F 2 Left 6.3 Diazepam –
11 47 F 2.8 Left 4.1 – –
12 40 F 1.5 Right 7.8 Ibuprofen Pregabalin, carbamazepine
13 35 F 2 Left 4.9 – –
14 46 F 0.6 Left 3.6 – –
15 52 F 0.8 Right 2.7 – –
16 58 M 1.8 Left 9.6 Ibuprofen –
17 58 F 10 Right 5.1 – –
18 42 F 2.8 Right 4.5 – –
19 44 M 3.3 Bilateral 7.5 Acetylsalicylic acid, ibuprofen Dextroamphetamine, metaprolol
tartrate
20 47 F 0.4 Right 2 – –
21 65 F 10 Left 6.1 Paracetamol –
22 64 F 0.2 Right 1.5 – –
23 24 F 2.6 Left 0 – –
24 28 F 0.2 Bilateral 7.2 Ibuprofen, paracetamol, oxycodone
hydrochloride
Pregabalin
25 58 F 0.5 Right 2.3 Ibuprofen, paracetamol Pregabalin
26 44 F 2.3 Right 4 – Desvenlafaxine
27 39 F 0.6 Left 3.1 Ibuprofen, paracetamol, codeine
28 55 F 1 Right 0.8 – –
29 41 M 0.5 Right 5.1 – –
30 36 F 0.3 Left 0 – –
31 20 F 0.5 Left 1.7 – –
32 39 F 2.6 Left 5.6 – –
33 74 F 0.4 Bilateral 4.2 – –
34 53 M 0.6 Right 2.1 – –
35 29 M 5.8 Left 4.8 Tramadol –
36 73 F 3 Right 7.5 – Efexor
37 53 F 2.3 Right – – –
Mean ± SEM 46.1 ± 2.5 4.1 ± 0.9 3.8 ± 0.4
Fig. 1. Pain distribution and quality of pain in 37 subjects with chronic orofacial neuropathic pain.
A) Individual pain distribution patterns in all 37 chronic pain (NP) subjects. B) Frequency (percentage of subjects) of descriptors chosen from the McGill Pain
Questionnaire to describe the quality of on-going pain, in NP subjects.
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“radiating”. There was no signiﬁcant diﬀerence in age (t-test;
p > 0.05) or gender composition (chi-squared test, p > 0.05) between
the two subject groups. Compared with controls, NP subjects had higher
BDI scores (mean ± SEM: controls: 5.0 ± 1.0, NP: 26.6 ± 2.0,
p < 0.001) and PCS scores (controls: 12.2 ± 1.7, NP: 15.8 ± 1.5,
p < 0.001).
3.2. T2 relaxation times
Wholebrain analysis revealed that NP subjects displayed sig-
niﬁcantly decreased T2 relaxation times relative to controls in a number
of brain regions (Fig. 2, Table 2). These included the left (contralateral
to highest pain) mid-cingulate cortex (mean ± SEM ms: controls:
101.2 ± 1.4, NP: 95.4 ± 1.1), left anterior cingulate cortex (controls:
96.8 ± 1.1, NP: 92.7 ± 1.0), left primary somatosensory cortex
(controls: 107.5 ± 1.1, NP: 100.1 ± 1.3), left dorsolateral prefrontal
cortex (controls: 122.4 ± 4.6, NP: 105.5 ± 3.2) and the left hippo-
campus/parahippocampus (controls: 145.2 ± 2.2, NP: 131.3 ± 1.9).
Brainstem-speciﬁc analysis also revealed regions in which T2
relaxation times were signiﬁcantly lower in NP subjects than in controls
in three discrete brainstem regions (Fig. 3, Table 2). Decreased T2 re-
laxation times in NP subjects occurred in the region encompassing the
right spinal trigeminal nucleus (controls: 106.8 ± 1.1, NP:
101.2 ± 1.3), the right spinal trigeminal tract (controls: 118.2 ± 1.7,
NP: 108.9 ± 2.1) and in the region of the right trigeminal nerve entry
(controls: 107.3 ± 2.0, NP: 98.1 ± 1.8). In no brainstem region was
there a signiﬁcant increase in T2 relaxation time in NP subjects com-
pared with controls.
In NP patients, there were no signiﬁcant relationships between pain
intensity or duration and T2 relaxation times in the left mid-cingulate
cortex (intensity: r= 0.08, duration: r= 0.08), left anterior cingulate
cortex (intensity: r= 0.11, duration: r= 0.36), left primary somato-
sensory cortex (intensity: r= 0.05, duration: r= 0.22), left dorsolateral
prefrontal cortex (intensity: r= 0.25, duration: r= 0.26), left hippo-
campus/parahippocampus (intensity: r= 0.23, duration: r= 0.26),
right trigeminal nerve entry (intensity: r= 0.22, duration: r= 0.13),
right spinal trigeminal tract (intensity: r= 0.11, duration: r= 0.20),
and right spinal trigeminal nucleus (intensity: r= 0.09, duration:
r= 0.14, all p > 0.05). Furthermore, in NP subjects there were no
signiﬁcant linear relationships between PCS or BDI values and T2 re-
laxation times in the left mid-cingulate cortex (PCS: r= 0.26, BDI:
r= 0.31), left anterior cingulate cortex (PCS: r= 0.16, BDI: r= 0.06),
left primary somatosensory cortex (PCS: r= 0.38; BDI: r= 0.22), left
dorsolateral prefrontal cortex (PCS: r= 0.19, BDI: r= 0.28), left hip-
pocampus/parahippocampus (PCS: r= 0.08, BDI: r= 0.01), right tri-
geminal nerve entry (PCS: r= 0.03, BDI: r= 0.26), right spinal tri-
geminal tract (PCS: r= 0.04, BDI: r= 0.24), and right spinal trigeminal
nucleus (PCS: r= 0.07, BDI: r= 0.11; all p > 0.05).
Finally, exploring the eﬀects of medication use on T2 relaxation
times in NP subjects revealed that in no cluster was T2 relaxation time
signiﬁcantly diﬀerent in those taking either acute analgesic or pro-
phylactic medications compared with those not taking medication: left
mid-cingulate cortex (mean ± SEM ms: acute meds: 96.5 ± 3.4, pro-
phylactic meds: 89.9 ± 1.4, no meds: 91.6 ± 1.1, acute v control
p= 0.08; prophylactic vs controls p= 0.36), left anterior cingulate
cortex (acute meds: 94.2 ± 0.6, prophylactic meds: 91.0 ± 1.3, no
Fig. 2. Signiﬁcant diﬀerences in T2 relaxation times in individuals with chronic neuropathic pain compared with controls.
A) Regions where chronic neuropathic pain (NP) subjects had signiﬁcantly reduced T2 relaxation times compared with controls. Reductions are indicated by the cool
colour scale and overlaid onto a mean T1-weighted anatomical image set derived from all 77 subjects. Note the decreases within the orofacial region of the primary
somatosensory cortex (S1), mid-cingulate cortex (MCC), anterior cingulate cortex (ACC), dorsolateral prefrontal cortex (dlPFC) and hippocampus. Slice locations in
Montreal Neurological Institute space are indicated at the top right of each slice. B) Plots of mean ± SEM T2 relaxation times (ms) in control (black bars) and NP
(blue bars) groups for signiﬁcant clusters. ⁎denotes signiﬁcant diﬀerences derived from the voxel-by-voxel random-eﬀects analysis (p < 0.05, false discovery rate
corrected). ipsi: ipsilateral to side of highest on-going pain. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
Table 2
Location, cluster size and signiﬁcance level of T2 relaxation time decreases in
individuals with chronic neuropathic pain compared with controls. Cluster peak
locations are indicated in Montreal Neurological Institute (MNI) space.
Brain region MNI co-ordinate Cluster size t-score
Whole brain T2 relaxation time
Left mid cingulate cortex 6 −11 39 75 4.18
−3 −24 38 55 4.31
Left medial prefrontal cortex −6 24 24 10 3.88
Left primary somatosensory cortex −61 0 21 40 4.40
Left dorsolateral prefrontal cortex −56 24 9 18 4.11
Left hippocampus/
parahippocampus
20 −32 −17 313 4.42
Brainstem T2 relaxation time
Right spinal trigeminal tract 9 30 −11 17 4.67
Right trigeminal nerve entry 11 −26 −37 54 5.03
Right spinal trigeminal nucleus 10 −42 −46 30 4.62
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meds: 93.3 ± 1.6, p= 0.78, p= 0.36), left primary somatosensory
cortex (acute meds: 99.8 ± 3.6, prophylactic meds: 103.0 ± 0.2.4, no
meds: 98.5 ± 1.7, p=0.73, p=0.12), left dorsolateral prefrontal
cortex (acute meds: 101.4 ± 8.5, prophylactic meds: 101.9 ± 5.4, no
meds: 108.8 ± 4.4, p=0.46, p= 0.34), left hippocampus/para-
hippocampus (acute meds: 134.6 ± 6.5, prophylactic meds:
130.9 ± 2.8, no meds: 130.6 ± 2.8, p=0.54, p= 0.95) and right
spinal trigeminal nucleus (acute meds: 79.8 ± 5.8, prophylactic meds:
87.7 ± 5.4, no meds: 91.4 ± 3.4, p=0.12, p= 0.53).
4. Discussion
The results of this investigation reveal signiﬁcant decreases in T2
relaxation times in patients with chronic orofacial neuropathic pain at
multiple points along the ascending pain pathway. Changes occurred in
NP subjects in the region of the trigeminal nerve entry, the region of the
ipsilateral (to pain) spinal trigeminal nucleus and in the contralateral
orofacial representation of the primary somatosensory cortex. In addi-
tion, changes occurred in higher processing regions such as the cingu-
late and prefrontal cortices. These anatomical changes are consistent
with pathological processes associated with astrocyte activation.
T2 relaxation times are inﬂuenced by the chemical characteristics of
tissue. One factor that will signiﬁcantly aﬀect T2 relaxation time is the
static dipolar ﬁelds created by neighbouring dipoles; in solids and
polymers the static dipolar ﬁeld is large. Thus, an increase in the pro-
portion of solids and polymers within a region of the brain for example,
would result in an increase in T2 relaxation rate, i.e. decrease in T2
relaxation time, in that region (Goldman and Shen, 1966; Solomon,
1955). Such an increase in solids/polymers within a speciﬁc brain re-
gion could result from numerous factors, including astrogliosis. In mild
to moderate astrogliosis, there is an increase in glial ﬁbrillary acidic
protein, an intermediate ﬁlament composed of a variety of proteins,
which would contribute to an increase in static dipolar ﬁeld and a de-
crease in T2 relaxation time (Sofroniew, 2009; Sofroniew and Vinters,
2010; Stewart, 1993). Consistent with this, an experimental animal
study that investigated changes following stroke reported decreased T2
relaxation times in areas of increased astrocyte and microglial activa-
tion and iron deposition (Justicia et al., 2008). Furthermore, a human
post mortem study of two individuals with multiple system atrophy
reported reduced T2 relaxation times in the putamen, an area that also
displayed pronounced reactive astrogliosis and microgliosis (Schwarz
et al., 1996). Whilst there are other anatomical changes besides astro-
gliosis that could have contributed to the change in T2 relaxation times
shown in this investigation, several lines of evidence suggest that as-
trogliosis is a likely contributing factor.
We found decreased T2 relaxation time in the region encompassing
the ipsilateral (to pain) spinal trigeminal nucleus, the area in which
orofacial nociceptor aﬀerents terminate. It is known from both human
post-mortem and experimental animal investigations that the presence
of chronic pain following nerve injury is associated with prolonged
astrocyte (and not microglial) activation at the level of the primary
aﬀerent synapse (Garrison et al., 1991; Okada-Ogawa et al., 2009; Shi
et al., 2012). In a previous investigation, we found an increase in on-
going infra-slow oscillatory activity in the region encompassing the
spinal trigeminal nucleus in individuals with chronic orofacial neuro-
pathic pain (Alshelh et al., 2016). Importantly, these increased infra-
slow oscillations were at similar frequencies as calcium waves in acti-
vated astrocytes, which are associated with the release of glio-
transmitters and the subsequent modulation of neural activity (Parri
and Crunelli, 2001). We speculated that although chronic neuropathic
pain is not associated with increased on-going activity in the ascending
pain pathways, the modulation of this pathway by gliotransmitters re-
sults in altered activity patterns, thalamocortical dysrhythmia and the
constant perception of pain (Alshelh et al., 2016; Henderson and Di
Pietro, 2016). A decrease in spinal trigeminal nucleus T2 relaxation
time is consistent with this hypothesis, although whether this change in
relaxation time represents astrocyte activation remains debatable.
In our previous investigation, we also found altered infra-slow os-
cillation increases associated with chronic neuropathic pain in the re-
gion of the ventrocaudal thalamus, thalamic reticular nucleus and in
the primary somatosensory cortex (Alshelh et al., 2016). In addition,
others have reported increased [11C](R)-PK11195 binding, a marker of
glial activation, in the thalamus and primary somatosensory cortex in
individuals with NP (Banati et al., 2001; Loggia et al., 2015). Whilst
altered [11C](R)-PK11195 binding may reﬂect changes in microglial or
astrocyte activation, surprisingly we found no change in T2 relaxation
Fig. 3. Signiﬁcant diﬀerences in T2 relaxation times
in individuals with chronic neuropathic pain com-
pared with controls, within the brainstem only.
A) Regions in which chronic neuropathic pain (NP)
subjects had signiﬁcantly reduced T2 relaxation
times compared with controls. Reductions are in-
dicated by the cool colour scale and overlaid onto a
brainstem template image set. Note the decreases
within the region where orofacial nociceptor aﬀer-
ents terminate – the spinal trigeminal nucleus (SpV),
as well as the area where the trigeminal nerve (V)
enters the pons. Slice locations in Montreal
Neurological Institute space are indicated at the top
right of each slice. B) Plots of mean ± SEM T2 re-
laxation times (ms) in control (black bars) and NP
(blue bars) groups for signiﬁcant clusters. ⁎denotes
signiﬁcant diﬀerences derived from the voxel-by-
voxel random-eﬀects analysis (p < 0.05, false dis-
covery rate corrected). ipsi: ipsilateral to side of
highest on-going pain. (For interpretation of the re-
ferences to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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time in the thalamus in this investigation, despite showing changes in
the spinal trigeminal nucleus and primary somatosensory cortex. Why
no change in T2 relaxation rate occurred in the thalamus is unknown,
but it might be the case that the thalamus is somehow more resistant to
the development of astrogliosis than the primary aﬀerent synapse or
somatosensory cortex, or that recurrent circuits between the thalamus
and cortex somehow reduces the potential for thalamic astrocyte acti-
vation following nerve injury. Indeed, in contrast to reports of pro-
longed astrocyte activation at the primary aﬀerent synapse, it has been
reported in the chronic constriction model of neuropathic pain that the
ventroposterior thalamus displays microglial and not astrocyte activa-
tion at 7 and 14 days post injury, and that inhibiting microglial acti-
vation reduces thermal hyperalgesia (LeBlanc et al., 2011). This raises
the possibility that increased infra-slow oscillations in the ventrocaudal
thalamus in individuals with NP are driven by such changes at the
primary aﬀerent synapse. This is consistent with the ﬁnding of a pre-
clinical study that shows infra-slow oscillatory activity in the ven-
troposterior thalamus was eliminated by severing the connection be-
tween the primary aﬀerent synapse and the thalamus (Iwata et al.,
2011).
Whilst the focus of this investigation was on changes in the as-
cending pain pathway, it is likely that other brain regions are also in-
volved in the maintenance of neuropathic pain. We also found de-
creases in T2 relaxation time in the cingulate, dorsolateral prefrontal
and hippocampal cortices in individuals with neuropathic pain. There is
evidence from preclinical models of chronic pain of astrocyte activation
in the anterior cingulate cortex and suggestions that these changes are
associated with sleep disturbances (Kuzumaki et al., 2007; Yamashita
et al., 2014). Whilst we did not measure sleep patterns in our chronic
pain subjects it is possible that the altered T2 relaxation in the cingulate
cortex may reﬂect changes in sleep patterns that occur in individuals
with various forms of chronic pain (Pilowsky et al., 1985). Alter-
natively, there is growing evidence that the cingulate cortex codes the
aﬀective dimension of pain and thus cingulate astrocyte activation may
reﬂect this aspect of the chronic pain condition, an idea that has sup-
port from preclinical investigations (Chen et al., 2012; Narita et al.,
2006).
Indeed it is well established that neuropathic pain is often asso-
ciated with psychological changes such as depression and pain cata-
strophizing (Bair et al., 2003; Keefe et al., 2004) and we found sig-
niﬁcant diﬀerences in pain catastrophizing scores and depression scores
between the healthy controls and NP subjects. We did ﬁnd signiﬁcant
changes in T2 relaxation times in the cingulate cortex, whose function
is associated with depression (Fonseka et al., 2017; Guo et al., 2012).
Although we found no correlation between T2 relaxation in any brain
region and depressive scores, there is evidence of increased infra-slow
oscillation power in the anterior cingulate cortex of individuals with
treatment-resistant depression (Guo et al., 2012). Furthermore, these
regions were also not correlated to pain intensity or duration of neu-
ropathic pain. Whilst the lack of linear correlations does not exclude the
possibility that the changes in these areas are related to pain and psy-
chological measures, it may be that the underlying mechanisms re-
sponsible for T2 relaxation time alterations reﬂect anatomical changes
that are simply not linearly coupled to changes in neural activity.
In contrast to the cingulate cortex, we know of no investigation
exploring astrocyte changes in the dorsolateral prefrontal cortex or
hippocampus in individuals with neuropathic pain or in preclinical
models. Whilst the role of the dorsolateral prefrontal cortex in neuro-
pathic pain remains unclear, there is evidence that its anatomy and
function is altered in various pain conditions (Apkarian et al., 2004;
Lorenz et al., 2003; Seminowicz and Moayedi, 2017). Furthermore,
there is evidence for a role for the dorsolateral prefrontal cortex in
descending pain modulation, which is altered in individuals with
chronic pain (Bingel and Tracey, 2008; Youssef et al., 2016). We also
found T2 relaxation time diﬀerences in the ventral aspect of the hip-
pocampus, a region thought to control hypothalamopituitary adrenal
(HPA) axis function (Strange et al., 2014). Consistent with the idea that
these T2 relaxation time changes represent astrogliosis, there are mul-
tiple investigations that report hippocampal volume increases in in-
dividuals with chronic pain, although there are some inconsistencies
(Schweinhardt et al., 2008; Smallwood et al., 2013; Tu et al., 2010;
Younger et al., 2010). Since chronic pain is also associated with the
presence of stress-related disorders and HPA axis dysfunction (Griep
et al., 1998; Korszun et al., 2002; Tennant and Hermann, 2002), it is
possible that the changes in ventral hippocampal T2 relaxation times
are related to changes in HPA axis function in our chronic pain subjects.
We found that neither acute analgesic nor prophylactic medication
use had signiﬁcant eﬀect on T2 relaxation times in NP subjects, making
it unlikely that medication itself has a signiﬁcant eﬀect on T2 relaxation
times and the relationship between T2 relaxation times and pain and
psychological measures. Whilst the eﬀects of medication use on re-
gional astrocyte activation and T2 relaxation rate needs to be explored
in a longitudinal manner, our hypothesis that neuropathic pain results
from chronic astrocyte activation is consistent with ﬁnding that neu-
ropathic pain medications such as valproate, phenytoin and gaba-
pentin, reduce astrocyte calcium signalling (Tian et al., 2005). This
raises the propect that other medications with potential astrocytic
modulatory functions, such as Clozapine, Riluzole, Chromipramine and
Palmitoylethanolamide, may also be eﬀective at treating neuropathic
pain.
In addition to reduced T2 relaxation rates, we have previously
shown in individuals with chronic orofacial pain, the SpV displays re-
duced gray matter density, reduced mean diﬀusivity, increased infra-
slow oscillations and increased functional connectivity strengths with
brainstem endogenous pain modulation circuitry (Alshelh et al., 2016;
Mills et al., 2018; Wilcox et al., 2015). Despite altered functional con-
nectivity, we did not observe anatomical or infra-slow oscillatory
changes in brainstem pain modulating regions such as the periaque-
ductal gray, dorsolateral pons, subnucleus reticularis dorsalis or ros-
troventromedial medulla. Given this, we speculate that the anatomical
changes and resting oscillation changes that occur in SpV reﬂect as-
trocyte activation that results from excitotoxic damage and is ex-
acerbated by reduced endogenous analgesic circuitry action at the level
of SpV. Future studies are needed to provide solid evidence that such a
chain of events occurs.
Finally, there are several limitations that need to be noted. Firstly,
as mentioned above, altered T2 relaxation times are not a direct index
of astrocyte activation and further combined MRI and histochemical
investigations are needed to determine precisely how astrocyte acti-
vation alters T2 relaxation times. Although PET studies may provide a
more accurate measure of glial activation, at this stage they are not
suited to measure changes at the primary aﬀerent synapse in the
brainstem or spinal cord. Secondly, it is diﬃcult to accurately localize
clusters to speciﬁc nuclei, particularly those in the brainstem, due to the
relatively low spatial resolution and the ﬁne compartmentalization of
brainstem nuclei. Increasing MRI ﬁeld strengths and greater accuracy of
brainstem spatial normalization procedures will improve our con-
ﬁdence in brainstem-speciﬁc analysis in future investigations. Thirdly,
whilst we found that medication use had no eﬀect on T2 relaxation
times, this ﬁnding should be interpreted with caution given the small
number of subjects taking acute and preventive medications. Despite
these limitations, the discrete localization of decreases in T2 relaxation
times found in chronic orofacial neuropathic pain subjects in this in-
vestigation, together with existing human and pre-clinical evidence,
makes us conﬁdent that astrocytes play a critical role in the develop-
ment and the maintenance of neuropathic pain following nerve injury.
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CHAPTER FOUR 
EFFECTS OF GLIAL MODULATOR PALMITOYLETHANOLAMIDE 
ON CHRONIC PAIN INTENSITY AND BRAIN FUNCTION 
Chapter Four was submitted to Nature Medicine 
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ABSTRACT: 
Background: Chronic neuropathic pain is a complex disease that results from damage or 
presumed damage to the somatosensory nervous system. Current treatment regimens are 
often ineffective and have significant side-effects. The major impediment in developing more 
effective treatments is our limited understanding of the underlying mechanisms. Preclinical 
and post-mortem evidence suggests that glial changes are crucial for the development of 
neuropathic pain and a recent brain imaging study reported slow oscillatory activity differences 
within the ascending pain pathway at frequencies similar to that of cyclic gliotransmission in 
neuropathic pain. Furthermore, there is evidence that glial modifying medications may be 
effective in treating neuropathic pain. The aim of this phase 1 open-label clinical trial is to 
determine if the glial modifying medication palmitoylethanolamide (PEA) will reduce 
neuropathic pain and if this is associated with reductions in oscillatory activity within the pain 
pathway. Methods: Using resting state functional magnetic resonance imaging and arterial 
spin labelling, we investigated whether 6 weeks of PEA treatment would reduce on-going pain 
and infra-slow oscillatory activity within the ascending trigeminal pathway in 22 individuals with 
chronic orofacial neuropathic pain. Results: PEA reduced pain in 16 (73%) of the 22 subjects, 
11 subjects had a pain reduction of over 20%. Those that responded to PEA had an average 
pain reduction of 2.1±0.3 (out of 10) and non-responders an increase of 0.6±0.5. Whilst both 
the responders and non-responders showed reductions in infra-slow oscillatory activity where 
orofacial nociceptor afferents terminate in the brainstem, only responders also displayed 
reductions in the thalamus. Furthermore, functional connections between the brainstem and 
thalamus were altered only in PEA responders. Interpretation: PEA is effective at relieving 
neuropathic pain without side-effects. This reduction is coupled to a reduction in resting 
oscillations along the ascending pain pathway that are likely driven by rhythmic astrocytic 
gliotransmission. Funding: Australia NMHRC, G160279 and G182968 and NGW Macintosh 
memorial fund. 
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Chronic neuropathic pain is a complex disease state that results from damage or presumed 
damage to the somatosensory nervous system. Current treatment regimens such as non-
steroidal anti-inflammatory medication, tricyclic antidepressants and anticonvulsants are often 
ineffective and have significant side-effects and consequently, many individuals suffer with 
considerable pain for years or even decades. The major impediment in developing more 
effective treatment regimens for neuropathic pain is our limited understanding of the 
mechanisms responsible for the development and maintenance of neuropathic pain following 
injury. 
 
Critically, neuropathic pain is not associated with prolonged activity increases in the classic 
“pain pathways” but instead is associated with altered brain rhythm. This altered rhythm is 
characterized by increased thalamic burst firing, thalamocortical power, and infra-slow 
oscillations (<0.1Hz) along the ascending pain pathway 1-3. Whilst it is not known how these 
altered rhythms are generated, the infra-slow oscillation increases occur at approximately the 
same frequency range as calcium waves in astrocytes, i.e. 0.03-0.06Hz 4. Astrocytes can 
modulate synaptic activity by the release of gliotransmitters and there is preclinical and post-
mortem human evidence of prolonged astrocyte activation in the dorsal horn/spinal trigeminal 
nucleus in neuropathic pain 5,6. Furthermore, preclinical studies have shown that following 
nerve injury, increased astrocyte activation is associated with allodynia and hyperalgesia 7,8 
and blocking astrocyte activation reverses this allodynia and hyperalgesia 9-11. 
 
Palmitoylethanolamide (PEA) is a naturally occurring fatty acid amide that belongs to the N-
acetylethanolamine family. It is thought that PEA targets alpha peroxisome proliferator-
activated receptors (PPAR-α) 12-16, which are expressed on neurons and  astrocytes 17,18 and 
are activated as a response to nerve damage 19,20. There have been numerous clinical trials 
exploring the effects of PEA in various pain states and critically, PEA has reportedly no serious 
side-effects 21. If PEA can reduce neuropathic pain without any serious side-effects, this would 
be a major advance in the way in which we treat chronic neuropathic pain and significantly 
reduce the economic and social burden of this debilitating condition. The aim of this 
investigation is to provide evidence that PEA reduces the intensity of on-going pain and 
reverses the increase in infra-slow oscillatory activity within the primary afferent synapse in 
individuals with chronic neuropathic pain.  
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RESULTS:  
 
Psychophysics: 
 
Prior to PEA treatment, NP subjects had on-going pain of 4.5±0.4 VAS, pain duration of 
4.1±1.3 years and 5 NP subjects were taking Serotonin-Noradrenaline Reuptake Inhibitors. 
PEA treatment resulted in no reported side-effects and an overall reduction in on-going pain 
intensity of 0.7±0.4 VAS or 21.2±11.4% (Table 1). Overall, PEA treatment reduced pain in 16 
(73%) of the 22 NP subjects. Dividing subjects into responders (>20% pain reduction) and 
non-responders (<20% pain reduction) resulted in 11 subjects as responders and 11 as non-
responders (Figure 1A). Responders had an average pain reduction of 2.1±0.3 VAS or 
61.9±7.2% and non-responders an overall increase of 0.6±0.5 VAS or 19.6±12.8% (Figure 
1B). Cohen’s D showed that as a whole group, the effect size was small (d=0.3). However, in 
the responders, the effect size is large (d=1.8) and in the non-responders, the effect size is 
small (d=0.3). Although there was a significant difference in the magnitude of pain intensity 
reduction between groups, there was no significant change in the area of pain in response to 
PEA treatment in either group (mean±SEM pixels: responders prePEA 1143±494, postPEA 
416±187; non-responders prePEA 7935±4325, postPEA 6890±3841, both p>0.05) (Figure 
1C). 
 
In addition to differences in the responsiveness to PEA treatment, responders had a 
significantly lower pain intensity (3.4±0.3 VAS) compared with non-responders (5.6±0.7 VAS) 
prior to PEA treatment (p<0.05). There was however, no significant difference in pain duration 
(responders 3.0±1.5 years, non-responders 5.2±2.1 years, p>0.05) or the area of perceived 
pain (responders 1143±494 pixels, non-responders 7935±4325 pixels, p>0.05) between 
groups before PEA treatment.  
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 Figure 1: Subject psychophysics. A) daily pain intensity ratings in each of the 22 patients pre- 
palmitoylethanolamide (PEA) treatment and post-PEA treatment separated into responders (>20% pain 
reduction) and non-responders (<20% pain reduction). Pain intensity was rated three times daily on a 
10cm visual analogue scale (VAS); B) mean (±SEM) pain intensity ratings pre- and post-PEA in the 
responder (n=11) and non-responder (n=11) groups; C) areas of on-going pain pre- and post-PEA in 
the responder and non-responder groups. 
 
 
Infra-slow oscillatory activity and functional connectivity: 
 
PEA treatment had a significant effect on regional resting infra-slow oscillations in both the 
responder and non-responder groups. Remarkably, in both the responder and non-responder 
groups, PEA treatment significantly reduced on-going infra-slow oscillatory activity in the 
region encompassing the ipsilateral (to side of on-going pain) spinal trigeminal nucleus (SpV), 
i.e., the region where nociceptor afferents from the area of on-going pain terminate (Figure 2, 
Table 2). Whilst both responders and non-responders displayed reduced oscillatory activity in 
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SpV, only the responders also displayed significant oscillatory activity reductions in the 
upstream target of SpV, i.e., in the region of the ventroposterior (VP) thalamus (Figure 3). In 
addition to changes in the ascending trigeminal pathway, the non-responders displayed 
oscillation decreases in the midbrain including the region of the periaqueductal gray matter 
(PAG), the anterior and posterior cingulate cortices and increases in the precuneus. 
Furthermore, in the responders, PEA treatment also resulted in oscillation decreases in the 
dorsolateral pons, hippocampus, lateral prefrontal cortex and precuneus. 
 
 
Figure 2: Effects of palmitoylethanolamide (PEA) on infra-slow oscillations. A) Differences in 
fractional amplitude of low-frequency fluctuations (fALFF) pre-PEA compared with post-PEA 
treatment on non-responders. Significant increases (hot colour scale) and decreases (cool colour scale) 
in fALFF are overlaid onto a series of axial and sagittal T1-weighted anatomical slices. Slice locations 
in Montreal Neurological Institute space are indicated at the top right of each slice. B) Differences in 
fALFF pre-PEA compared with post-PEA treatment in responders. Note that fALFF decreased in the 
spinal trigeminal nucleus (SpV) in both responders and non-responders and in the ventroposterior (VP) 
thalamus only in responders.  ACC: anterior cingulate cortex; dlPons: dorsolateral pons; PAG: midbrain 
periaqueductal gray matter; PCC: posterior cingulate cortex. 
 
The extraction of fALFF values from the SpV and VP thalamus confirmed that PEA treatment 
resulted in significant reductions in infra-slow oscillations in the SpV in both responders and 
non-responders and reductions in the VP thalamus in the responder group only (Figure 3). 
Furthermore, only responders displayed a significant change in resting connectivity between 
the SpV and VP thalamus in response to PEA treatment. That is, prior to PEA treatment there 
was a significant signal covariation between the SpV and VP thalamus in responders which 
was subsequently completely eliminated by PEA treatment (SpV-VP thalamus connectivity: 
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responders prePEA 0.18±0.07 post PEA 0.01±0.04, p<0.05). In contrast, PEA treatment had 
no effect on SpV-VP thalamus connectivity in the non-responders (prePEA 0.09±0.06 post 
PEA 0.04±0.05, p>0.05).  
 
 
Figure 3: Effects of palmitoylethanolamide (PEA) on ascending pain pathway. To the right are 
plots of mean (±SEM) fractional amplitude of low-frequency fluctuations (fALFF) and cerebral blood flow 
(CBF) in responders (blue) and non-responders (green), pre-PEA and post-PEA treatment. Note that 
both the responders and non-responders have a significant reduction in infra-slow oscillations in the 
spinal trigeminal nucleus, but only the responders have a decrease in the ventroposterior thalamus. In 
contrast there are no changes in CBF. The regions in which fALFF decreases as a consequence of 
PEA treatment are colour coded blue (responders) and green (non-responders) and overlaid onto axial 
T1-weighted anatomical slices. To the left of these overlays are plots of mean (±SEM) resting functional 
connectivity between the spinal trigeminal nucleus and ventroposterior thalamus. Note that functional 
connectivity decreases significantly following PEA treatment in the responders only. *p<0.05 derived 
from voxel-by-voxel analysis; # p<0.05 derived from two-sample t-test. 
 
 
In addition, the change in infra-slow oscillations within the ascending trigeminal pathway was 
not associated with changes in overall activity levels as evidenced by no change in resting 
blood flow in either the SpV (ml/min/100g: responders prePEA 98.7±7.9 post PEA 87.4±10.7, 
non-responders prePEA 79.9±10.5 post PEA 81.8±9.4, p>0.05) or the VP thalamus 
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(responders prePEA 43.9±6.1 post PEA 54.8±8.5, non-responders prePEA 28.9±5.4 post 
PEA 45.8±8.6, p<0.05). 
 
Correlations between changes in pain intensity and changes in infra-slow oscillations revealed 
significant clusters in the SpV and VP thalamus overlapping those significant clusters revealed 
in the pre versus post fALFF analysis (Figure 4). In responders, the magnitude of the decrease 
in infra-slow oscillations was significantly positively correlated with a decrease in pain intensity 
during PEA treatment in both the region of the SpV (r=0.83, p<0.05) and VP thalamus (r=0.93, 
p<0.05). In contrast, no significant correlations occurred in non-responders in the SpV (r=0.04, 
p>0.05) or VP thalamus (r=0.28, p>0.05). 
 
Figure 4: Relationships between changes in pain intensity and infra-slow oscillations as a result 
of palmitoylethanolamide (PEA) treatment. Significant positive linear relationships between changes 
in on-going pain and fractional amplitude of low-frequency fluctuations (fALFF) in the thalamus and 
medulla are shown overlaid onto axial T1-weighted anatomical slices for the responder group only 
(yellow shading). Note no such relationship occurred in the non-responders. Slice locations in Montreal 
Neurological Institute space are indicated at the top right of each slice. The location of significant 
decreases in infra-slow oscillations (ISO) pre- versus post-PEA are also shown (light blue shading); 
note the overlap within the spinal trigeminal nucleus and ventroposterior thalamus. To the right are plots 
of change in fALFF versus percent change in pain for the SpV and VP thalamus cluster in responders 
and non-responders pre- versus post-PEA treatment. In responders, the greater the reduction in fALFF 
the greater the reduction in pain intensity. 
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DISCUSSION: 
 
This investigation describes the effects of PEA on on-going pain and brain function in patients 
with chronic orofacial neuropathic pain. PEA reduced pain intensity in almost 75% of patients 
with 50% of all patients exhibiting an overall decrease of over 20% with no recorded side-
effects. Additionally, PEA altered regional brain function by reducing infra-slow oscillatory 
activity in the ascending trigeminal pain pathway. More specifically, our results show that 
altered activity patterns and connectivity within the trigeminal pathway is associated with an 
individual’s pain relief responsiveness to PEA treatment. Whilst three previous investigations 
have reported neuropathic pain relief as a result of PEA treatment 22-24 this is the first to show 
that the effectiveness of PEA is associated with altered activity patterns in the ascending pain 
pathway. Critically, like our study, no clinical trial using PEA for pain or any other condition 
has reported significant side-effects. 
 
We have previously shown that chronic orofacial neuropathic pain is associated with an 
increase in resting infra-slow oscillations along the ascending trigeminal pain pathway, 
including the SpV, VP thalamus, thalamic reticular nucleus and primary somatosensory cortex 
25,26. Given that there is preclinical and human post-mortem evidence of chronic astrogliosis in 
the SpV/dorsal horn in individuals with neuropathic pain and that the oscillations were at the 
same approximate frequencies in which astrocyte calcium and gliotransmission release have 
been recorded, we speculate that these oscillatory activity increases were the result of chronic 
astrogliosis. Astrocyte calcium can propagate to neighbouring astrocytes either directly 
through connecting channels or indirectly through the release of gliotransmitters to produce 
synchronous oscillatory gliotransmitter release 27,28. This oscillatory astrocyte function can 
elicit long-lasting NMDA-mediated currents in surrounding neurons 4 and there is recent 
evidence that astrocytes can elicit long lasting increases in neural firing 29. We have proposed 
that following nerve injury, excess activity within primary afferent neurons results in neural 
death and elicits astrocyte activation at the primary afferent synapse. This results in more 
regular and increased oscillatory gliotransmitter release and increased infra-slow neural 
oscillations which are transferred along the ascending pain pathway. The recurrent nature of 
thalamocortical circuits results in self-sustaining thalamocortical dysrhythmia, paroxysmal 
events and the constant perception of pain 1,30,31.  
 
Consistent with this hypothesis, the present investigation found that PEA administration 
resulted in a reduction in both pain intensity and oscillatory activity within the ascending 
trigeminal pain pathway. PEA is abundant in the central nervous system and there is 
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preclinical evidence that neuropathic pain is associated with reductions in PEA levels in the 
ipsilateral spinal cord and that these levels increase following pain relief 32. PEA is produced 
by glial cells 33 and has been studied primarily for its anti-inflammatory and neuroprotective 
effects 34-36. Whilst PEA can exert its effects via multiple mechanisms, critically, it has been 
shown to blunt astrocyte activation in vitro and improve neuronal survival through selective 
peroxisome proliferator activated receptor-alpha (PPAR-α) activation 37. Indeed, PEA fails to 
exert its anti-nociceptive effects in PPAR-α knockout mice 12,14,38-40. 
 
We found that in all patients, oral administration of PEA resulted in significant reductions in 
infra-slow oscillations specifically at frequencies similar to those of astrocyte calcium waves 
(0.03-0.06Hz) in the ipsilateral SpV. However, only in individuals in which PEA evoked a 
significant reduction in pain did a similar reduction in neural oscillations also occur in the VP 
thalamus. Furthermore, PEA treatment eliminated the resting neural covariation between SpV 
and VP thalamus only in responders. These results suggest that whilst PEA blunts the 
increase in resting neural oscillatory activity at the region of the primary afferent synapse in all 
patients, only when this reduction is then transferred to higher brain centres such as the 
thalamus does an analgesia result. Indeed, only in responders was the reduction in neural 
oscillation power significantly correlated to the reduction in pain, i.e. the greater the reduction 
in oscillations the greater the reduction in on-going pain. This is entirely consistent with the 
results from an experimental animal model of neuropathic pain in which infra-slow oscillatory 
activity in the VP thalamus was eliminated by severing the connection between the primary 
afferent synapse and the thalamus 41.  
 
Whilst we suggest that in individuals with chronic neuropathic pain, PEA produces pain relief 
via its effects on astrocyte function, PEA may also exert effects via a number of other 
mechanisms. Within the central nervous system, PPAR-α receptors act via two main 
mechanisms; a rapid effect which involves activation of calcium dependant potassium 
channels which has a silencing effect on neuronal firing 15 and a slower effect which is 
comprised of neurosteroid de novo synthesis which increases allopregnanolone production 
42,43. Allopregnanolone is a positive allosteric modulator of GABA action and slows the rate of 
recovery of GABA receptors 44,45. In addition to a potential action on neuronal GABA receptors, 
PEA may influence GABA receptors on astrocytes, which when activated can increase 
intracellular calcium levels 46. Interestingly, astrocyte calcium wave propagation is dependent 
upon mechanisms which include the removal of excess calcium by mitochondria to prevent 
IP3 receptor desensitisation 47,48. It is possible that PEA increases calcium concentrations 
thereby reducing the propagation of astrocyte calcium waves and associated gliotransmission. 
Interestingly, all of the five patients in this investigation that were also taking SSRIs reported 
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pain relief, although four of these subjects reported reductions that were small and were 
categorized as nonresponders. Whilst the precise mechanism of SSRIs it not known, it has 
been shown that they can increase the expression of GABAB receptors and alter astrocyte 
function directly, evoking astrocyte calcium transients in an often oscillatory manner, even 
when neural activity is inhibited 49,50. Given this, it is possible that SSRIs partially counteract 
the mechanism of PEA and thus reduce its overall analgesic effectiveness. 
 
It is also a possibility that PEA may act on other targets in the nervous system such as 
cannabinoids in neurons and astrocytes 51,52, PPAR-γ 53, or mast cells 54 to reduce pain. It is 
possible that PEA acts on multiple receptors in a number of sites to attenuate inflammation 
and pain associated with nerve damage 54. Furthermore, given that this was an open-label 
clinical trial, we did not control for the potential effects of placebo. However, it is unlikely that 
the decrease in pain intensity in the responders was solely due to the placebo effect. In fact, 
a Cochrane meta-analysis showed that over a number of investigations, the effect size of a 
placebo response, measured as Cohen’s d, is 0.27 55. In this investigation, the effect size as 
a whole group is 0.3, which may indeed be due to a placebo effect. However, in the responders 
only, the effect size is 1.8, suggesting that the response in the responders in not a placebo 
effect. Nonetheless, the decreases in pain intensity correlate with a change in neural activity 
in the responders as a result of PEA. 
 
 
 
 
 
 
 
 
 
 
  
70
Online methods: 
 
Subjects: Twenty two subjects with chronic orofacial neuropathic pain (17 females; 
mean±SEM age, 50.5± 3.0 years) were recruited for the study. Neuropathic pain (NP) subjects 
were diagnosed using the Liverpool criteria as having posttraumatic neuropathy 56. Subjects 
were excluded if they had any psychiatric conditions, any other pain conditions or did not meet 
standard MRI inclusion criteria. Informed written consent was obtained for all procedures 
according to the Declaration of Helsinki, and our local Institutional Human Research Ethics 
Committees approved the study.  
 
Study Design: All subjects completed two magnetic resonance imaging (MRI) sessions, 6 
weeks apart. During the 7 days prior to the start of PEA treatment and the first MRI session, 
subjects kept a pain diary in which they recording the intensity of their on-going pain, three 
times a day. Subjects rated the intensity of their pain using a 10 cm horizontal visual analogue 
scale (VAS), with 0 indicating “no pain” and 10 indicating “the most intense imaginable pain”. 
These 21 pain intensity scores were then averaged over the 7 day period to create a mean 
pain intensity score prior to PEA treatment. On the day of their first MRI scanning session, 
each NP subject outlined the location of their on-going pain on a standard drawing of the head 
and completed a McGill Pain Questionnaire. Following their first MRI scanning session, each 
NP subject began PEA treatment and at six weeks, a second MRI session was performed. 
During the 7 days prior to the second MRI scan, subjects kept another pain diary recording 
the intensity of their on-going pain. On the day of the second MRI scan, subjects outlined the 
location of their on-going pain on a standard drawing of the head and completed a McGill Pain 
Questionnaire. 
 
Interventions: NP subjects obtained the PEA from Visionary Health Compounding Chemist, 
Newcastle, Australia in the form of 300mg capsules, with dosage individualised between 
600mg to 900mg, 3 times a day.  
 
 
 
MRI Acquisition: For each MRI scanning session, NP and control subjects lay supine on the 
bed of a 3 Tesla MRI scanner (Achieva; Phillips) with their head immobilized in a tight-fitting 
head coil. With each subject relaxed and at rest, a series of 180 gradient echo echo-planar 
functional MRI (fMRI) image volumes using blood oxygen level-dependent contrast were 
collected. Each image volume contained 35 axial slices covering the entire brain (field of view 
240x240mm; matrix size 80x78; slice thickness 4mm; repetition time 2000ms; echo time 
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30ms; flip angle 90⁰). Following this, a series of 108 pseudocontinuous arterial spin labeling 
(pCASL) images containing 50 axial slices covering the entire brain was collected (54 
label/control image pairs, field of view 240x240mm; matrix size 100x100; slice thickness 3mm; 
repetition time 5084ms, echo time 12.7ms, labelling time 1600ms, slice time 36.6ms, labeling 
efficiency 0.85, blood T1 relaxation time 1667ms). Finally, in each subject, a high-resolution 
3D T1-weighted anatomical image set covering the entire brain was also collected (turbo field 
echo; field of view, 250x250 mm; matrix size 288x288; slice thickness 0.87mm; repetition time 
5600ms; echo time 2.5ms; flip angle 8⁰).  
 
Pain intensity changes: At the completion of the 6 week treatment period, NP subjects’ pain 
intensity changes were assessed. To explore the association between pain intensity 
reductions and changes in brain function, NP subjects were divided into those that responded 
to PEA treatment, i.e. responders: greater than 20% reduction in pain intensity, and non-
responders: less than 20% reduction in pain intensity. To determine the effect size of changes 
in pain intensity in responders and non-responders, Cohen’s d was calculated. This is used to 
determine whether the effect size is small (d=0.2), medium (d=0.5) or large (d=0.8) 57. 
Changes in pain distributions before and after treatment for each subject in the two groups 
separately, were determined using a paired t test (p<0.05, Bonferroni corrected).  
 
MRI Analysis; Infra-slow oscillations: Using SPM12 58, all functional magnetic resonance 
images were motion corrected, global signal drifts removed 59 and co-registered to each 
individual’s T1-weighted image set. Each subject’s T1-weighted anatomical image was then 
spatially normalized to a template in Montreal Neurological Institute (MNI) space and the 
parameters applied to the fMRI image sets. All images were then spatially smoothed (6mm 
full-width half-maximum [FWHM] Gaussian filter). In those subjects with pain restricted to the 
left side of the face (n=12), resting fMRI scans were reflected across the midline so that, in all 
subjects, the right side was ipsilateral to on-going pain. To perform a brainstem specific 
analysis, the fMRI images were cropped to include only the brainstem and cerebellum and a 
mask of these regions created automatically using the SUIT toolbox 60. These 
brainstem/cerebellum masks were then manually adjusted to accurately encompass the 
brainstem and cerebellum only. Using this mask, fMRI brainstem images were spatially 
normalized to the Spatial Unbiased Infratentorial Template in MRI space and spatially 
smoothed using a 3mm FWHM Gaussian filter. 
 
To determine regional changes in infra-slow oscillation (ISO) power, we used the SPM toolbox 
REST 61 to calculate the sum of amplitudes of low frequency fluctuations (ALFF) in the 
frequency band 0.03-0.06Hz for the brainstem only and wholebrain fMRI image sets. ALFF 
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values were then divided over the entire frequency range to obtain fractional ALFF (fALFF) 
value for each voxel. Using the wholebrain and brainstem only images, the effects of PEA 
treatment on fALFF were determined in all 22 NP subjects using a paired random effects 
procedure. In addition, the effects of PEA on fALFF values were determined in the responder 
and non-responder groups separately using paired random effects procedures. Following an 
initial threshold of p<0.001, small volume corrections were used to account for the effects of 
multiple comparisons (p<0.05 Bonferonni corrected). For each analysis, the 6 movement 
parameters derived from the realignment step and signal intensity derived from a 3mm sphere 
located in the 4th ventricle were included as nuisance variables. For each significant cluster, 
fALFF values were extracted from each subject and the mean (±SEM) plotted. 
 
We also determined the relationships between changes in fALFF over the treatment period 
and the associated change in pain intensity. In each voxel, the change in fALFF during PEA 
treatment (pre-post PEA) were calculated and voxel-by-voxel correlations between this fALFF 
change and the percent change in pain intensity were performed for the responder and non-
responder groups separately (movement and CSF signal included as nuisance variables). 
Following an initial threshold of p<0.001, small volume corrections were used to account for 
the effects of multiple comparisons (p<0.05 Bonferonni corrected).  
 
In addition, we also performed a functional connectivity analysis using a seed placed into the 
region of the spinal trigeminal nucleus (SpV). This seed was based on the results of the fALFF 
comparison pre compared to post PEA treatment in the responder group. Signal intensity 
changes from the SpV were extracted in each individual subject and correlations between this 
signal and every voxel in the brainstem only and wholebrain image sets determined 
(movement parameters and CSF signal included as nuisance variables). Connectivity values 
between the SpV and the ventroposterior thalamus (a cluster based on the results from the 
fALFF analysis) were extracted for each subject and significant differences between pre and 
post PEA treatment and between responder and non-responder groups determined using 
paired and two group t tests (p<0.05, Bonferroni corrected). 
 
MRI Analysis; resting blood flow: All pCASL image sets were realigned, co-registered to each 
individual’s T1-weighted image set, the label and control images averaged and a mean 
cerebral blood flow (CBF) image created using the subtraction method using the ASL toolbox 
(Wang et al., 2008). Wholebrain and brainstem only CBF maps were then normalized into MNI 
space and smoothed in the same manner as the fMRI images sets. For each significant cluster 
derived from the fALFF analysis, blood flow values were extracted for each subject and the 
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mean values plotted for each subject before and after treatment and significance differences 
determined using paired t tests (p<0.05, Bonferroni corrected).  
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Table 1: Subject characteristics: PEA: palmitoylethanolamide; SSRI: Selective Serotonin 
Reuptake Inhibitors; VAS: visual analogue scale. 
 
 
 
 
  
subject age 
(years) 
gender pain 
duration 
(years) 
Site pain rating 
pre PEA 
(VAS) 
pain rating 
post PEA 
(VAS) 
pain rating 
change  
(VAS[%]) 
medication 
(not including 
PEA treatment) 
860 33 F 7 left 2.1 0.8 -1.3 [-61.9] - 
864 21 M 0.3 left 3.7 1.3 -2.4 [-64.9] - 
867 64 F 17 right 3.8 0.3 -3.5 [-92.1] - 
869 76 F 25 left 5.5 4.7 -0.8 [-14.5] SSRI 
871 47 F 2.8 left 3.6 0.6 -3.0 [-83.3] - 
873 40 F 1.5 right 5.1 2.9 -2.2 [-43.1] - 
874 46 F 0.6 left 3.2 0.7 -2.5 [-78.1] - 
875 52 F 0.8 right 2.7 1.0 -1.7 [-63.0] SSRI 
876 58 M 1.8 left 9.6 8.8 -0.8 [-8.3] SSRI 
882 44 M 3.3 bilateral 7.3 8.2 +0.9 [+12.3] - 
883 47 F 0.4 right 1.9 3.8 +1.9 [+100] - 
884 65 F 10 left 6.1 7.6 +1.5 [+24.6] - 
890 64 F 0.3 right 1.4 1.1 -0.3 [-21.4] - 
898 44 F 2.3 right 3.8 3.2 -0.6 [-15.8] SSRI 
945 39 F 2.6 left 5.6 5.8 +0.2 [+3.6] - 
947 74 F 0.4 bilateral 4.4 8.7 +4.3 [+97.7] - 
950 29 M 5.8 left 6.6 5.6 -1.0 [-15.2] opioid+SSRI 
956 46 F 1.0 right 3.6 1.2 -2.3 [-66.7] - 
958 55 F 1.1 right 2.6 0.4 -2.3 [-84.6] - 
975 57 F 0.7 left 5.2 4.0 -1.2 [-23.1] - 
990 65 M 4 left 3.5 4.7 +1.2 [+34.3] - 
996 46 F 1.8 left 7.5 7.3 -0.2 [-2.7] - 
mean 
±SEM 
50.5±3.0  4.1±1.3  4.5±0.4 3.8±0.6 -0.7±0.4 
[-21.1±11.4] 
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Table 2. Montreal Neurological Institute (MNI) coordinates, cluster size and t-score for regions of 
significant differences in fractional amplitude of low-frequency fluctuations between pre- and post-
palmitoylethanolamide treatment. 
 
 
Brain region MNI Co-ordinate 
cluster 
size t-score   
 x y z   
Responders      
pre>post palmitoylethanolamide treatment 
 
dorsolateral pons 
spinal trigeminal nucleus 
left ventroposterior thalamus 
right dorsal thalamus 
anterior cingulate cortex 
hippocampus 
precuneus 
 
posterior parietal association cortex 
ventrolateral prefrontal cortex 
 
post>pre palmitoylethanolamide treatment 
caudate nucleus 
cerebellar cortex 
 
 
Correlations with pain 
increases 
spinal trigeminal nucleus 
ventroposterior thalamus 
anterior cingulate cortex 
decreases 
dorsolateral prefrontal cortex 
 
 
6 
10 
-14 
18 
4 
-32 
-10 
-4 
52 
-46 
 
 
-14 
-4 
 
 
 
 
8 
-18 
-8 
 
-48 
-44 
 
 
-30 
-44 
-22 
-22 
26 
-12 
-44 
-66 
-54 
30 
 
 
20 
-74 
 
 
 
 
-46 
-26 
34 
 
26 
26 
 
 
-19 
-53 
6 
12 
32 
-22 
48 
26 
24 
-10 
 
 
0 
-16 
 
 
 
 
-55 
8 
20 
 
14 
30 
 
 
15 
5 
10 
17 
10 
19 
15 
9 
15 
16 
 
 
10 
23 
 
 
 
 
3 
18 
17 
 
26 
12 
 
 
4.62 
5.40 
4.18 
4.76 
6.16 
7.17 
5.24 
3.74 
3.93 
5.70 
 
 
4.32 
4.25 
 
 
 
 
3.89 
6.36 
8.78 
 
5.95 
9.34 
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CHAPTER FIVE 
CONCLUSIONS 
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The overarching aim of this thesis was to investigate altered neural and glial activity in chronic 
orofacial neuropathic pain and the effects of palmitoylethanolamide (PEA) on neural activity. This 
chapter will summarise the main findings of each investigation, discuss the implications of these 
findings, and finally will provide recommendation for future research based on the questions that 
were raised by this thesis.  
5.1 Main findings 
The primary aim of Chapter 2 was to explore infra-slow oscillatory activity using resting state 
functional magnetic resonance imaging (fMRI) in patients with chronic orofacial neuropathic pain 
compared to healthy controls. Initially, resting oscillatory activity was explored at frequencies 
between 0.01 – 0.25 Hz, which was subsequently restricted to a frequency band between 0.03 – 0.06 
Hz. Furthermore, Chapter 2 also assessed the effects of the infra-slow oscillatory (ISO) activity on local 
network connectivity (degree centrality), and local signal covariations (regional homogeneity) in 
patients and compared to controls.  
The results of Chapter 2 revealed a significant increase in resting infra-slow oscillatory activity in 
patients with orofacial neuropathic pain in areas of the ascending pain pathway, that is, the spinal 
trigeminal nucleus, the ventral posterior (VP) thalamus, the thalamic reticular nucleus (TRN) and the 
primary somatosensory cortex (S1). Interestingly, this increase in infra-slow oscillatory activity in 
patients was restricted to the frequency band of 0.03 – 0.06 Hz in all regions of the ascending pain 
pathway. The study also revealed an increase in degree centrality in the same regions of the ascending 
pain pathways in patients and a significant increase in regional homogeneity in the spinal trigeminal 
nucleus in patients compared with controls. Furthermore, resting infra-slow oscillations within the 
ascending pain pathway were temporally coupled, suggesting that these signals may be generated at 
spinal trigeminal nucleus and then transmitted to the thalamus and the S1.  
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To assess whether the increase in infra-slow oscillatory activity was a characteristic of chronic 
neuropathic pain or whether similar increases also occurred along the ascending pain pathway in pain-
free controls during an acute orofacial noxious stimulus, the same analysis during acute orofacial pain 
in healthy controls was performed. There were no increases in infra-slow oscillatory activity in these 
subjects in regions of the ascending pain pathway. There were, however, some decreases in infra-slow 
oscillatory activity in other regions of the central nervous system (CNS) and this is addressed in another 
research article in the appendix.  
 
There is growing evidence that astrocytes can modulate neural activity through the release of 
gliotransmitters and that this release occurs in an oscillatory manner at similar frequencies to that of 
the increases along the ascending pain pathway identified in Chapter 2. This hypothesis led directly to 
the research that comprises Chapter 3 of this thesis. Chapter 3 aims to investigate whether the ISO 
changes observed in Chapter 2 are due to astrogliosis, measured using T2 relaxometry. While T2 
relaxometry is not widely used to measure astrocyte activation, research suggests that a decrease in 
T2 relaxation time is associated with an increase in astrocyte activation, and can therefore be used as 
an indirect measure of astrocyte activation. Results of Chapter 3 demonstrated that in patients with 
chronic orofacial neuropathic pain, there were decreases in T2 relaxation time in specific regions of 
the ascending pain pathway, that is; the spinal trigeminal nucleus and the primary somatosensory 
cortex. These decreases in T2 relaxation time are characteristic of an increase in astrocyte activity in 
these regions of the ascending pain pathway, which is consistent with our hypothesis of increased 
astrocyte activation along the ascending pain pathway in individuals with chronic orofacial pain.  
 
Together, the results of Chapter 2 and 3 suggest that chronic neuropathic pain is associated with an 
increase in ISOs due to chronic astrocyte activation. Therefore, it is possible that decreasing astrocyte 
activity may reduce pain intensity or abolish pain in these patients. As such, Chapter 4 explores the 
82
effects of exogenous palmitoylethanolamide (PEA), an astrocyte modulator, on infra-slow oscillatory 
activity and pain intensity in patients with orofacial neuropathic pain. The results of Chapter 4 showed 
that there is a pain reduction in over 75% of patients and half of all the patients have an overall 
decrease in pain intensity of over 20% (responders). Whilst all patients displayed a significant 
reduction in ISO within the spinal trigeminal nucleus following PEA treatment, only those patients with 
a pain reduction of 20% or more, also displayed ISO reductions in higher regions of the trigeminal 
pathway, that is in the VP thalamus. Furthermore, only in these responders did PEA treatment evoke 
a significant decrease in resting connectivity between the spinal trigeminal nucleus and thalamus only 
suggesting that a decrease in connectivity within regions of the pain pathway is essential for pain 
relief.  
 
5.2 Implications 
The findings of this thesis indicate that infra-slow oscillatory activity is a fundamental part of pain 
processing and may be modulated by astrocytes. The findings indicate that the role of astrocytes in 
chronic neuropathic pain is more important than previously suggested, which was to provide 
metabolic and physical support to other neural cells (Kıray et al., 2016). While it is currently not 
possible to non-invasively measure astrocyte activity in patients with neuropathic pain, our results 
strongly suggest that there in an increase in astrocyte activity associated with increase in ISOs in 
neuropathic pain and that reducing astrocyte activity and ISOs in certain regions of the ascending pain 
pathway reduces the intensity of pain in some patients. 
 
The role of ISOs in the brain is fundamental to cerebral and thalamic function and has been studied in 
several investigations. In the somatosensory thalamus of the cat, ISOs are sustained largely by 
adenosine receptor mediated signalling, and this can be enabled by the activation of metabotrophic 
glutamate and/or acetylcholine receptors (Lőrincz et al., 2009). While the underlying mechanisms 
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responsible for ISOs is not yet well understood, it is suggested that astrocytes may play an important 
role. As astrocytes can display spontaneous intracellular calcium oscillations at frequency similar to 
ISOs, which can then propagate to nearby astrocytes, it is thought that within the thalamus, astrocytes 
release adenosine to modulate neural activity (Parri and Crunelli, 2003). Astrocytes are also responsive 
to glutamate and acetylcholine, and a link between ATP and ISOs has been demonstrated in the cortex 
(Cunningham et al., 2006). 
 
In the somatosensory thalamus of neonatal rats, astrocytes display spontaneous calcium oscillations 
that can be regular or irregular in nature (Parri and Crunelli, 2002), and a proportion of astrocytes, 
called pacemaker cells, display regular oscillations with a periodicity of approximately 0.01 Hz (Parri 
and Crunelli, 2002). A recent investigation showed that astrocytes have the capability of directly 
generating action potentials in interneurons, which can last for tens of seconds and this correlated 
with calcium wave signalling (Deemyad et al., 2018). These calcium waves can propagate to 
surrounding astrocytes and elicit long lasting NMDA-mediated currents in neurons (Crunelli et al., 
2002). It is believed that the mechanisms that underlie the irregular oscillations in astrocytic calcium 
waves are the same as the mechanism that generate the calcium wave oscillations. Therefore, it is 
possible that astrocytes are capable of transitioning from cells with irregular calcium oscillations to 
pacemaker-type cells (Parri and Crunelli, 2001). On the other hand, as astrocytes are capable of 
activating nearby astrocytes via calcium wave propagation through inositol triphosphate receptors 
(IP3) (Scemes and Giaume, 2006), it is also possible that astrocytes cause an increase in ISOs by 
increasing the number of activated astrocytes in a wave-like pattern to produce waves of glutamate. 
These waves of glutamate then activate neurons in an oscillatory pattern and increase astrocytic 
processes (Lavialle et al., 2011).  
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 In our patient population, there is evidence of a change in the pattern of firing within regions of the 
ascending pain pathway when compared to healthy controls in the frequency range of 0.03-0.06 Hz. 
In this series of investigations, it is suggested that astrocytes play a role in developing these ISOs 
through either a transition between spontaneous irregular astrocytes to the pacemaker astrocytes, or 
by an increase in the production of calcium waves. It is possible that following nerve damage, 
astrocytes are transitioning into pacemaker astrocytes and result in an increase in regular pacemaker-
like activity or that neural damage results in an increase in the production of calcium waves causing 
the increase in astrocytic wave-like activity. Additionally, nerve damage may result in an increase in 
glutamine or acetylcholine, which results in the increase in adenosine from the activated astrocytes, 
causing the increase in ISO power (Parri and Crunelli, 2001).  
 
Importantly, animal studies using the chronic constriction model of neuropathic pain, report an 
increase in astrocyte activation in the primary afferent synapse of the spinal cord (Garrison et al., 
1991) and an increase in astrocytic processes in the periaqueductal gray (Mor et al., 2010a). 
Interestingly, it has been shown that astrocytic, and not microglial, activation contributes to the 
mechanical allodynia that occurs in a chemotherapy-induced neuropathic pain model (Ji et al., 2013). 
While some may argue that microglia also plays an important role in chronic neuropathic pain, it is 
likely that the initiation may indeed be due to microglia, however the chronicity is due to astrocytic 
activation in pain related regions such as the dorsal horn (Raghavendra et al., 2003). Another pain 
related regions that has also shown astrocytic changes is the midbrain periaqueductal grey following 
chronic constriction injury (Mor et al., 2010b). Remarkably, the increase in astrocyte activity was only 
evident in rats that showed sensory and behavioural changes, such as social interactions and 
dominance which suggests that changes in astrocyte activity may reflect sensory and/or behavioural 
changes. While there were no correlations between ISOs and depression or pain catastrophizing 
scores in Chapter 2, there is a correlation between reduced pain intensity and ISOs in the primary 
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afferent synapse and the thalamus in Chapter 4 of this investigation. This correlation suggests that the 
changes in astrocyte activity likely reflect sensory changes in our patient population rather than other 
complex behavioural changes, however, other behavioural changes and non-linear correlations with 
ISOs may also be possible.  
 
Consistent with this animal literature, there is evidence of altered anatomy of the primary synapse in 
patients with orofacial neuropathic pain, that is, a decrease in mean diffusivity which is a measure of 
free water movement (Wilcox et al., 2015). This decrease is could be attributed to increased astrocytic 
processes which occurs in neuropathic pain models in rats (Mor et al., 2010a), causing increased 
barriers for water. This investigated led to the suggestion that the increase in astrocyte activity at the 
primary synapse are associated with increase in ISOs which may be transferred to the thalamus. 
Interestingly, some studies have linked ISOs in the somatosensory system of humans with high 
frequency power fluctuations (Mantini et al., 2007). Evidently, an activation of glutamate receptors 
have shown to cause an increase in ISOs in the thalamus which causes rhythmic oscillations and 
paroxysmal events (Hughes et al., 2011). This result suggests that changes in astrocyte function at the 
primary synapse may result in an increase in thalamic ISOs, which underlies an increase in EEG power 
(Sarnthein et al., 2006). As the thalamocortical circuits are in a constant loop, this results in a self-
sustaining thalamocortical dysrhythmia and the constant perception of pain.  
 
Astrocytes play an important role in chronic neuropathic pain, therefore it would be ideal to directly 
measure astrocyte activity. However, with the current technology, it is impossible to non-invasively 
measure astrocytes in humans. Positron emission tomography can measure microglial activity with 
the use of radio ligands as markers (Banati et al., 2001; Loggia et al., 2015), however, the brainstem 
cannot be imaged using positron emission tomography due to technical limitations. Alternatively, T2 
relaxometry (an MRI sequence) can be used to indirectly measure astrocyte activity as it has been 
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associated with astrocyte activity (Jackson et al., 1994; Schwarz et al., 1996; Wagner et al., 2012). In 
Chapter 3 of this investigation there is a decrease in T2 relaxation time in regions of the ascending 
pain pathway and this is associated with an increase in astrocyte activity (Schwarz et al., 1996). 
Specifically, there are decreases in T2 relaxation time in the spinal trigeminal nucleus in patients with 
orofacial neuropathic pain. This suggests that, compared to controls, patients have an increase in 
astrocyte activity in the spinal trigeminal nucleus, yet no changes in thalamus. Although no changes 
were evident in the VP thalamus, it is possible that astrocytic activation in the spinal trigeminal nucleus 
may modulate thalamic activity via its direct neural connections. This is supported by Chapter 2, in 
which changes in ISOs in the spinal trigeminal nucleus and in the thalamus that were temporally 
coupled.  
 
If an increase in astrocyte activity was critical for the development of the increase in ISOs in the 
ascending pain pathway and the intensity of on-going pain, then reducing astrocyte activation should 
reduce ISOs and reduce the intensity of pain. This led to the suggestion that in trigeminal neuropathic 
pain, reducing astrocyte activity may reduce ISOs in areas of the trigeminal pain pathway and 
ultimately, reduce the intensity of orofacial pain. This theory was addressed in Chapter 4. An astrocyte 
modulator, PEA, was given to patients with chronic orofacial neuropathic pain and then these patients 
were grouped into two groups. Responders had a pain decrease of at least 20% and the remaining 
patients were classed as non-responders.  
 
In chronic neuropathic pain conditions, there is a decrease in endogenous PEA levels due to an 
increase in fatty acid amide hydrolase (FAAH) levels. FAAH has been shown to degrade PEA in the 
spinal cord and regions of the brainstem involved in pain modulation (Petrosino et al., 2007), and an 
inhibition of FAAH (such as non-steroidal anti-inflammatory (NSAID) drugs) has an analgesic effect by 
increasing endogenous PEA levels (Jhaveri et al., 2006). While these types of drugs may not entirely 
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be effective in abolishing pain in patients with trigeminal neuropathic pain, it is likely that 
administration of exogenous PEA may be necessary to reduce pain intensity by increasing PEA levels 
(Guindon and Beaulieu, 2006). Indeed a number of clinical trials have proven the effects of PEA in 
reducing pain intensity in a number of disease states (Hesselink and Hekker, 2012), however, none 
have measured neural effects of PEA administration.  
 
In Chapter 4, PEA administration decreased ISO activity in patients with orofacial neuropathic pain in 
regions of the ascending pain pathway. While the precise mechanism of PEA is unknown, there are 
multiple mechanisms of action that may explain its anti-inflammatory and analgesic effects. The most 
widely accepted mechanism is through PEA activation of the peroxisome proliferator activated 
receptor-alpha (PPAR-α). In PPAR-α knockout mice, PEA failed to exhibit its analgesic properties 
(D'Agostino et al., 2009; D'Agostino et al., 2007; Haller et al., 2006; LoVerme et al., 2005a; LoVerme et 
al., 2005b) and in the periphery, activation of this receptor can reduce pain and inflammation by 
switching off the signalling cascade responsible for the production of pro-inflammatory mediators 
(D'Agostino et al., 2009; Mattace Raso et al., 2014). These data suggest that it is likely that PPAR-α is 
involved in the analgesic and anti-inflammatory effects of PEA.  
 
Activation of PPAR-α reduces astrocyte activation through potentially several mechanisms. In the 
central nervous system, PPAR-α is expressed on a number of cells, including on astrocytes and neurons 
(Cimini et al., 2005) and its activation leads to a fast response and a slow response. The slow response 
on astrocytes involves a neurosteroidal de novo synthesis of allopregnanolone (ALLO). ALLO is a 
positive allosteric modulator of GABA. This means that ALLO binds to GABA at a site other than the 
active site and increases its activity. Through this process, ALLO has demonstrated an ability to exert 
a neuroprotective effect in the central nervous system (Neigh and Merrill, 2016; Tsutsui and 
Haraguchi, 2016). GABA receptors are expressed on astrocytes, and the increase in GABA activity due 
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to ALLO synthesis will elicit an increase in GABA receptor activation in astrocytes. Interestingly, 
activation of GABA receptors in astrocytes causes an increase in calcium concentrations which 
depolarises the cell (Meier Silke et al., 2008). The increase in calcium concentrations suggests an 
increase in calcium wave propagation, an increase in astrocytic processes and an increase in ISOs, 
rather than the evident decrease in ISOs. 
 
However, calcium propagation between astrocytes is dependent upon IP3 which are activated by 
calcium (Scemes and Giaume, 2006). Indeed, propagation of calcium waves is dependent upon 
mitochondrial removal of excess calcium to prevent IP3 receptor desensitisation (Boitier et al., 1999; 
Simpson et al., 1998). Sensitivity of this receptor is shaped like a bell curve, i.e. low calcium 
concentrations have an excitatory effect, while higher concentrations (up to about 300nM) have an 
inhibitory effect on IP3 (Bezprozvanny et al., 1991; Finch et al., 1991). Based on the calcium 
concentration-dependant sensitization, it is proposed that the decrease in ISOs evident in the results 
of Chapter 4 are due to increase calcium concentrations (due to PEA activation of GABA receptors) 
reaching threshold levels for IP3 receptors to become inhibitory. This prevents calcium waves from 
propagating to neighbouring astrocytes, decreases astrocytic processes and dampens ISO activity.  It 
is also possible that with PEA administration, calcium concentrations did not reach threshold levels 
and this causes an increase in calcium propagation between astrocytes. This possibly underlies 
increases in pain intensity in a number of patients.  
 
The fast response of activation of PPAR-α does not directly involve astrocyte activity, however, it may 
also play a role in reducing ISOs. This response involves the activation of calcium dependant potassium 
channels in neurons (LoVerme et al., 2006). These voltage gated channels are fundamental regulators 
of neural excitability. Activation of these channels results in hyperpolarisation of the neurons leading 
to a silencing of neural activity in neighbouring cells (Faber and Sah, 2003). It is possible that in our 
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responders, the increase in PEA increases the hyperpolarisation of the neurons and hence decreases 
neural oscillatory firing. Furthermore, the increase in GABA activity through the slow response 
reinforces the decrease in neural firing as GABA is the main inhibitory neurotransmitter in the central 
nervous system (Chebib and Johnston, 1999).  
 
Another mechanism of action of PEA is through cannabinoid receptors. PEA is an endocannabinoid-
like compound with a low affinity binding property to cannabinoid receptors. There are two main 
types of cannabinoid receptors, CB1 which is expressed in the central nervous system and CB2 which 
is expressed in the peripheral nervous system (Pertwee, 1997). In the CNS, cannabinoid receptors are 
expressed on neurons and immune cells, such as astrocytes (Navarrete et al., 2014; Pertwee, 1997) 
and their activation has shown to produce analgesic effects. Anatomical and electrophysiological 
studies have shown that activation of CB1 targets presynaptic terminals on neurons to inhibit the 
release of neurotransmitters and provide analgesic effects (Elphick and Egertová, 2001; Pertwee, 
1997). Through the same processes, PEA activation of endocannabinoid receptors could be 
contributing to the analgesic effects of PEA as evident in Chapter 4. Furthermore, activation of 
cannabinoid receptors in astrocytes cause an increase in calcium concentration (Navarrete et al., 
2014). This increase in calcium concentration can contribute to the overall increase in calcium levels 
causing IP3 receptors to become inhibitory and preventing calcium wave oscillations (discussed 
earlier). Therefore, PEA can act through a number of pathways to increase calcium levels up to 
threshold levels so that IP3 receptors become inhibitory. This then prevents the propagation of 
calcium waves and therefore decrease overall astrocyte activity. The decrease in astrocyte activity, 
along with the increase in GABA concentrations silences neural firing and infra-slow oscillatory activity, 
which may otherwise be transferred along the ascending pain pathway. 
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Consistent with this idea, in Chapter 4, although PEA decreased ISO activity in all patients, it only 
produced pain relief when this ISO decrease was transferred to higher brain centres such as the VP 
thalamus. That is, only patients in which PEA evoked a significant reduction in pain, did PEA also 
decrease ISOs within the VP thalamus. Furthermore, this Spv-VP thalamus ISO reduction was 
associated with a significant reduction in resting functional connectivity between the SpV and VP 
thalamus. This result is consistent with those reported in Chapter 3, whereby a decrease in T2 
relaxometry/increase in astrocyte activity was evident only in the SpV, yet Chapter 2 reports increases 
in infra-slow oscillatory activity in both the SpV and VP thalamus. These results suggest that astrocytic 
changes in chronic neuropathic pain are confined to the dorsal horn/SpV, causing a change in neural 
activity locally which are then transferred to higher centres such as the thalamus. This is entirely 
consistent with an animal investigation which showed that in animals with neuropathic pain, increased 
ISOs in the VP thalamus were eliminated by severing the connection between the dorsal horn and the 
thalamus (Iwata et al., 2011).  
 
In Chapter 1 of this thesis, the role of thalamocortical rhythms in chronic neuropathic pain was 
discussed such that a change in the circuitry between the thalamus and the cortex is associated with 
chronic neuropathic pain. Therefore, in chronic neuropathic pain, the changes in pattern of activity 
that were transferred from the dorsal horn to the thalamus have caused a change in thalamocortical 
circuity, leading to the constant perception of pain. Yet, with administration of PEA, these changes in 
the pattern of activity are abolished as the connectivity between the dorsal horn and the thalamus 
are eliminated and ISOs in the thalamus are dampened. This may reset thalamocortical rhythms and 
reduce the constant perception of pain.  
 
Overall, the evidence provided in this thesis strongly suggest that chronic neuropathic pain is 
associated with an increase in infra-slow oscillatory activity in areas of the ascending pain pathway; 
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the spinal trigeminal nucleus, the somatosensory thalamus and the primary somatosensory cortex. 
These increases are associated with an increase in astrocyte activity, which was evident through 
measuring T2 relaxation which indirectly showed increases in astrocyte activity in regions of the 
ascending pain pathway.  These increases in astrocyte activity were reduced with PEA treatment at 
the spinal trigeminal nucleus. PEA also reduced connectivity between the spinal trigeminal nucleus 
and the thalamus which then prevents the transfer of oscillatory activity along the ascending pain 
pathway, resulting in significant reductions in the intensity of on-going pain.   
 
5.3 Recommendations for future research 
This investigation identified changes in the pattern of activity in patients with trigeminal neuropathic 
pain that could be reversed with PEA. However, no placebo group was used in Chapter 4. While the 
results strongly suggest that the outcomes of from Chapter 4 were not due to placebo, future 
investigations should utilize a randomised double blind, placebo-controlled study on a larger sample 
size. It would be ideal to extract blood samples from these patients to measure changes pain related 
protein levels that may affect whether a patient responds to the treatment and for genetic testing 
(Andersson et al., 1996; Diatchenko et al., 2005).  
 
To determine the precise mechanisms of action of PEA on astrocyte activity and infra-slow oscillations, 
it may be useful to use animal investigations using a neuropathic pain model, such as the chronic 
constriction injury. Such investigation will give the opportunity to address a number of theories that 
have been proposed in this thesis. Firstly, animal investigations would provide the opportunity to 
measure the role of endogenous PEA in chronic neuropathic pain and the effect of PEA concentration 
on calcium oscillations and ISOs. Based on this series of investigations, an increase in PEA 
concentration should cause an increase in calcium waves, a decrease in calcium oscillations and a 
decrease in ISOs. Secondly, the model will be able to determine whether abolishing calcium 
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oscillations in the primary synapse will also abolish calcium oscillations in the thalamus and whether 
this will reduce pain intensity. Thirdly, such investigations will be able to determine the specific 
pathways and mechanisms of action of PEA that allow it to have its analgesic response.  
 
While it is necessary to determine the effects of PEA of pain intensity in animal models of neuropathic 
pain, it would be ideal to also determine whether infra-slow oscillations are evident at same 
frequencies in regions of the ascending pain pathway. Although this investigation strongly suggests 
that the increases in ISOs are due to increases in astrocyte activity, animal investigations will provide 
the opportunity to directly measure the relationship between astrocytes and infra-slow oscillations, 
such as by testing whether blocking astrocyte activity will abolish infra-slow oscillations. In Chapter 3 
of this thesis, T2 relaxation time was associated with astrocyte activity, this was based on physical 
properties of the MRI sequence and astrocytes. However, provided the role of glia in pain has become 
increasingly studied, for future investigations to use this non-invasive technique to measure astrocyte 
activity, animal models may be necessary to confirm that a decrease in T2 relaxation time is indeed 
associated with an increase in astrocyte activity.  
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A B S T R A C T
It has been proposed that pain competes with other attention-demanding stimuli for cognitive resources, and
many chronic pain patients display signiﬁcant attention and mental ﬂexibility deﬁcits. These alterations may
result from disruptions in the functioning of the default mode network (DMN) which plays a critical role in
attention, memory, prospection and self-processing, and recent investigations have found alterations in DMN
function in multiple chronic pain conditions. Whilst it has been proposed that these DMN alterations are a
characteristic of pain that is chronic in nature, we recently reported altered oscillatory activity in the DMN
during an acute, 5 minute noxious stimulus in healthy control subjects. We therefore hypothesize that altered
DMN activity patterns will not be restricted to those in chronic pain but instead will also occur in healthy
individuals during tonic noxious stimuli. We used functional magnetic resonance imaging to measure resting
state infra-slow oscillatory activity and functional connectivity in patients with chronic orofacial pain at rest and
in healthy controls during a 20-minute tonic pain stimulus. We found decreases in oscillatory activity in key
regions of the DMN in patients with chronic pain, as well as in healthy controls during tonic pain in addition to
changes in functional connectivity between the posterior cingulate cortex and areas of the DMN in both groups.
The results show that similar alterations in DMN function occur in healthy individuals during acute noxious
stimuli as well as in individuals with chronic pain. These DMN changes may reﬂect the presence of pain per se
and may underlie alterations in attentional processes that occur in the presence of pain.
1. Introduction
Chronic pain is a disease state with an enormous socioeconomic
burden. Whilst most investigations focus on understanding the under-
lying pathophysiology of chronic pain largely center on sensory aspects,
many chronic pain patients also report signiﬁcant alterations in their
sleep-wake cycle, family and social relations and cognitive function
(Iverson and McCracken, 1997; Smith-Seemiller et al., 2003). It has
been proposed that chronic pain is attention demanding, competing
with other attention-demanding stimuli for cognitive resources
(Eccleston and Crombez, 1999). Indeed, attention deﬁcits are displayed
in individuals with chronic pain conditions (Eccleston, 1994; Grisart
and Van der Linden, 2001; Van Damme et al., 2010), and signiﬁcant
associations between chronic pain and sustained attention and mental
ﬂexibility have been reported (Karp et al., 2006; Sjogren et al., 2000;
Verdejo-Garcia et al., 2009).
One cortical network that is thought to be involved in higher order
functions is the default mode network (DMN). This network consists of
a set of regions that are functionally highly connected and include the
medial prefrontal cortex (mPFC), posterior cingulate cortex (PCC), in-
ferior parietal cortex (IPC) and precuneus (Raichle et al., 2001;
Shulman et al., 1997). This network was ﬁrstly shown to be more active
during passive task conditions than during numerous goal-directed
tasks. More recently it has been hypothesized that in addition to a role
in memory, prospection and self-processing (Cavanna and Trimble,
2006; Spreng and Grady, 2010), all of which require a continuous level
of background activity, the DMN also may act as a sentinel by mon-
itoring the external environment (Buckner et al., 2008).
Some recent investigations using resting state functional magnetic
resonance imaging (fMRI) have reported signiﬁcant changes in DMN
function in many chronic pain conditions (Baliki et al., 2008; Baliki
et al., 2014; Letzen et al., 2013; Napadow et al., 2012; Tagliazucchi
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et al., 2010). These studies clearly show that chronic pain is associated
with altered DMN dynamics, and it has been strongly suggested that
chronic pain reorganizes “the dynamics of the DMN and as such reﬂect
the maladaptive physiology of diﬀerent types of chronic pain” (Baliki
et al., 2008). Whilst this may be true, acute pain in a healthy, non-
chronic pain individual is unquestionably attention demanding, com-
peting with other attention-demanding stimuli for cognitive resources.
Though Seminowicz and Davis (2007a) found little eﬀect of acute pain
on cognitive performance, this lack of eﬀect might be due to the short
stimulus duration (14 s). Indeed, there is considerable brain imaging
evidence showing that pain and cognitive-related brain activities in-
teract, possibly due to similar neural circuitries (Bantick et al., 2002;
Petrovic et al., 2000; Remy et al., 2003; Valet et al., 2004).
In a separate investigation, Seminowicz and Davis also found that
whilst performing an attention-demanding cognitive task during acute
noxious stimuli, activity in the DMN was anti-correlated (one signal
increased whilst the other decreased) to activity in a task-positive
network and that these networks were operating at a frequency be-
tween 0.03 and 0.08 Hz (Seminowicz and Davis, 2007b). Curiously,
although not the focus of the investigation, we recently reported sig-
niﬁcant decreases in oscillatory power in areas of the DMN during a 6
minute muscle pain stimulus in healthy control subjects (Alshelh et al.,
2016). Although we did not explore these oscillation decreases in detail,
given the evidence presented above, it is possible that altered DMN
dynamics also occur during acute pain stimuli in healthy controls; these
acute pain stimuli simply need to be of long enough duration to allow
for reliable detection. The aim of this study is to use resting state fMRI
to investigate infra-slow oscillations and connectivity within the DMN
in individuals with chronic orofacial neuropathic pain and in healthy
individuals during tonic orofacial pain. We hypothesize that altered
DMN activity patterns will not be restricted to those in chronic pain but
will also occur in healthy individuals during tonic noxious stimuli.
2. Materials and methods
2.1. Subjects
Forty-three subjects with chronic orofacial neuropathic pain (32
females; mean age 47.3 ± 2.3 years [± SEM]) and 57 pain-free con-
trols (35 females; mean age 43.4 ± 1.7 years) were recruited for the
study. There was no signiﬁcant diﬀerence in age (t-test; p= 0.08) or
gender composition (chi-squared test, p= 0.25) between groups. All
chronic pain subjects were diagnosed using the Liverpool criteria as
having post-traumatic trigeminal neuropathy (Nurmikko and Eldridge,
2001).
During the seven days prior to the MRI session, each chronic pain
subject kept a pain diary recording the intensity of their on-going pain,
three times a day using a 10 cm horizontal visual analogue scale (VAS)
with 0 indicating “no pain” and 10 indicating “the most intense imagin-
able pain”. These pain intensity scores were then averaged over the 7-
day period to create a mean diary pain intensity score. On the day of the
MRI scanning, each chronic pain subject outlined the location of their
on-going pain on a standard drawing of the head, completed a McGill
Pain Questionnaire and listed their current medication use. Informed
written consent was obtained for all procedures according to the
Declaration of Helsinki and the study was approved by our local
Institutional Human Research Ethics Committees. Data from 27 of the
43 chronic pain subjects were used in previous investigations (Alshelh
et al., 2016; Gustin et al., 2011; Henderson et al., 2013; Wilcox et al.,
2015).
2.2. MRI acquisition
All subjects lay supine on the bed of a 3 Tesla MRI scanner (Philips,
Achieva) with their head immobilized in a tight-ﬁtting head coil. With
each subject relaxed and at rest, a series of 180 gradient echo echo-
planar functional MRI image volumes using BOLD contrast were col-
lected. Each image volume contained 35 axial slices covering the entire
brain (repetition time = 2000 ms; echo time = 30 ms, ﬂip
angle = 90°, raw voxel size = 3 × 3× 4 mm). In each subject, a high-
resolution 3D T1-weighted anatomical image set, covering the entire
brain, was collected (turbo ﬁeld echo; repetition time = 5600 ms; echo
time = 2.5 ms, ﬂip angle = 8°, raw voxel size 0.87 mm3).
In 16 of the 57 control subjects (5 females, age 24.9 ± 1.2 years) a
tonic pain stimulus was delivered. A catheter connected to a syringe
ﬁlled with hypertonic saline (5%) was placed into the right masseter
muscle midway between its upper and lower borders. The catheter was
attached to an infusion pump with a 10 ml syringe placed outside the
scanner room. With the subject relaxed, 500 gradient echo echo-planar
fMRI image volumes using BOLD contrast were collected over a 25-
minute period. Each image volume contained 42 axial slices covering
the entire brain (repetition time = 3000 ms, echo time = 30 ms, ﬂip
angle = 90°, raw voxel size = 1.5 × 1.5 × 4 mm3). Following a 5-
minute baseline period (100 fMRI volumes), a 0.2 ml bolus of hyper-
tonic saline was injected into the masseter muscle followed by a con-
tinuous infusion for the remaining 20 min. During the infusion we
aimed to keep a moderate pain intensity of approximately 5 out of 10.
This was achieved by instructing each subject to push a buzzer once if
the pain fell below 5 and twice if it increased above 5, and the infusion
rate was adjusted accordingly to maintain the pain intensity at 5 out of
10. Following the scan, each subject was asked to rate the average pain
during the scan on a 10 cm horizontal VAS, outline the location of the
pain on a standard drawing of the head and complete a McGill Pain
Questionnaire describing the qualities of the pain.
2.3. MRI analysis
2.3.1. Overall changes in infra-slow oscillatory power
Using SPM12 (Friston et al., 1995), all fMRI images were motion
corrected, global signal drifts removed using the detrending method
described by Macey et al. (2004), spatially normalized to the Montreal
Neurological Institute (MNI) template, and spatially smoothed using a
6 mm full-width-half-maximum Gaussian ﬁlter. In no subject was there
signiﬁcant movement (> 0.5 mm in any direction). Furthermore,
comparison of the mean movement in 6 directions (X, Y, Z, roll, yaw,
tilt) revealed no signiﬁcant diﬀerences between chronic pain and con-
trol groups (p > 0.05, two-sample t-test, Bonferroni corrected for
multiple comparisons), or between the baseline and pain periods in the
tonic pain group (p > 0.05, paired t-test, Bonferroni corrected for
multiple comparisons).
2.3.2. Identifying the default mode network using independent components
analysis
To identify the DMN we used ICA on the control (n= 57), chronic
pain (n= 43) and tonic pain (n= 16) groups using the Group ICA
toolbox (Calhoun et al., 2001). This technique can extract independent
sources of activity within a recorded mixture of sources and can
therefore detect various networks (Brown et al., 2001; Frigyesi et al.,
2006). Using the Infomax ICA algorithm, we estimated 20 independent
component maps in which signal intensity within multiple regions
covaried. All components were displayed (p < 0.05, false discovery
rate corrected for multiple comparisons with a minimum of 10 con-
tiguous voxels) and for each group, the component map that included
the major regions that deﬁne the DMN such as the medial prefrontal
cortex, inferior parietal cortex, precuneus and posterior cingulate
cortex was selected. The DMN component map for each of the three
groups was then added together to create a single DMN mask, which
was used in further analyses.
2.3.3. Voxel-by-voxel infra-slow frequency amplitude analysis
To explore regional diﬀerences in infra-slow oscillation (ISO) power
we used the SPM toolbox REST (Song et al., 2011) to calculate the sum
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of amplitudes of low frequency ﬂuctuations (ALFF) in the frequency
band 0.03–0.06 Hz. We also divided these ALFF values by total power
over the entire frequency range to obtain fractional ALFF (fALFF) va-
lues for each voxel. Signiﬁcant diﬀerences within the DMN between
control and chronic pain subjects were then determined using a two-
sample random-eﬀects procedure with age and gender added as nui-
sance variables (p < 0.05, false discovery rate corrected for multiple
comparisons, minimum 10 contiguous voxels). For each of the com-
parisons, ALFF and fALFF values from signiﬁcant clusters were ex-
tracted from the control and chronic pain groups and plotted. The eﬀect
of pain intensity and pain duration was determined by comparing its
relationship with 0.03–0.06 Hz power in signiﬁcant clusters in chronic
pain subjects (p < 0.05, Bonferroni corrected for the number of cor-
relations examined). The eﬀects of medication on infra-slow oscillations
were determined by comparing 0.03–0.06 Hz power in each signiﬁcant
cluster in chronic pain subjects taking analgesic medications (n= 16)
with those not taking medication (n= 27) (p < 0.05, 2-tailed, 2-
sample t-test).
For the tonic pain group, ALFF power was calculated for the base-
line and tonic pain periods and signiﬁcant diﬀerences within the DMN
were determined using a paired random eﬀects procedure (p < 0.05,
false discovery rate corrected for multiple comparisons, minimum 10
Fig. 1. Pain distribution and quality of pain in chronic pain subjects
and in individuals during tonic pain. A) Individual pain distribution
patterns in 43 chronic pain subjects and 16 healthy controls during
experimentally induced tonic pain. B) Frequency (percentage of
subjects) of descriptors chosen from the McGill Pain Questionnaire
to describe the on-going pain in chronic pain subjects (white bars)
and in healthy controls during tonic pain (grey bars).
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contiguous voxels). These comparisons were made between the baseline
period (100 volumes) and each of the four 5-minute periods (100 vo-
lumes each) during the tonic pain period. Using the signiﬁcant clusters
derived from the baseline versus the ﬁrst 5-minute pain period, ALFF
values were extracted from the baseline and each of the 5-minute pain
periods and plotted. Signiﬁcant diﬀerences between baseline and pain
periods were then determined (paired t-test, p < 0.05, Bonferroni
corrected for multiple comparisons). In addition, for each signiﬁcant
cluster, the percentage change in signal intensity relative to the baseline
period was calculated for each of the four 5-minute pain periods in each
subject and plotted. Signiﬁcant diﬀerences between signal intensity
during the baseline and each of the pain periods were determined
(paired t-test, p < 0.05, Bonferroni corrected).
2.3.4. Voxel-by-voxel functional connectivity analysis
Results from the infra-slow frequency analysis revealed an area of
the posterior cingulate cortex (PCC) in which both chronic and tonic
pain groups displayed signiﬁcant decreases in infra-slow frequency
amplitude relative to controls and baseline, respectively. This PCC re-
gion was used as a “seeding area” to assess the eﬀects of pain on PCC
functional connectivity within the DMN. For the control and chronic
pain groups, PCC signal intensity was extracted for each subject and the
strength of covariation between this signal and each voxel within the
DMN was determined. Cerebrospinal ﬂuid signal intensity, calculated as
the average signal intensity of a 4 mm diameter sphere placed in the 4th
ventricle in each individual subject, in addition to the 6-direction
movement parameters derived from the realignment step, were in-
cluded as nuisance variables. Comparisons of PCC resting connectivity
strength between controls and chronic pain subjects were determined
using a two-group random eﬀects analysis. For the tonic pain group,
diﬀerences in PCC connectivity strength between the baseline and each
of the tonic pain periods were determined using paired random eﬀects
analysis. For each of these analyses, following an initial threshold of
p < 0.001 with a minimum cluster extent of 10 contiguous voxels, we
used cluster correction to correct for multiple comparisons (p < 0.05,
Bonferroni corrected for the number of voxels in each cluster). For the
chronic pain analysis, functional connectivity values were extracted
from each signiﬁcant cluster and plotted. The eﬀect of pain intensity
and pain duration was determined by comparing its relationship with
PCC connectivity strengths in signiﬁcant clusters in chronic pain sub-
jects (p < 0.05, Bonferroni corrected for the number of correlations
examined). For the tonic pain analysis, PCC connectivity strength va-
lues were extracted from each signiﬁcant cluster for the baseline and
each of the 5-minute pain periods and plotted. Signiﬁcant diﬀerences
between baseline and each pain period were then determined (paired t-
test, p < 0.05, Bonferroni corrected).
Fig. 2. The default mode network in controls, chronic pain and tonic pain groups as deﬁned by an independent component analysis. Areas displaying signiﬁcant signal intensity
covariation are indicated by the hot colour scale and overlaid onto an individual's T1-weighted anatomical image set. The default mode network consists of the precuneus, posterior
cingulate cortex (PCC), inferior parietal cortex and the medial prefrontal cortex (mPFC). Slice locations in Montreal Neurological Institute space are indicated at the top right of each slice
in the top panel.
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3. Results
3.1. Subject characteristics
The mean (± SEM) diary pain of the chronic pain group was
3.8 ± 0.4 and the mean VAS scores for the tonic pain group was
4.8 ± 0.3. Both chronic and tonic pain groups reported pain encom-
passing the maxillary and mandibular distributions of the trigeminal
nerve, although the chronic pain subjects generally reported a wider
spread of on-going pain that often included the ophthalmic trigeminal
division (Fig. 1A). Furthermore, 29 of the chronic pain subjects re-
ported left sided only pain, and 14 right side only. Chronic pain subjects
most often described their on-going pain as “shooting”, “throbbing” and
“nagging”, and similarly the tonic pain was described as “throbbing”,
“annoying” and “nagging” (Fig. 1B). The mean pain duration of the
chronic pain group was 6.0 ± 0.9 years and 16 of the chronic pain
subjects were taking some form of daily analgesic medication. ICA re-
vealed a component comprising of the DMN in the control, chronic pain
and tonic pain groups. This component encompassed vast regions of the
precuneus, PCC, anterior cingulate cortex, medial prefrontal cortex
(mPFC) and the inferior parietal cortex (IPC) (Fig. 2).
3.2. Voxel-by-voxel infra-slow frequency amplitude analysis
3.2.1. Chronic pain
A comparison of infra-slow oscillation power between 0.03 and
0.06 Hz revealed signiﬁcantly reduced power in chronic pain subjects
in multiple regions of the DMN (Fig. 3A, Table 1A). That is, decreased
power occurred in the region encompassing the precuneus (mean ±
SEM 0.03–0.06 Hz ALFF: controls: 1.52 ± 0.04, chronic pain:
1.26 ± 0.05), PCC (controls: 1.64 ± 0.05, chronic pain: 1.37 ± 0.06),
left and right IPC (left: controls: 1.12 ± 0.02, chronic pain:
0.91 ± 0.03; right: controls: 1.28 ± 0.04, chronic pain: 1.01 ± 0.05)
and the mPFC (controls: 1.28 ± 0.05, chronic pain: 1.05 ± 0.05)
(Fig. 3B). Similarly, comparison of infra-slow oscillation power relative
to an individual's total power (fALFF) also revealed signiﬁcantly re-
duced power in chronic pain subjects compared with controls in the
precuneus (controls: 1.22 ± 0.02 chronic pain: 1.10 ± 0.03), PCC
(controls: 1.23 ± 0.02, chronic pain: 1.10 ± 0.03), left and right IPC
(left: controls: 1.21 ± 0.02, chronic pain: 1.07 ± 0.02; right: controls:
1.30 ± 0.02, chronic pain: 1.16 ± 0.02) and the mPFC (controls:
1.14 ± 0.02, chronic pain: 1.03 ± 0.03) (Fig. 3C). In no region of the
DMN was power greater in chronic pain subjects compared with
Fig. 3. Signiﬁcant changes in infra-slow oscillatory
power (ISO: 0.03–0.06 Hz) in individuals with
chronic pain. A) Regions where chronic pain sub-
jects have signiﬁcantly reduced amplitude of low-
frequency ﬂuctuations (ALFF) and fractional ALFF
(fALFF) compared with controls within the default
mode network. Power reductions are indicated by
the cool colour scale and overlaid onto an in-
dividual's T1-weighted anatomical image set. Note
the decreases within the precuneus, posterior cin-
gulate cortex (PCC), inferior parietal cortex and
medial prefrontal cortex (mPFC). Slice locations in
Montreal Neurological Institute space are indicated
at the top right of each slice in the top panel. B)
Plots of mean ± SEM ALFF and C) mean ± SEM
fALFF in controls and chronic pain groups for sig-
niﬁcant clusters. ‡ signiﬁcant diﬀerences derived
from the voxel-by-voxel random eﬀects analysis
(p < 0.05, false discovery rate corrected).
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controls.
In no region was either ALFF or fALFF power signiﬁcantly corre-
lated to diary pain (ALFF: precuneus r=−0.13, PCC r=−0.17, left
IPC r=−0.14, right IPC r= 0.01, mPFC r= 0.11; fALFF: precuneus
r =−0.17, PCC r=−0.18, left IPC r=−0.11, right IPC r=−0.07,
mPFC r= 0.06; all p > 0.05) or pain duration (ALFF: precuneus
r= 0.17, PCC r= 0.13, left IPC r = 0.01, right IPC r=−0.04, mPFC
r= 0.03; fALFF: precuneus r= 0.22, PCC r= 0.23, left IPC r = 0.01,
right IPC r = 0.03, mPFC r= 0.32; all p > 0.05). In addition, in no
region was there a signiﬁcant diﬀerence in power between those taking
medication compared with those that were not (mean ± SEM power
medication versus no medication: ALFF: precuneus 1.22 ± 0.06 vs
1.29 ± 0.04, PCC 1.31 ± 0.05 vs 1.40 ± 0.06, left IPC 0.90 ± 0.03
vs 0.92 ± 0.03, right IPC 0.97 ± 0.04 vs 1.03 ± 0.04, mPFC
1.14 ± 0.06 vs 0.99 ± 0.03; fALFF: precuneus 1.16 ± 0.03 vs
1.07 ± 0.02, PCC 1.16 ± 0.03 vs 1.07 ± 0.02, left IPC 1.10 ± 0.02
vs 1.06 ± 0.02, right IPC 1.13 ± 0.02 vs 1.17 ± 0.02, mPFC
1.01 ± 0.03 vs 1.04 ± 0.02; all p > 0.05).
3.2.2. Tonic pain
A comparison of infra-slow oscillation power during tonic pain with
baseline revealed signiﬁcant reductions in the same DMN regions as
those that occurred in individuals with chronic pain (Fig. 4A, Table 1B).
That is, decreased power occurred in the region of the precuneus
(mean ± SEM 0.03–0.06 Hz ALFF: baseline: 1.59 ± 0.07, 1st 5 min
tonic pain: 1.24 ± 0.06, 2nd 5 min: 1.44 ± 0.07, 3rd 5 min:
1.43 ± 0.07, 4th 5 min: 1.49 ± 0.07), PCC (baseline: 1.10 ± 0.05, 1st
5 min tonic pain: 0.89 ± 0.05, 2nd 5 min: 0.98 ± 0.05, 3rd 5 min:
0.98 ± 0.06, 4th 5 min: 1.00 ± 0.06), left IPC (baseline: 1.15 ± 0.05,
1st 5 min tonic pain: 0.94 ± 0.05, 2nd 5 min: 1.11 ± 0.07, 3rd 5 min:
1.17 ± 0.07,4th 5 min: 1.13 ± 0.05) and the mPFC (baseline:
1.23 ± 0.06, 1st 5 min tonic pain: 1.02 ± 0.05, 2nd 5 min:
1.08 ± 0.07, 3rd 5 min: 1.22 ± 0.05, 4th 5 min: 1.14 ± 0.07). In the
precuneus and PCC, the signiﬁcant reduction in power was sustained
for the tonic pain period, whereas in the IPC and mPFC the power re-
ductions were transient and returned to baseline by the 3rd 5-minute
pain period.
The reduction in infra-slow oscillation power within the precuneus
and PCC was accompanied by signiﬁcant signal intensity increases that
were sustained for the tonic pain period (mean ± SEM %signal in-
tensity increase: precuneus: 1st 5 min tonic pain: 0.47 ± 0.15, 2nd
5 min: 0.60 ± 0.16, 3rd 5 min: 0.69 ± 0.16, 4th 5 min: 0.78 ± 0.16;
PCC: 1st 5 min tonic pain: 0.62 ± 0.15, 2nd 5 min: 0.69 ± 0.14, 3rd
5 min: 0.68 ± 0.14, 4th 5 min: 0.71 ± 0.14: all p < 0.05). In con-
trast, within the IPC and mPFC, signal intensity did not change sig-
niﬁcantly during the tonic pain period (IPC: 1st 5 min tonic pain:
−0.19 ± 0.17, 2nd 5 min: −0.06 ± 0.19, 3rd 5 min: 0.15 ± 0.19,
4th 5 min: 0.35 ± 019; mPFC: 1st 5 min tonic pain:−0.05 ± 0.23, 2nd
5 min: 0.28 ± 0.24, 3rd 5 min: 0.54 ± 0.22, 4th 5 min: 0.71 ± 0.23:
all p > 0.05).
3.3. Functional connectivity of PCC
The PCC region that displayed decreased infra-slow oscillation
power in both the chronic and tonic pain groups and also a sustained
increase in signal intensity during tonic pain was used to explore con-
nectivity changes within the DMN. Similar to the infra-slow oscillation
power changes, chronic pain subjects displayed signiﬁcantly reduced
PCC connectivity strengths compared with controls in the precuneus
(mean ± SEM PCC connectivity strength: controls: 0.42 ± 0.02,
chronic pain: 0.32 ± 0.02), left and right IPC (left: controls:
0.39 ± 0.02, chronic pain: 0.29 ± 0.03; right: controls: 0.29 ± 0.02,
chronic pain: 0.18 ± 0.03) and the mPFC (controls: 0.37 ± 0.02,
chronic pain: 0.26 ± 0.02) (Fig. 5A, Table 2A). In no DMN region was
PCC connectivity strength greater in the chronic pain subjects com-
pared with controls.
In no region was PCC connectivity strength signiﬁcantly correlated
to diary pain (precuneus r=−0.01, left IPC r= 0.08, right IPC
r= 0.01, mPFC r=−0.09; all p > 0.05) or pain duration (precuneus
r=−0.12, left IPC r= 0.18, right IPC r=−0.11, mPFC r = 0.01; all
p > 0.05). In addition, in no region was there a signiﬁcant diﬀerence
in PCC connectivity strength between those taking medication com-
pared with those that were not (mean ± SEM PCC connectivity
strength medication versus no medication: precuneus 0.30 ± 0.03 vs
0.33 ± 0.03, left IPC 0.28 ± 0.04 vs 0.29 ± 0.04, right IPC
0.13 ± 0.06 vs 0.22 ± 0.03, mPFC 0.25 ± 0.04 vs 0.27 ± 0.03; all
p > 0.05).
The tonic pain group displayed reduced PCC connectivity strength
during pain compared to baseline in the right IPC (baseline:
0.18 ± 0.05; 1st 5 min tonic pain: 0.07 ± 0.05, 2nd 5 min:
0.08 ± 0.06, 3rd 5 min: 0.07 ± 0.04, 4th 5 min: 0.08 ± 0.04), left
mPFC (baseline: 0.26 ± 0.04; 1st 5 min tonic pain: 0.04 ± 0.05, 2nd
5 min: 0.12 ± 0.05, 3rd 5 min: 0.12 ± 0.04, 4th 5 min: 0.12 ± 0.05)
and right mPFC (baseline: 0.27 ± 0.06; 1st 5 min tonic pain:
0.07 ± 0.05, 2nd 5 min: 0.14 ± 0.06, 3rd 5 min: 0.14 ± 0.04, 4th
5 min: 0.10 ± 0.0.05) (Fig. 5B, Table 1B). These signiﬁcant reductions
in PCC connectivity were sustained for the entire tonic pain period. In
no DMN region was PCC connectivity strength greater during tonic pain
compared with baseline.
4. Discussion
Consistent with our overall hypothesis, we found that DMN func-
tional properties were signiﬁcantly altered in both subjects with chronic
pain and in healthy individuals during tonic painful stimuli. Indeed, we
found decreased ISO power in both chronic pain and tonic pain groups
Table 1
Location of signiﬁcant infra-slow oscillation power decreases within the default mode
network in individuals with chronic pain (A) and during tonic pain (B). Locations are in
Montreal Neurological Institute (MNI) space.
Cluster size t value MNI co-ordinate
X Y Z
(A) Chronic pain
ALFF
Precuneus 16 3.49 −4 −66 26
10 3.44 8 −68 38
Posterior cingulate cortex 32 3.26 4 −48 28
Inferior parietal cortex
Left 51 4.26 −30 −76 32
Right 53 3.73 −42 −58 22
36 3.88 34 −66 36
40 3.80 46 −60 42
Medial prefrontal cortex 38 4.94 −6 38 12
25 4.62 −12 38 42
fALFF
Precuneus 663 4.75 −8 −54 20
Posterior cingulate cortex 144 3.86 4 −28 32
Inferior parietal cortex
Left 75 4.68 −42 −54 18
94 4.10 −32 −76 32
Right 139 4.26 44 −60 42
77 4.15 36 −70 28
Medial prefrontal cortex 12 3.39 2 66 8
(B) Tonic pain
ALFF
Precuneus 585 4.32 −6 −70 38
Posterior cingulate cortex 24 4.78 −10 −54 10
12 4.58 −4 −22 36
68 4.55 −6 −44 44
Inferior parietal cortex
Left 411 6.63 −38 −74 36
Right 18 3.91 −48 −60 46
29 4.89 46 −72 26
Medial prefrontal cortex 12 4.11 8 60 6
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over most of the DMN, including in the precuneus, PCC, IPC and mPFC.
Additionally, in healthy controls, tonic pain evoked sustained ISO de-
creases in the precuneus and PCC which were associated with sustained
overall signal intensity increases. Finally, both chronic and tonic pain
groups displayed signiﬁcant reductions in PCC connectivity within the
DMN, and these changes were sustained for the entire pain period in the
tonic pain group.
Consistent with previous investigations we found altered DMN dy-
namics in individuals with chronic pain (Baliki et al., 2008; Baliki et al.,
2014; Letzen et al., 2013; Loggia et al., 2013; Napadow et al., 2012;
Tagliazucchi et al., 2010). Although in one of these previous studies,
ISOs were investigated and no signiﬁcant diﬀerences at low frequencies
(0.01–0.05 Hz) were found within the DMN (Baliki et al., 2014), ISO
power was averaged over the entire DMN network, which would
eliminate the opportunity of ﬁnding changes within discrete regions of
the DMN. More importantly, we found that similar DMN changes to
those in chronic pain subjects also occurred in healthy individuals
during a tonic noxious stimulus. Both chronic and tonic pain were as-
sociated with reduced ISOs within multiple regions of the DMN, in-
cluding the precuneus, PCC, mPFC and IPC. This clearly indicates that
DMN functional changes are not a unique characteristic of chronic pain
but instead likely represent the presence of pain itself. It has been
proposed that ISO activity is a fundamental property of brain function
that is maintained by adenosine receptor-mediated signalling (Hughes
et al., 2011; Lorincz et al., 2009). Adenosine is likely released by as-
trocytes since they can display spontaneous intracellular infra-slow
calcium oscillations (Parri and Crunelli, 2001), are responsive to glu-
tamate and acetylcholine, and a link between adenosine and infra-slow
Fig. 4. Signiﬁcant changes in infra-slow oscillatory
power (ISO: 0.03–0.06 Hz) during tonic pain. A)
Regions of the default mode network where the
amplitude of low-frequency ﬂuctuations (ALFF) are
signiﬁcantly reduced during the 1st, 2nd, 3rd and
4th 5 minute periods of tonic pain compared with
a baseline period. Power reductions are indicated
by the cool colour scale and overlaid onto an in-
dividual's T1-weighted anatomical image set. Note
the decreases within the precuneus, posterior cin-
gulate cortex (PCC), inferior parietal cortex and
medial prefrontal cortex (mPFC). Slice locations in
Montreal Neurological Institute space are indicated
at the top right of each slice in panel A. B) Plots of
mean ± SEM ALFF during baseline and the four 5
minute pain periods for signiﬁcant clusters. C) Plots
of mean ± SEM % signal intensity changes re-
lative to baseline for the four 5 minute pain per-
iods for clusters with signiﬁcantly reduced ALFF
power. Note that only the precuneus and PCC dis-
play both reduced ALFF and increased signal in-
tensity changes during all of the tonic pain periods.
The grey shading indicates the tonic pain period. *
p < 0.05, 2-tailed paired t-test.
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oscillatory activity has been demonstrated in the cortex (Cunningham
et al., 2006). Whilst we have previously speculated that increased ISO
activity in the ascending pain pathways of chronic orofacial pain pa-
tients results from astrocyte activation (Alshelh et al., 2016; Henderson
and Di Pietro, 2016), what ISO power reductions represent is unclear.
The rapid nature of the ISO decreases during tonic pain suggests
that they do not result from astrogliosis. During tonic pain, decreased
ISOs were sustained for the entire 20 min pain period in the precuneus
and PCC, two regions which also displayed sustained increases in
overall signal intensity. In contrast, ISOs within the inferior parietal
cortex and mPFC were transient, and overall signal intensity in these
two regions did not change. Similarly, we have previously shown that
chronic orofacial pain is associated with increased on-going activity in
the DMN as indicated by increased cerebral blood ﬂow in the DMN,
particularly within the precuneus (Youssef et al., 2014). These data
suggest that within the DMN, decreased ISOs are coupled with overall
activity increases which together may result from increased aﬀerent
drive rather than longer-term changes mediated by mechanisms such as
Fig. 5. Signiﬁcant changes in posterior cingulate
cortex (PCC) functional connectivity in chronic and
tonic pain groups. A) Regions where PCC con-
nectivity strength within the default mode network
is signiﬁcantly reduced in chronic pain subjects
compared with controls. Connectivity strength re-
ductions are indicated by the cool colour scale and
overlaid onto an individual's T1-weighted anato-
mical image set. Note decreases in the precuneus,
inferior parietal cortex (IPC) and medial prefrontal
cortex (mPFC). Slice locations in Montreal
Neurological Institute space are indicated at the top
right of each slice. Plots of mean ± SEM PCC
connectivity strength are also shown. ‡ signiﬁcant
diﬀerences derived from the voxel-by-voxel
random eﬀects analysis (p < 0.05, false discovery
rate corrected). B) Regions where PCC connectivity
strength is signiﬁcantly reduced during tonic pain
compared with the baseline period. Connectivity
strength reductions are indicated by the cool colour
scale and overlaid onto an individual's T1-weighted
anatomical image set. Note the decreases within the
IPC and mPFC. Plots of mean ± SEM PCC con-
nectivity strength are also shown for the baseline
and each of the 5 min tonic pain periods. The grey
shading indicates the tonic pain period. *
p < 0.05, 2-tailed paired t-test.
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astrogliosis. As mentioned above, Seminowicz and Davis found that
during an attention-demanding cognitive task in the presence of acute
pain, the DMN and task-positive networks displayed anti-correlated ISO
ﬂuctuations within a similar frequency range as those explored in this
study (Seminowicz and Davis, 2007b). This further supports the notion
that changes in ISO power may represent a fundamental property of
brain function.
In addition to altered ISO and overall activity levels, we found that
both chronic and tonic pain groups displayed decreased PCC con-
nectivity strengths with other DMN regions. Decreased PCC con-
nectivity with the mPFC and IPC occurred in both chronic and tonic
pain groups, and also with the precuneus in chronic pain subjects.
These decreases are consistent with previous studies reporting de-
creased DMN connectivity in individuals with chronic back pain,
complex regional pain syndrome and osteoarthritis (Baliki et al., 2014),
although in individuals with temporomandibular disorder, DMN con-
nectivity strengths reportedly increase (Kucyi et al., 2014). The PCC is a
key neural hub in the DMN (Fransson and Marrelec, 2008) and is ac-
tivated during the regulation of attention (Gusnard et al., 2001; Hahn
et al., 2007; Small et al., 2003) and displays hypometabolism in in-
dividuals with cognitive impairment (Liang et al., 2008; Minoshima
et al., 1997; Valla et al., 2001). Since there is evidence of decreased
connectivity between the PCC and other DMN areas, such as the pre-
cuneus, in attention deﬁcit hyperactivity disorder, a condition char-
acterised by a reduced ability in paying attention (Castellanos et al.,
2008; Rubia et al., 2005; Uddin et al., 2008), it is possible that reduced
PCC connectivity during pain also underlies an altered ability to attend
to particular tasks.
If as hypothesized, the DMN is acting as a sentinel by monitoring the
external environment (Buckner et al., 2008), ISO and connectivity
changes within the DMN may underpin such monitoring during pain
and reduce the ability of other stimuli to attract an individual's atten-
tion away from the pain. Indeed, connectivity strength within the DMN
in chronic pain subjects is correlated to pain rumination, a measure of
an individual's continual focus on his/her pain and its potential nega-
tive outcomes (Kucyi et al., 2014). Consistent with this previous study,
we did not ﬁnd any signiﬁcant relationships between either ISO power
or PCC connectivity strengths with either on-going pain intensity or
pain duration in chronic pain subjects. However, others have reported
relationships between DMN connectivity and ongoing pain intensity
and duration and there is evidence that connectivity strengths between
the DMN and areas such as insular cortex are related to the on-going
pain intensity in individuals with chronic lower back pain (Loggia et al.,
2013) and also in those with ﬁbromyalgia (Napadow et al., 2012).
These data raise the prospect that diﬀerences in the relationships be-
tween DMN connectivity and clinical pain variables may depend on the
speciﬁc type of pain investigated, the modality and/or analysis of the
acquired data or the speciﬁc circuitry examined. Our study does how-
ever, show that DMN changes occur during experimentally applied
painful stimuli in healthy controls, suggesting that it is the presence of
pain per se that is more likely responsible for such DMN changes.
Furthermore, it is curious that this decreased DMN connectivity
strength is coupled to decreased ISO power, raising the prospect that
DMN functional coupling at rest is signiﬁcantly inﬂuenced by signal
coupling within the 0.03–0.06 Hz range.
Whilst we have clearly shown that altered DMN dynamics occur in
healthy individuals during experimentally applied painful stimuli, the
interpretation of what these changes represent remain unknown.
One limitation of this study is that during the tonic pain experiment,
we asked each subject to indicate when deviations from the target pain
intensity percept occurred. Although this could have introduced a po-
tential motor confound, given that most subjects indicated a deviation
no more than 5 times over the course of the entire 20 min pain period,
we suggest that this potential for such a confound is negligible.
Furthermore, we did not measure behavioural changes such as changes
in cognitive or attention-demanding tasks, particularly in the tonic pain
group. Future investigations could explore the eﬀect of changes in DMN
function evoked by both tonic and chronic pain.
5. Conclusions
We have found that altered DMN dynamics is not unique to chronic
pain but also occurs during tonic pain in healthy controls. Both chronic
and tonic pain are attention demanding stimuli competing for cognitive
resources, and functional changes within the DMN may underlie some
of the attentional and cognitive alterations that occur in the presence of
pain.
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Brainstem Pain-Control Circuitry Connectivity in Chronic
Neuropathic Pain
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and XLuke A. Henderson1
1Department of Anatomy and Histology and 2Faculty of Dentistry, University of Sydney, Sydney 2006, New South Wales, Australia
Preclinical investigations have suggested that altered functioning of brainstem pain-modulation circuits may be crucial for the mainte-
nance of some chronic pain conditions. While some human psychophysical studies show that patients with chronic pain display altered
pain-modulation efficacy, it remains unknownwhether brainstempain-modulation circuits are altered in individuals with chronic pain.
The aim of the present investigationwas to determine whether, in humans, chronic pain following nerve injury is associated with altered
ongoing functioning of the brainstem descending modulation systems. Using resting-state functional magnetic resonance imaging, we
found thatmale and female patients with chronic neuropathic orofacial pain show increased functional connectivity between the rostral
ventromedial medulla (RVM) and other brainstem pain-modulatory regions, including the ventrolateral periaqueductal gray (vlPAG)
and locus ceruleus (LC).We also identified an increase in RVM functional connectivity with the region that receives orofacial nociceptor
afferents, the spinal trigeminal nucleus. In addition, the vlPAG and LC displayed increased functional connectivity strengths with higher
brain regions, including the hippocampus, nucleus accumbens, and anterior cingulate cortex, in individuals with chronic pain. These
data reveal that chronic pain is associated with altered ongoing functioning within the endogenous pain-modulation network. These
changes may underlie enhanced descending facilitation of processing at the primary synapse, resulting in increased nociceptive trans-
mission to higher brain centers. Further, our findings show that higher brain regions interact with the brainstem modulation system
differently in chronic pain, possibly reflecting top–down engagement of the circuitry alongside altered reward processing in pain
conditions.
Key words: analgesia; chronic pain; locus ceruleus; midbrain periaqueductal gray; rostral ventromedial medulla; spinal trigeminal
nucleus
Introduction
Experimental animal studies have revealed that the brainstem
contains multiple neural circuits that can profoundly inhibit or
facilitate incoming nociceptive information at the level of the
primary afferent synapse. These descending modulatory circuits
include direct and indirect descending projections to the dorsal
horn and spinal trigeminal nucleus (SpV) from such regions as
the midbrain periaqueductal gray matter (PAG), the rostral ven-
tromedial medulla (RVM), the locus ceruleus (LC), and the
subnucleus reticularis dorsalis (SRD; Basbaum and Fields, 1984;
Heinricher et al., 2009; Ossipov et al., 2010; Mason, 2012). In
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Significance Statement
Experimental animal models and human psychophysical studies suggest that altered functioning of brainstem pain-modulation
systems contributes to the maintenance of chronic pain. However, the function of this circuitry has not yet been explored in
humans with chronic pain. In this study, we report that individuals with orofacial neuropathic pain show altered functional
connectivity between regionswithin thebrainstempain-modulationnetwork.Wesuggest that these changes reflect largely central
mechanisms that feed back onto the primary nociceptive synapse and enhance the transfer of noxious information to higher brain
regions, thus contributing to the constant perception of pain. Identifying the mechanisms responsible for the maintenance of
neuropathic pain is imperative for the development of more efficacious therapies.
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addition to a presumed role inmodulating acute noxious stimuli,
these circuits might be involved in the generation and mainte-
nance of chronic pain, particularly that following nerve damage
or presumed damage (i.e., chronic neuropathic pain), as sug-
gested by recent preclinical data (Burgess et al., 2002; Pertovaara,
2013; Wang et al., 2013).
While it remains unknown whether the function of these
brainstemmodulatory circuits is altered in humans with chronic
pain, multiple psychophysical investigations have suggested that
they are. For example, some studies using conditioned painmod-
ulation, in which the perceived pain intensity of one noxious
stimulus is modified by another at a distant site, have provided
evidence that the effectiveness of these pain-modulation circuits
is significantly altered in individuals with various chronic pain
conditions (Yarnitsky, 2010; Garrett et al., 2013; Nasri-Heir et al.,
2015). There is evidence from experimental studies in both ani-
mals and humans that the effects of these pain-modulatory sys-
tems are mediated by structures in the brainstem, in particular
the area of the SRD (Le Bars et al., 1979; De Broucker et al., 1990;
Youssef et al., 2016). These studies strongly suggest that altera-
tions in the ongoing functioning of brainstem nociceptive mod-
ulation systemsmay play a critical role in the initiation and/or the
maintenance of various human chronic pain conditions.
To date, no study has focused on the ongoing function of
brainstem nociceptive modulation circuits, including the PAG,
RVM, LC, and SRD in humans with chronic pain. The aim of the
present study was to use resting-state functional magnetic reso-
nance imaging (fMRI) to explore the ongoing function of these
brainstem circuits in individuals with painful trigeminal neurop-
athy (PTN), a chronic orofacial neuropathic pain disorder. We
hypothesize that individuals with PTN would display enhanced
fMRI signal covariation between regions involved in endogenous
pain modulation, such as the ventrolateral PAG (vlPAG), RVM,
LC, and SRD, and the region where orofacial nociceptive infor-
mation enters the CNS, i.e., the SpV. Such changes may result in
greater facilitation of ongoing activity within the SpV, enhanced
noxious information transfer to higher brain centers, and the
constant perception of pain. Furthermore, these brainstem cir-
cuits can be engaged by higher brain regions, such as the orbito-
frontal cortex and ventral striatum (Bandler et al., 2000; Floyd et
al., 2000) and so we hypothesize that PTN subjects will display
altered functional connectivity strengths between these rostral
brain regions and the PAG and LC.
Materials andMethods
Subjects and pain measures
Twenty-four subjects with PTN [eight males; mean (SEM) age, 46 3
years; range, 19–71 years] and 46 pain-free subjects (17 males; age, 42
2 years; range, 22–66 years) were recruited for the study between 2011
and 2017. There was no significant difference in age (t test; p 0.05) or
gender distribution ( 2 test, p  0.05) between the two subject groups.
PTN subjects were recruited and diagnosed in accordance with the
Liverpool criteria (Nurmikko and Eldridge, 2001) by clinicians (C.C.P,
E.R.V, G.M.M) in the research group. Control participants were re-
cruited by word ofmouth. Informedwritten consent was obtained for all
procedures, which were conducted with the approval of local institu-
tional human research ethics committees and are consistent with the
Declaration of Helsinki. Other data from several subjects used in this
investigation have been used in previous studies (Gustin et al., 2011;
Henderson et al., 2013; Wilcox et al., 2015a; Alshelh et al., 2016).
The PTN subjects assessed the intensity of their ongoing pain using a
visual analog scale (0, no pain, to 10, worst pain imaginable) three times
per day for 7 consecutive days during the week of the scanning session.
The average of these pain ratings was taken as a measure of current pain
intensity. Subjects also described their pain distribution by outlining the
area of their chronic pain on a standard drawing of the face and described
the quality of their ongoing pain by completing aMcGill Pain Question-
naire (MPQ).
MRI scans
Each subject was positioned supine onto theMRI scanner bed and placed
into a 3 tesla MRI scanner (Achieva, Philips Medical Systems), with the
head immobilized in a 32-channel head coil to which padding was added
to prevent head movement. A series of 180 gradient echo echo-planar
image sets with blood oxygen level-dependent contrast were collected.
Each image volume was positioned to cover the entire brain and extend
caudally to include the caudal brainstem (37 axial slices; repetition
time 2000 ms; echo time 30 ms; raw voxel size, 3.0 3.0 4.0 mm
thick). In all 70 subjects, a high-resolution T1-weighted anatomical im-
age of the entire brain was also collected (288 axial slices; repetition
time 5600 ms; raw voxel size, 0.87 0.87 0.87 mm thick).
MRI and statistical analysis
Image preprocessing
Using SPM12 (Friston et al., 1995) and custom software, fMRI images
were realigned andmovement parameters examined to ensure no subject
displayed 1 mm volume-to-volume movement in the X, Y, and Z
planes and 0.05 radians in the pitch, roll, and yaw directions. Physiolog-
ical (i.e., cardiovascular and respiratory) noise was modeled and re-
moved using the drifter toolbox (Sa¨rkka¨ et al., 2012). The fMRI images
were detrended to remove global signal-intensity changes and then
coregistered to the same subject’s T1-weighted anatomical image. The
T1-weighted image was then spatially normalized to the Montreal Neu-
rological Institute (MNI) template. The normalization parameters were
then applied to the fMRI images. This process resulted in the fMRI im-
ages being resliced into 2  2  2 mm voxels. To improve brainstem
normalization accuracy, the brainstems of the fMRI image sets were
isolated using the SUIT (A Spatially Unbiased Atlas Template of the
Figure 1. Locations of functional connectivity seeds overlaid onto axial slices of a wet spec-
imen, a representative T1-weighted anatomical image, and a representative brainstem fMRI
image normalized to the SUIT template. Slice locations in MNI space are indicated at the top
right. Thepresent study focusedon the following regionsof interest: themidbrain vlPAG, theLC,
the RVM, and the SpV.
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Cerebellum and Brainstem) toolbox in native space (Diedrichsen, 2006).
Binary masks of the brainstem were created and these masks were then
used to spatially normalize each image set to the SUIT brainstem tem-
plate in MNI space. The resulting normalized fMRI images remained
unsmoothed so as to maintain spatial accuracy of small brainstem
structures.
Resting functional connectivity analysis
Voxel-by-voxel analysis. We performed brainstem-only functional con-
nectivity analyses using the RVM region as the seed. Our previous inves-
tigations have shown that the nucleus raphe magnus within the RVM
region displays anatomical changes in individuals with chronic pain
(Wilcox et al., 2015b). The RVM seed comprised six contiguous voxels:
two voxels each at three rostrocaudal levels from z coordinate 53 to
49 inMNI space (Fig. 1). In each subject, signal intensity changes were
extracted from this RVM seed and voxel-by-voxel analyses were per-
Figure 2. Regions within the brainstem endogenous analgesic pathways that show signifi-
cantly greater RVM functional connectivity in subjects with PTN compared with pain-free con-
trols. Left, Diagram of the endogenous analgesic pathways that modulate nociceptive
transmission at the spinal dorsal horn (DH) and SpV. Yellow, Nociceptor afferent projection;
blue, efferent projections from vlPAG; red, efferent projections from LC; green, efferent projec-
tions from RVM. Middle, Regions with enhanced RVM functional connectivity in subjects with
PTN (hot color scale) overlaid onto template axial T1-weighted images. Slice locations in MNI
space are indicated at the top right of each slice. The location of the RVM seed is indicated in
green. Subjects with PTN show an increase in RVM connectivity with the right vlPAG, bilateral
LC, right SRD, and left SpV. Right, Bar graphs ofmean (SEM) RVMconnectivity strengthswith
significant clusters identified in the voxel-by-voxel analysis. *, Significant difference deter-
mined in the voxel-by-voxel analysis. Connectivity strength in arbitrary units.
Table 1. PTN subject characteristics
Subject
Age
(years) Gender Site
Pain intensity
(visual analog scale)
Pain duration
(months) Medications
1 56 Male Right lower jaw 2.4 72 Amitriptyline
2 45 Female Bilateral (left jaw and temple) 4.8 132 Carbamazepine
3 45 Female Left upper jaw 4.5 42 None
4 42 Female Bilateral lower jaw 4.0 42 Paracetamol, ibuprofen
5 67 Female Left upper jaw and temple 8.4 168 None
6 43 Male Left upper jaw and temple 5.8 192 Desvenlafaxine
7 44 Female Bilateral upper and lower jaw 1.2 18 Ibuprofen, codeine phosphate, paracetamol
8 65 Female Left face and neck 2.5 84 Amitriptyline, paracetamol
9 50 Female Right lower jaw 0.1 84 None
10 67 Female Right upper jaw 3.9 240 Thyroxine sodium, rosuvastatin, venlafaxine,
pregabalin, phenylethylamine, ergotamine
11 27 Female Left upper jaw 6.9 29 Ibuprofen, duloxetine
12 65 Male Bilateral: left lower and right upper jaw 0.4 26 Amitriptyline
13 38 Female Left lower jaw 3.4 96 Gabapentin, amitriptyline
14 45 Female Bilateral jaw 2.8 17 Ibuprofen
15 19 Male Right upper jaw 5.0 88 None
16 59 Female Left lower jaw 4.4 115 None
17 59 Female Left upper jaw 4.4 120 None
18 27 Male Left upper jaw and under eye 3.6 8 Palmitoylethanolamide, paracetemol, benzodiazepines
19 71 Female Left upper jaw 5.1 9 Meloxicam, paracetamol, gabapentin, nortriptyline
20 37 Male Left upper jaw and under eye 2.0 84 Oxycodone, gabapentin, paracetamol
21 35 Female Bilateral upper jaw 6.1 27 Flavonoids, paracetamol
22 27 Male Right upper and lower jaw 0.5 41 Palmitoylethanolamide, sertraline
23 21 Female Right upper jaw 1.3 144 Palmitoylethanolamide
24 35 Male Right upper jaw 1.5 96 Palmitoylethanolamide
Table 2. Location of clusters in MNI space, t values, and sizes of clusters that had
significantly different resting RVM and LC connectivity strengths in subjects with
PTN compared to control subjects
MNI coordinates
t value Cluster sizeX Y Z
RVM connectivity
PTN Control
Right vlPAG 4 32 9 2.72 9
LC
Right 4 38 23 3.92 24
Left 2 36 21 3.67
Right SRD 6 44 41 2.81 2
Left SpV 6 42 53 3.22 6
Right LC connectivity
PTN Control
Left SRD 4 44 55 2.71 1
RVM 0 36 47 3.11 6
Control PTN
Right vlPAG 6 28 5 3.10 28
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formed to determine which brainstem areas
displayed significant signal-intensity cova-
riations with the RVM. The movement para-
meters derived from the realignment step were
included as nuisance variables. The connectiv-
ity maps were smoothed using a 2 mm full-
width half-maximum Gaussian filter and then
placed into a second-level random-effects pro-
cedure to determine significant differences in
RVM connectivity strength in arbitrary units,
(A.U.), betweenPTNand control subjects. Fol-
lowing an initial uncorrected threshold of p 
0.001, small-volumecorrections were applied on
the PAG, RVM, LC, SRD, and SpV using 40
mm3 hyper-rectangles centered at the location
of each region based on the Duvernoy Brains-
tem Atlas (Naidich et al., 2009).
The resulting clusters of significant differ-
ence were used to extract connectivity strength
values in each subject, and the mean (SEM)
values were plotted to provide a measure of
connectivity direction. In PTN subjects, we in-
vestigated the significance of relationships be-
tween RVM connectivity strengths and pain
characteristics (i.e., pain intensity and dura-
tion) using regression analyses (Pearson’s r,
p  0.05).
The brainstem RVM connectivity analysis
resulted in a significant cluster in the region of
the LC. Since this region is known to be in-
volved in nociceptive modulation (Taylor and
Westlund, 2017), we also explored the resting
connectivity of this brainstem region. The LC
seed comprised six contiguous voxels: two vox-
els each at three rostrocaudal levels from z coordinate 23 to 19 in
MNI space (Fig. 1).We performed a brainstem resting connectivity anal-
ysis of the right LC in the same way as that described above for the RVM.
Additionally, in PTN subjects, the significance of relationships between
LC connectivity strengths and pain characteristics (i.e., pain intensity
and duration) were determined for significant clusters using regression
analyses (Pearson’s r, p 0.05).
In addition to brainstem-specific analyses, resting connectivity strengths
from the PAG and LC to higher brain regions were explored. Resting
signal intensities from the right LC seed used for the brainstem analysis
and from a right PAG seed (six voxels in size, derived from RVM con-
nectivity analysis and spread across z coordinates 11, 9, 7) were
extracted and voxel-by-voxel analyses performed to determine connec-
tivity strengths with higher brain regions. Movement parameters were
included as nuisance variables and the resultant connectivity maps were
smoothed using a 6mm full-width half-maximumGaussian filter. These
connectivity maps were placed into a second-level random-effects pro-
cedure to determine significant differences in connectivity strengths
between PTN and control subjects. Following an initial uncorrected
threshold of p 0.001, we applied small-volume corrections (familywise
error, p 0.05). The resulting clusters of significant difference were used
to extract connectivity strength values in each subject and the mean
(SEM) values plotted to provide ameasure of connectivity direction. In
PTN subjects, the significance of relationships between LC and PAG
connectivity strengths and pain characteristics (i.e., pain intensity and
duration) were determined for significant clusters using regression anal-
yses (Pearson’s r, p 0.05).
Subdivision analysis. To determine whether there are variations in ros-
trocaudal connectivity strengths within the vlPAG and SpV, we exam-
ined resting functional connectivity between these regions and both the
RVM and LC. Rostrocaudal subdivisions of the vlPAG and SpV were
created based on our voxel-by-voxel analyses and the Duvernoy Human
Brainstem Atlas (Naidich et al., 2009). For the vlPAG, five four-voxel
volumes of interest were created along the rostrocaudal axis on the left
and right sides, extending from the caudal vlPAG at z coordinate 13,
rostrally to z coordinate5 (Fig. 1). Similarly, for the SpV, 14 four-voxel
volumes of interest were created along the rostrocaudal axis on the left
and right sides, extending from the caudal SpV at z coordinate 61,
rostrally to z coordinate 35. RVM and LC connectivity strengths of
these vlPAG and SpV volumes of interest were extracted and differences
between controls and PTN subjects determined (p 0.05, two-sample t
test, Bonferroni corrected for multiple comparisons). Two PTN subjects
were excluded from the SpV subdivision analyses due to their fMRI
images not covering the entire caudal brainstem at z level61.
Results
Pain characteristics
Individual PTN subject characteristics are shown in Table 1. All
24 PTN subjects were classified as having post-traumatic neurop-
athy. In 19 PTN patients, chronic pain was unilateral (7 right, 12
left), and the remaining five PTN subjects reported bilateral pain.
In all PTN subjects, pain was located in the second and third
trigeminal nerve divisions, with one patient also reporting pain in
the firstdivision.Theirmean(SEM)pain intensitywas3.50.4of
10 and their mean duration of pain was 82.2 12.5 months. Using
the MPQ, PTN subjects most frequently described their pain as
throbbing (58%), shooting (54%), and nagging (67%).
Brainstem resting functional connectivity
RVM voxel-by-voxel analysis
The brainstem voxel-by-voxel analysis revealed several key areas
that display altered resting RVM functional connectivity in PTN
subjects compared with controls (Fig. 2, Table 2). PTN subjects
showed a significant increase in RVMconnectivity strength in the
region encompassing the right vlPAG (mean  SEM functional
connectivity, a.u.: control,0.19 0.05; PTN, 0.11 0.09), the
region of the LC bilaterally (control,0.12 0.04; PTN, 0.18
0.07), the right dorsomedial medulla in the area of the SRD (con-
Figure 3. Subjects with PTN show increased RVM functional connectivity in discrete regions within the SpV. Middle, Locations
of rostrocaudal vlPAG and SpV volumes of interest are indicated in green, with slice locations inMNI space indicated at the top left
of each slice. Top,Mean (SEM) RVMconnectivity strengths along the rostrocaudal axis of the left and right vlPAG in subjectswith
PTN and healthy controls. Comparedwith controls, PTN subjects show a trend toward increased RVM connectivity with the vlPAG.
However, this did not reach statistical significance. Bottom, RVM connectivity strengths in PTN and control subjects with the left
and right SpV. Comparedwith controls, subjects with PTN show enhanced RVM connectivitywithin the left SpVi (z level53) and
SpVo (z level51), and no connectivity differences within the SpV caudalis (SpVc). *p 0.05, Bonferroni corrected for multiple
comparisons. Connectivity strength in arbitrary units.
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trol, 0.11  0.03; PTN, 0.29  0.06), and in the region encom-
passing the left SpV (control, 0.23 0.03; PTN, 0.42 0.05). In
no brainstem region did controls show significantly greater RVM
connectivity than PTN patients. In PTN subjects, there were no
significant correlations between RVM connectivity strength in
these brainstem regions and pain intensity (vlPAG: r 0.21; LC:
r  0.11; SRD: r  0.15; SpV: r  0.03, all p’s  0.05) or pain
duration (vlPAG: r 0.18; LC: r 0.05; SRD: r 0.19; SpV: r
0.38, all p’s 0.05).
RVM to vlPAG and SpV subdivision analysis
The subdivision analysis of RVM connectivity over the rostro-
caudal extent of the bilateral vlPAG revealed that PTN subjects
showed a trend toward higher RVM connectivity. However, this
did not reach significance at the threshold we set (Fig. 3). In no
vlPAG subdivision did controls show greater RVM connectivity
than PTN subjects. In contrast, RVM–SpV subdivision analysis
revealed that PTN subjects displayed greater connectivity strength
with the left SpV (Fig. 3). This significantly greater RVM connec-
tivity strength was restricted to the SpV within the region of the
subnucleus interpolaris (SpVi; z53: control, 0.24 0.03; PTN,
0.46  0.06, p  0.001) and subnucleus oralis (SpVo; z 51:
control, 0.27 0.03; PTN, 0.46 0.06, p 0.002). Therewere no
differences between groups in RVM–SpV connectivity strength
on the right side and, again, in no SpV region did controls show
greater connectivity than PTN subjects.
LC voxel-by-voxel analysis
The brainstem voxel-by-voxel analysis revealed two brainstem
regions in which PTN subjects displayed greater LC connectivity
compared with controls (Fig. 4, Table 2). Significantly greater LC
connectivity in PTN subjects occurred within the left caudal SRD
(control, 0.02 0.03; PTN, 0.21 0.06) and in the region of the
RVM (control, 0.06  0.05; PTN, 0.21  0.06). In contrast,
PTN subjects showed significantly reduced LC connectivity
strength with the right rostral vlPAG (control, 0.21 0.04; PTN,
0.03 0.05). In PTN subjects, there were no significant corre-
lations between LC connectivity strength in these three brainstem
regions and pain intensity (SRD: r 0.26; RVM: r 0.06; vlPAG:
r 0.33; all p’s 0.05) or pain duration (SRD: r 0.11; RVM:
r 0.12; vlPAG: r 0.21; all p’s 0.05).
LC to vlPAG and SpV subdivision analysis
The subdivision analysis revealed that, in direct contrast to the
RVM, LC connectivity strength with the right vlPAG was signif-
icantly reduced in PTN subjects (Fig. 5). PTN subjects showed
significantly reduced LC connectivity strength in a discrete re-
gion of the rostral vlPAG (z 5: control, 0.25  0.05; PTN,
0.04  0.07, p  0.001). There were no differences between
groups in LC–vlPAG connectivity strength on the left side and in
no vlPAG region did controls show greater LC connectivity than
PTN subjects. In contrast, the LC–SpV subdivision analysis re-
vealed that PTNs did not differ from controls in LC connectivity
strength at any region of the SpV.
Whole-brain resting functional connectivity
PAG voxel-by-voxel analysis
The whole-brain voxel-by-voxel analysis revealed several key ar-
eas that display altered resting vlPAG functional connectivity
in PTN subjects compared with controls (Fig. 6, Table 3). PTN
subjects showed a significant increase in vlPAG connectivity
strength in the region of the left nucleus accumbens (NAc; con-
trol, 0.02  0.03; PTN, 0.16  0.04), the bilateral posterior
hippocampus (left: control, 0.01  0.03; PTN, 0.18  0.05;
right: control, 0.003  0.02; PTN, 0.17  0.06), the bilateral
thalamus in the region of the mediodorsal nucleus (left: control,
0.02 0.04; PTN, 0.26 0.06; right: control,0.03 0.03; PTN,
0.17  0.06), and in the bilateral anterior hippocampus (left:
control,0.01 0.03; PTN, 0.24 0.06; right: control,0.01
0.02; PTN, 0.18 0.04). In PTN subjects, there were no signifi-
cant correlations between vlPAG connectivity strength in these
brain regions and pain intensity (NAc, r  0.09; left posterior
hippocampus, r 0.32; right posterior hippocampus, r 0.027;
left thalamus, r  0.04; right thalamus, r  0.27; left anterior
hippocampus, r 0.15; right anterior hippocampus, r 0.08; all
p’s  0.05) or pain duration (NAc, r  0.31; left posterior hip-
pocampus, r 0.21; right posterior hippocampus, r 0.20; left
thalamus, r  0.14; right thalamus, r  0.09; left anterior hip-
pocampus, r  0.17; right anterior hippocampus, r  0.06; all
p’s 0.05).
LC voxel-by-voxel analysis
The whole-brain voxel-by-voxel analysis revealed several regions
in which PTN subjects displayed greater LC connectivity com-
pared with controls (Fig. 6, Table 3). Significantly greater LC
connectivity in PTN subjects occurredwithin the left insula (con-
trol, 0.001  0.02; PTN, 0.11  0.04), the left NAc (control,
0.003  0.03; PTN, 0.16  0.04), the right anterior cingulate
cortex (ACC; control, 0.02 0.01; PTN, 0.08 0.02), andwithin
the bilateral frontal cortex (left: control, 0.02 0.02; PTN, 0.15
Figure4. Regionswithin the brainstempain-modulation system inwhich subjectswith PTN
showaltered LC functional connectivity comparedwithpain-free controls. Areaswith enhanced
(hot color scale) and reduced (cool color scale) LC connectivity in PTN subjects are overlaid onto
template axial T1-weighted images. Slice locations inMNI space are indicated at the top right of
each slice, with the location of the LC seed indicated in green. Subjects with PTN showed an
increase in LC connectivity with the left caudal SRD and the RVM, as well as a decrease in LC
connectivitywith the right vlPAG. Right, Bar graphs ofmean (SEM) LC connectivity strengths
with significant clusters identified in the voxel-by-voxel analysis. *, Significant difference de-
termined in the voxel-by-voxel analysis. Connectivity strength in arbitrary units.
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0.03; right: control, 0.002  0.02; PTN,
0.13 0.04). In PTN subjects, there was a
significant positive correlation between
LC–ACC connectivity strength and pain
intensity (r 0.42, p 0.047). That is, the
greater the pain intensity, the greater the
LC–ACC connectivity strength. No other
significant correlations were observed.
Discussion
The results of this study demonstrate that
PTN, a chronic neuropathic pain condi-
tion, is associatedwith ongoing functional
alterations within the brainstem endog-
enous pain-modulation circuitry. Spe-
cifically, PTN patients showed increased
functional connectivity between the RVM
and the vlPAG, SRD, and LC, as well as
with the brainstem region that receives
orofacial nociceptor afferents, the SpV.
Furthermore, PTN subjects showed in-
creased functional connectivity strengths
between these brainstemcircuits andhigher
brain regions, such as the hippocampus,
NAc, and ACC. These data show that
chronic neuropathic pain is associated
with ongoing functional changes in brain-
stem pain-modulation circuits that are
likely involved in maintaining pain fol-
lowing nerve injury.
It is well known from experimental animal investigations that
the vlPAG can evoke an opioid-mediated analgesia and that this
effect is mediated by a projection to the spinal dorsal horn and
SpV via the RVM (Basbaum and Fields, 1984; Fields and Hei-
nricher, 1985; Bandler and Shipley, 1994). While it is well known
that the RVM can inhibit incoming noxious information, it can
also facilitate it and it has been suggested that opposing RVM
inhibitory and facilitatory effects are finely balanced at rest in
pain-free individuals (Fields and Heinricher, 1985; Heinricher et
al., 2009; Ossipov et al., 2010). In contrast, in individuals with
neuropathic pain, it has been proposed that this brainstem cir-
cuitry shifts to favor pronociceptive processes that contribute
significantly to the maintenance of chronic pain (Pertovaara et
al., 1996; Burgess et al., 2002; Vera-Portocarrero et al., 2006;
Wang et al., 2013). Indeed, in rodents, deactivation of the PAGor
RVM eliminates the hyperalgesia, allodynia, and spontaneous
pain evoked by spinal nerve ligation (Pertovaara et al., 1996; Bur-
gess et al., 2002; Wang et al., 2013). This functional shift appears
to influence only the primary synapse ipsilateral to the side of
nerve injury, since these analgesic effects are produced following
interruption of the ipsilateral but not the contralateral RVM–
dorsal horn pathway (Wang et al., 2013). Furthermore, this pro-
nociceptive shift in RVM function appears to be strictly related to
the presence of pain behaviors and not to the nerve injury itself
(De Felice et al., 2011).
The increased resting functional coupling between between
the PAG and RVM and between the RVM and SpV reported in
neuropathic pain subjects in this study is consistent with these
preclinical findings and may reflect a state of continuous de-
scending facilitation of nociceptive transmission at the SpV
driven by the vlPAG via the RVM. Interestingly, in PTN subjects
we found increased RVM connectivity specifically within the
transition between the interpolaris and oralis regions of the left
SpV. This was expected given that the majority of our PTN sub-
jects reported left-sided pain and the location of these functional
coupling changes overlaps with our previous reports of structural
changes at the SpVi and SpVo in PTN patients (Wilcox et al.,
2015a).
Alongside the vlPAG and RVM, the LC can also directly and
indirectly modulate nociceptive transmission at the dorsal horn
and SpV (Sasa et al., 1979; Jones and Gebhart, 1986; Tsuruoka et
al., 2003; Pertovaara, 2006; Kaushal et al., 2016). The LC has
reciprocal connections with the vlPAG and the SpV (Sasa and
Takaori, 1973; Jones and Moore, 1977; Cedarbaum and Aghaja-
nian, 1978; Mantyh, 1983), and indeed we found a decrease in
right LC connectivity strength with the rostral region of the ipsilat-
eral vlPAG. However, we found no difference in LC connectivity
strength with the SpV in the PTN subjects. This is surprising, since
facilitation by the noradrenergic system contributes to mechan-
ical hypersensitivity in animal models of neuropathic pain
(Brightwell and Taylor, 2009; Kaushal et al., 2016). However, it
has been proposed that the LC inhibitory effects are engaged
through a direct connection to the dorsal horn and SpV (Sasa et
al., 1974), whereas LC pronociceptive effectsmay bemediated via
the SRD (Martins et al., 2013; Taylor and Westlund, 2017). Our
results are consistent with this idea, as PTN subjects displayed
enhancedLC–SRDconnectivity strength andno change in LC–SpV
connectivity strength. Alongside a decrease in LC–vlPAG con-
nectivity, we found that PTN subjects display greater LC–RVM
connectivity strength than controls, raising the prospect that the
endogenous opioid and noradrenergic pain modulation systems
interact differently in individuals with neuropathic pain. Al-
though tract-tracing studies have shown that direct connections
between the RVMand LC aremodest (Clark and Proudfit, 1991),
it has been demonstrated that the vlPAG–RVM and noradrener-
gic pain systems interact in experimental pain states to produce
inhibitory effects at the dorsal horn (Aimone et al., 1987).
Figure 5. Mean (SEM) LC connectivity strengths along the rostrocaudal axis of the vlPAG and SpV in subjects with PTN
comparedwithpain-free controls.Middle, Locations of rostrocaudal vlPAGandSpVvolumes of interest are indicated in green,with
slice locations inMNI space indicatedat the top left of each slice. Top, SubjectswithPTNshowreducedLC connectivitywith the right
rostral vlPAG at z level5. Bottom, LC connectivity with the left and right SpV does not differ between subjects with PTN and
controls at any point along the SpVc, SpVi, or SpVo subdivisions. *p 0.05, Bonferroni corrected for multiple comparisons.
Connectivity strength in arbitrary units.
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We cannot infer directionality from
functional connectivity analyses, and thus
ascending signal transmission may also
contribute to the alterations in fMRI sig-
nal coupling observed in PTN patients.
Indeed, there are ascending projections
from the SpV to the PAG, RVM, and LC
(Craig, 1992; Bandler and Shipley, 1994;
Sugiyo et al., 2005).While these ascending
influences may be important, we suggest
that the changes in brainstem connectivi-
ties that occur in PTN subjects most likely
represent changes in descending modula-
tion of the SpV since previous investiga-
tions suggest that neuropathic pain can be
maintained solely by central mechanisms,
even if initiated by a peripheral nerve in-
jury (Burgess et al., 2002; Henderson et
al., 2013; Wang et al., 2013).
While the brainstem contains the neu-
ral circuitry necessary for pain modula-
tion, this system can be engaged by higher
brain regions (Heinricher et al., 2009). In-
terestingly, we found increased resting
connectivity strengths between the PAG,
the mediodorsal thalamus, and the hip-
pocampus in PTN subjects compared with
controls. While it is possible that these re-
gions represent top–down modulation of
brainstem circuits, it has been suggested
that the midline thalamic nuclei, such as
the mediodorsal nuclei, receive ascending
communication from the PAG, which is
transferred to the ventral hippocampus to
influence pain-related behaviors (Balles-
teros et al., 2014). Furthermore, the hip-
pocampus sends extensive projections to
the NAc (Viard et al., 2011). The NAc is
involved in mediating reward processing
and goal-directed behavior, two processes
that are disrupted in individuals with chronic pain (Navratilova
and Porreca, 2014; Navratilova et al., 2016). Our PTN patients
also displayed enhanced LC connectivity with the NAc and ACC,
two regions involved in the rewarding effects of pain relief
(Navratilova et al., 2016). Indeed, the only significant linear rela-
tionship occurred between LC–ACC connectivity strength and
pain intensity in PTN subjects.
Several limitations are worth noting. First, given the small size
of brainstem nuclei and the limited spatial resolution of current
functional human brain-imaging techniques, it is difficult to as-
sign significant clusters to specific brainstem nuclei. This does
not, however, negate the validity of our results when placed into
context. That is, our brainstem clusters overlap with regions that
have been shown in preclinical studies to be critical for the ex-
pression of analgesia and our a priori hypothesis was that the
function of these regions would be altered in PTN subjects.
Furthermore, we did not smooth our images so that we could
maintain spatial accuracy, though all these factors do not elimi-
nate the possibility that closely neighboring nuclei are responsi-
ble for the reported differences. Second, the brainstem is
susceptible to physiological noise and movement-related arti-
facts. To limit the potential influence of these factors, we applied
a physiological noise correction and includedmovement param-
Figure 6. Rostral brain regions inwhich subjectswith PTN show increased vlPAG and LC functional connectivity comparedwith
healthy controls. Areas in which subjects with PTN display enhanced vlPAG or LC connectivity (hot color scale) are overlaid onto
template axial and coronal T1-weighted images. Slice locations in MNI space are indicated at the top right of each slice, with the
location of vlPAGand LC seeds indicated in greenon the far left. Top, Subjectswith PTN showenhanced vlPAG connectivitywith the
left NAc, bilateral posterior hippocampus (pHipp), bilateral anterior hippocampus (aHipp), and bilateral thalamus. Bottom, Sub-
jectswithPTNshow increasedLC connectivitywith the left insula andNAc, rightACC, andbilateral frontal cortex. Belowbrain slices,
plots of mean (SEM) vlPAG and LC connectivity strengths in significant clusters identified in the voxel-by-voxel analysis. *,
Significant difference determined in the voxel-by-voxel analyses. Connectivity strength in arbitrary units.
Table 3. Location of whole-brain clusters in MNI space, t values, and sizes of
clusters that had significantly different resting vlPAG and LC connectivity
strengths in subjects with painful PTN compared to control subjects
MNI coordinates
t value Cluster sizeX Y Z
Right vlPAG connectivity
PTN Control
Left NAc 18 2 16 3.44 25
Posterior hippocampus 14 36 6 4.29 43
Left 22 36 4 3.29 3
Right 30 30 12 3.98 14
Thalamus
Left 6 12 0 3.30 9
Right 6 12 2 3.10 3
Anterior hippocampus 24 14 24 4.17 67
Left 36 16 22 4.17 50
Right 26 12 20
Right LC connectivity
PTN Control
Left insula 24 20 12 3.26 8
Left NAc 18 8 16 3.47 17
Right ACC 12 32 16 3.41 2
Frontal cortex
Left 14 16 62 3.11 7
Right 16 12 62 3.37 13
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eters as nuisance variables. A further potential limitation is the
use of unflipped brain images for the PTN subjects. Most subjects
reported unilateral pain, making it unlikely inmost cases to observe
connectivity changes bilaterally. Finally, a possible limitation is that
when reporting between-group differences, we used a statistical
threshold that was not corrected for multiple comparisons. Al-
though this may introduce type-II errors, we limited this possi-
bility by applying small-volume corrections. As detailed above,
since numerous experimental animal investigations have re-
ported that the RVM, PAG, LC, and SRD are critically involved in
analgesic responses, we strongly suggest that small-volume cor-
rections of these brainstem regions are entirely appropriate. De-
spite these limitations, we are confident that the altered
brainstem connectivity presented here represents a functional
difference associated with the presence of chronic neuropathic
pain.
Overall, our findings show that chronic neuropathic pain in
humans is associated with ongoing functional alterations in the
brainstem endogenous pain-modulation system. These findings
complement a wealth of experimental animal data suggesting
that the functioning of brainstem modulation systems shifts to
promote the maintenance of pain behaviors following nerve in-
jury (Burgess et al., 2002; Ossipov et al., 2010; Wang et al., 2013).
Furthermore, it is likely that the resting functioning of these
brainstem circuits sets the ongoing gain of nociceptive process-
ing, and may promote maladaptive responses to experimental
noxious stimuli observed in various pain conditions (King et al.,
2009; Yarnitsky, 2010; Granovsky, 2013). Our findings also sug-
gest that higher brain regions, such as the hippocampus, NAc,
and ACC, interact with the brainstem modulation circuitry dif-
ferently in patients with neuropathic pain, possibly reflecting a
top–down engagement of the circuitry alongside altered reward-
circuit functioning in chronic pain states.
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Abstract
Recurrent thalamocortical connections are integral to the generation of brain rhythms and it is
thought that the inhibitory action of the thalamic reticular nucleus is critical in setting these
rhythms. Our work and others’ has suggested that chronic pain that develops following nerve
injury, that is, neuropathic pain, results from altered thalamocortical rhythm, although whether this
dysrhythmia is associated with thalamic inhibitory function remains unknown. In this investigation,
we used electroencephalography and magnetic resonance spectroscopy to investigate cortical
power and thalamic GABAergic concentration in 20 patients with neuropathic pain and 20
pain-free controls. First, we found thalamocortical dysrhythmia in chronic orofacial neuropathic
pain; patients displayed greater power than controls over the 4–25 Hz frequency range, most
marked in the theta and low alpha bands. Furthermore, sensorimotor cortex displayed a strong
positive correlation between cortical power and pain intensity. Interestingly, we found no differ-
ence in thalamic GABA concentration between pain subjects and control subjects. However, we
demonstrated significant linear relationships between thalamic GABA concentration and enhanced
cortical power in pain subjects but not controls. Whilst the difference in relationship between
thalamic GABA concentration and resting brain rhythm between chronic pain and control subjects
does not prove a cause and effect link, it is consistent with a role for thalamic inhibitory neuro-
transmitter release, possibly from the thalamic reticular nucleus, in altered brain rhythms in
individuals with chronic neuropathic pain.
K E YWORD S
chronic pain, electroencephalography, GABA, thalamocortical rhythm
1 | INTRODUCTION
There is a body of evidence that the thalamus plays a key role in the
development or maintenance of some forms of chronic pain. Direct
electrical stimulation of the thalamus can evoke pain (Lenz et al., 1993);
lesions in the somatosensory thalamus can lead to persistent pain (Kim,
Greenspan, Coghill, Ohara, & Lenz, 2007); and there are abnormal firing
patterns of thalamic neurons in the pain state (Gerke, Duggan, Xu, &
Siddall, 2003; Lenz, Kwan, Dostrovsky, & Tasker, 1989). Furthermore,
the thalamus and its recurrent connections with the cortex play an
integral role in the generation and sustenance of the brain rhythms
that underlie brain function (Buzsaki, 2006; Hughes & Crunelli, 2005).
Given that our perceptions arise from on-going activity within recur-
rent thalamocortical circuits, that is, thalamocortical rhythm, it has been
proposed than an aberration in this circuitry, that is, thalamocortical
dysrhythmia, is a characteristic of several central nervous system disor-
ders, and may be critical for the development and maintenance of
some forms of chronic pain (Jones, 2010; Sarnthein, Stern, Aufenberg,
Rousson, & Jeanmonod, 2006; Walton & Llinas, 2010).
A number of investigations have shown that chronic neuropathic
pain, that is, chronic pain that arises from damage to the nervous sys-
tem, is associated with thalamocortical dysrhythmia (Llinas, Ribary,
Jeanmonod, Kronberg, & Mitra, 1999; Sarnthein et al., 2006; Schulman,
Zonenshayn, Ramirez, Ribary, & Llinas, 2005; Stern, Jeanmonod, &
Sarnthein, 2006). While these previous studies used both electroence-
phalography and magnetoencephalography techniques to explore rest-
ing brain rhythms in individuals with neuropathic pain in different body
locations, they consistently found increases in resting low-frequency
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cortical power in individuals with neuropathic pain. Similarly, we used
resting-state functional magnetic resonance imaging to demonstrate
significantly increased infra-slow oscillation power (0.03–0.06 Hz)
within the ascending pain pathway, including the thalamus, in individu-
als with chronic orofacial neuropathic pain (Alshelh et al., 2016). We
demonstrated that increased infra-slow oscillations were temporally
coupled across specific regions in the ascending pain pathway, includ-
ing the ventroposterior medial thalamus, the thalamic reticular nucleus
(TRN), and the orofacial representation in the primary somatosensory
cortex.
We also previously showed that neuropathic pain is associated
with significantly reduced on-going activity in the region of the TRN
(Gustin et al., 2014; Henderson et al., 2013). The TRN surrounds the
rostral and lateral surface of the dorsal thalamus, contains exclusively
GABAergic neurons and, via extensive inhibitory outputs, modulates all
incoming sensory information on its way to the cerebral cortex (Buz-
saki, 2006; Guillery, Feig, & Lozsadi, 1998; Krause, Hoffmann, & Hajos,
2003; McAlonan, Cavanaugh, & Wurtz, 2008; Pinault, 2004; Zikopou-
los & Barbas, 2006). The TRN therefore plays a critical role in control-
ling the firing patterns of ventroposterior thalamic neurons and is
thought to play a critical role in controlling thalamocortical rhythm
(Fuentealba & Steriade, 2005). Indeed, preclinical studies have shown
that inhibition of the TRN increases power in the same low-frequency
range as that seen in individuals with neuropathic pain (Marini, Giglio,
Macchi, & Mancia, 1995; Marini, Ceccarelli, & Mancia, 2002). This is
consistent with our previous finding of significantly reduced thalamic
(TRN) GABAergic content in individuals with neuropathic pain (Gustin
et al., 2014; Henderson et al., 2013) and raises the prospect that fol-
lowing nerve injury, reduced GABAergic output from the TRN results
in thalamocortical dysrhythmia.
In this study, we used electroencephalography and magnetic reso-
nance spectroscopy to determine the relationship between thalamo-
cortical rhythm and thalamic GABA concentration in individuals with
chronic orofacial neuropathic pain compared to healthy pain-free
controls. We hypothesise that individuals with chronic orofacial neuro-
pathic pain would (a) display altered thalamocortical rhythm character-
ized by increased low frequency power, (b) display reduced thalamic
GABA content, and (c) show a magnitude of thalamocortical dysrhyth-
mia correlated with a reduction in thalamic GABA.
2 | MATERIALS AND METHODS
2.1 | Participants
Twenty subjects with chronic orofacial neuropathic pain (7 males;
mean6 SEM age 50.164.4 years), and 20 healthy pain-free control
subjects (7 males, mean age 42.262.9 years) were recruited. The two
groups were gender-matched and there was no significant difference in
age between the groups (t test; p> .05). Subjects with chronic (>3
months duration) orofacial neuropathic pain were referred by an oral
maxillofacial surgeon (author E.R.V.) after a diagnosis of post-traumatic
trigeminal neuropathy (Nurmikko & Eldridge, 2001). Standard MRI
safety contraindications (cardiac pacemaker, pregnancy, metal implants)
and EEG safety considerations (history of head injury or seizures) were
applied and potential participants were also excluded if they suffered
from psychiatric or neurological disorders.
As well as giving information on their relevant clinical history, each
chronic pain subject kept a pain diary during the seven days prior to or
following the EEG/MRI session. They recorded the intensity of their
on-going pain three times a day using a 10 cm horizontal visual ana-
logue scale (VAS), with 0 indicating “no pain” and 10 indicating “the
most intense imaginable pain.” These pain intensity scores were then
averaged over the 7-day period to create a mean pain intensity score.
Each chronic pain subject also outlined the location of their on-going
pain on a standard drawing of the head, listed their current medication
use and completed the McGill Pain Questionnaire (Melzack, 1975),
which directs respondents to select sensory, emotional, and cognitive
qualitative descriptors of their pain. Informed written consent was
obtained for all procedures according to the Declaration of Helsinki
and the study was approved by our local Institutional Human Research
Ethics Committees. A subset of the neuroimaging data (not spectros-
copy or EEG data) from 11 of the 20 chronic pain subjects was used in
a previous investigation (Alshelh et al., 2016).
2.2 | Electroencephalography (EEG)
The EEG assessment was carried out at approximately the same time
of day, in the morning, for all participants, to control for natural diurnal
changes in brain rhythms (Sarnthein et al., 2006). A 32-channel EEG
cap (NEURO PRAX, neuroCare Group, Germany) containing premeas-
ured electrode sites according to the 10–20 system was fitted to each
participant. Chest and eye electrodes were also fitted to monitor car-
diac activity, and eye/facial muscle contractions, respectively. EEG data
were acquired in a quiet, dimly-lit room for a continuous 5-min period
with the subject relaxed and with their eyes closed. EEG recordings
were sampled at a rate of 500 Hz and a band filter of 0.3–70 Hz with a
notch filter at 50 Hz was applied.
2.3 | Magnetic resonance spectroscopy (MRS)
MRS measurements were acquired immediately prior to the EEG and on
the same morning. All subjects lay supine on the bed of a 3 T MRI scan-
ner (Philips Achieva TX) with their head immobilized in a close-fitting
32-channel head coil. With each subject relaxed and at rest, a high
resolution T1-weighted anatomical scan was acquired (repetition
time55600 ms; echo time52.5 ms; flip angle588; voxel size5
0.87 mm3). Using this T1-weighted anatomical scan as a guide, a
20 3 20 3 20 mm voxel was placed on the thalamus contralateral to
the side of the on-going pain in the chronic pain subjects and on the
right thalamus of the control subjects. GABA-edited MEGA-PRESS
spectroscopy was then performed on this voxel (repetition
time52000 ms; echo time568 ms; 1024 data points) (Mullins et al.,
2014). One hundred averages were acquired with the MEGA-PRESS
editing pulse centered at 1.9 parts per million (ppm) (“on” spectra) and
100 averages were acquired with the pulse centered at 7.46 ppm (“off”
spectra). Following this, a single-voxel short-echo PRESS sequence was
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performed in the same voxel location in order to measure concentration
of other metabolites, including creatine for the relative quantification of
thalamic GABA (repetition time5 2000 ms; echo time528 ms; 1024
data points).
2.4 | Data analysis
2.4.1 | Electroencephalography
Using SPM12 software (Wellcome Trust Centre for Neuroimaging, Uni-
versity College London), EEG data were referenced to the average ref-
erence montage; filtered 0.5–30 Hz; downsampled to 200 Hz; and
manually inspected for artefacts in 2-s epochs (Boord et al., 2008; Jen-
sen et al., 2013; Stern et al., 2006). Channels or trials of data were
removed if the underlying EEG signal contained artefacts such that the
underlying signal was not clear. Noise was found across multiple data-
sets at frequencies <4 Hz, and for this reason we discarded these data
for all subjects. The remaining EEG signal between 4 and 25 Hz was
then Fourier time–frequency transformed and power values at each
frequency were determined. These power values were logarithmically
transformed (log 10) to achieve normality. Power values at each fre-
quency were then plotted for the control and chronic pain groups and
significant differences in power between groups over the entire fre-
quency range, 4–25 Hz, and between groups within the theta (4–8 Hz),
alpha (9–12 Hz), and beta (13–25 Hz) ranges were determined (p< .05,
one-way ANOVA, one-tailed).
To explore the spatial distribution of these power differences, we
compared the logged power of the chronic pain subjects with that of
controls at each frequency across each EEG channel (two-sample t
tests). We plotted the t values at each frequency for each of the 27
EEG channels. We also calculated t values for power differences
between controls and chronic pain subjects in the theta, alpha, and beta
ranges for each EEG electrode, plotted these values onto a surface rep-
resentation of the head, and determined electrodes with significant
power differences (two-sample t tests). In addition to power differences
between control and chronic pain groups, we explored linear relation-
ships between power at each EEG electrode and an individual’s on-
going pain intensity (Pearson’s correlation coefficient) and pain duration
(Spearman’s rank correlation coefficient). The rho values of these rela-
tionships for each electrode were then plotted onto a surface represen-
tation of the head and any significant relationships determined (p< .05).
2.4.2 | Magnetic resonance spectroscopy
The acquired spectra were analysed with the Java-based magnetic res-
onance users’ interface version 3 (jMRUI 3.0, MRUI Consortium). First,
the dominant water peak was removed using the Hankel Lanczos Sin-
gular Values Decomposition Filter tool, then the “on” and “off” spectral
subsets were summed. The 68 ms “on” and “off” subspectra were then
subtracted, resulting in GABA-edited difference spectra to measure
GABA at the resonance of 3.01 ppm. GABA concentration was quanti-
fied using AMARES, an Advanced Method for Accurate, Robust and
Efficient Spectral fitting (Vanhamme, van den Boogaart, & Van Huffel,
1997). Peak fitting for GABA was performed after manually defining
the center frequency and line width of the GABA peak, and modelling
the GABA peak as a Gaussian singlet. GABA concentration was
expressed relative to creatine concentration (GABA:Cr) as per recent
technical guidelines (Mullins et al., 2014). After the same process for
removal of the dominant water peak as for the GABA concentration,
creatine concentration was quantified using QUEST, a time-domain
algorithm that fits a weighted metabolite basis set to the spectra
acquired (Ratiney et al., 2005). Creatine concentration was measured at
3.02 ppm. Significant differences between chronic pain and control
groups were then determined (p< .05, one-tailed two-sample t test).
For the chronic pain group, significant linear relationships between tha-
lamic GABA:Cr and pain intensity and duration were determined
(p< .05).
2.4.3 | Electroencephalography versus magnetic resonance
spectroscopy
To explore the relationship between thalamic GABA levels and EEG
power, we performed regression analyses of linear relationships
between total theta, alpha and beta power and an individual’s thalamic
GABA:Cr levels (p< .05). In addition, to explore regional relationships,
we performed regression analyses of linear relationships between
power at each of the 27 EEG electrodes and an individual’s thalamic
GABA:Cr levels. The rho values of these relationships for each elec-
trode were then plotted onto a surface representation of the head for
the control and chronic pain groups and any significant relationships
determined (p< .05).
3 | RESULTS
3.1 | Participants
The pain subjects’ mean (6 SEM) pain intensity over a week was 3.76
0.4 and their median duration of pain was 66 months (range 4–302
months). Chronic pain subjects reported on-going pain encompassing
the maxillary and mandibular distributions of the trigeminal nerve (Fig-
ure 1a). Fifteen of the chronic pain subjects reported left-sided pain,
and five reported right-sided pain. (Two subjects reported bilateral
pain; however, the pain was only mild on one side therefore the pre-
dominantly painful side was used here.) Chronic pain subjects most
often described their on-going pain as “shooting,” “throbbing,” or “nag-
ging.” Eighteen of the 20 participants in the patient group were taking
some medication for pain. See Table 1 for other patient characteristics
and Figure 1a for the distribution of patients’ pain.
3.2 | Cortical EEG power
Power spectra over the entire frequency range (4–25 Hz) for both groups
are depicted in Figure 1b. Chronic pain subjects displayed significantly
greater power than controls over the entire frequency range 4–25 Hz
(mean6 SEM log10[mv
2/Hz]: controls 22.4360.10, chronic pain
22.2060.085, p5 .04), in the theta (controls22.0360.12, chronic pain
21.7360.11, p5 .04) and alpha (controls 22.2060.12, chronic pain
21.8960.10, p5 .03) ranges, but the two groups were not significantly
different in the beta range (controls 22.6660.09, chronic pain 22.486
0.07, p5 .07). In addition, chronic pain subjects exhibited greater power
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FIGURE 1 Pain distribution and EEG power: (a) Individual pain distribution patterns in 20 chronic orofacial pain subjects. (b) Plots of mean
(6SEM) resting EEG power between 4 and 25 Hz in controls (black) and chronic orofacial pain (grey) subjects, over all 27 cortical EEG
electrodes. Note that overall power is greater in chronic pain subjects than in controls over most frequencies
TABLE 1 Pain subject characteristics. Pro re nata (as needed)
Subject Age Sex
Primary site of pain
(if bilateral worse
side is in bold)
Pain diary
(ave/10)
Pain
duration
(months) Medications in last 24 h
01 67 F Right side, upper jaw 4.2 240 Palmitoylethanolamide, Lyrica, Efexor, Oroxine,
Crestor, Ergotamine, Diphenhydramine
02 27 F Left side, upper jaw 6.9 29 Nurofen PRN
03 65 M Bilateral (left side lower
jaw worse than right
side upper jaw)
0.4 26 Endep
04 73 M Right side lower jaw 2.9 264 Monopril, Aspirin PRN, Norvasc, Crestor, Lithicarb
05 37 F Left lower jaw 3.4 96 Gabapentin, Endep
06 43 F Bilateral (right upper and
lower jaw worse than
left-upper only)
2.8 24 Mobic
07 66 F Left upper jaw 3.7 22 Lyrica
08 59 F Left lower jaw 7.1 115 Aspirin RPN
09 25 M Left side upper jaw 3.6 8 Palmitoylethanolamide, Panadeine PRN
10 71 F Left side upper jaw 5.1 8.5 Mobic, Panadol PRN, Gabapentin, Nortriptyline
11 36 M Left side upper jaw - 84 Oxycontin, Gabapentin, Panadol PRN
12 19 M Right side upper jaw 5 84 None
13 59 F Left side upper jaw 4.4 120 None
14 27 F Left side upper and lower jaw 2.7 8 Palmitoylethanolamide
15 57 F Left side upper jaw 2.4 6 Palmitoylethanolamide, Coversyl
16 69 F Left upper and lower jaw 4.8 108 Palmitoylethanolamide
17 64 M Right side upper and lower jaw 1.2 66 Gabapentin, Endep, Zyloprim
18 21 M Left side lower jaw 1.9 4 Palmitoylethanolamide
19 33 F Left side upper jaw 2.3 88 Palmitoylethanolamide, Dienogest
20 76 F Left side upper jaw 4.8 302 Palmitoylethanolamide, Panadol PRN,
Prestiq, Somac, Alprazolam
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at the dominant frequency (controls21.7160.14, chronic pain21.336
0.13, p5 .03). Although the mean dominant frequency was lower in
patients than controls, this result was not significant (patients 6.7560.58
Hz, controls 7.8060.94 Hz, p5 .18). In the chronic pain group there
were no significant linear relationships between pain intensity and theta
power (r5 .21, p5 .40), alpha power (r5 .25, p5 .31), or beta power
(r5 .14, p5 .56), or between pain duration and theta power (Spearman’s
rho52.05, p5 .85), alpha power (rho5 .33, p5 .15), or beta power
(rho5 .19, p5 .42). Although only two of the chronic pain subjects were
not taking any medications, they both had greater power than control
subjects in the theta (20.60, 20.86), alpha (21.18, 21.41), and beta
(21.91,22.02) ranges.
3.2.1 | Spatial distribution of EEG power differences
Consistent with the evidence of an overall increase in power, an explo-
ration of the difference in power between groups at each EEG elec-
trode at each frequency revealed significant power increases in chronic
pain subjects compared with controls over several brain regions (Figure
2a). Power increases were particularly evident at frequencies below
15 Hz and were strong between 8 and 10 Hz. These power increases
in chronic pain subjects occurred in areas of the medial prefrontal cor-
tex (EEG electrodes FP1 and FP2), and the dorsolateral prefrontal cor-
tex (F8), primary sensorimotor and temporal cortices (FC5 and T3) and
parietal association cortex (P3, PZ, P4, and CP6). Plots of power differ-
ences separately within the theta, alpha and beta ranges mapped onto
a surface representation of the head again showed that although
power differences occurred primarily in the alpha range, differences
also occurred in both the theta and beta ranges (Figure 2b). Within the
alpha range, significant power increases in chronic pain subjects
occurred in the frontal (FP2, F4, and F8), primary sensorimotor (FC5),
temporal (T3), and parietal (CP1, P3, PZ, and P4) cortices. A similar pat-
tern of differences between groups, although less widespread, also
occurred in the theta and beta ranges (theta: F7, F8, FC5, T3, T5; beta:
F8, FC5, T3, CP2, T5, P3, PZ, O2). Importantly, in theta, alpha and beta
ranges, at no EEG electrode was power significantly greater in controls
compared to chronic pain subjects.
While there were significant power differences between controls
and chronic pain subjects over multiple areas of the cerebral cortex, in
FIGURE 2 Spatial distribution of power differences: (a) Plots of t values representing power differences between controls and chronic pain
subjects at each of the 27 EEG channels, across the 4–25 Hz frequency range. Note that power is greater in chronic pain subjects than in
controls. To the right is an outline showing the approximate location of each of the 27 EEG electrodes. (b) Plotted on a surface
representation of the head, t values representing power differences between controls and chronic pain subjects separately within the theta,
alpha, and beta bands
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only a few regions was power significantly linearly correlated to either
pain intensity (Figure 3a) or duration (Figure 3b) in the chronic pain sub-
jects. In the theta range no region displayed a significant relationship
between power and pain intensity. In the alpha range, only at T4 (r5 .60,
p5 .007) was there a significant positive correlation. Within the beta
range, significant positive relationships occurred between power and pain
intensity in the sensorimotor (FC6: r5 .53, p5 .02), parietal (CP6: r5 .57,
p5 .01) (Figure 3c) and occipital (O1: r5 .57, p5 .01) cortices. With
respect to pain duration, there were no significant relationships between
theta or beta power at any EEG electrode and pain duration. However,
there were significant positive relationships between alpha power and
pain duration in the frontal (FP2: r5 .52, p5 .02) and parietal cortices
(CP5: r5 .50, p5 .02, P4: r5 .66, p5 .002) (Figure 3c).
3.3 | Thalamic GABA concentration
GABA-edited MEGA-PRESS spectroscopy was not acquired in two of
the chronic pain subjects (patients declined MRI), and we excluded a
further two chronic pain and two control subjects due to either outly-
ing GABA:Cr values or inadequate signal-to-noise for the spectra analy-
sis. This resulted in data from 15 chronic pain subjects and 18 controls.
In direct contrast to our previous work (Henderson et al., 2013), we
FIGURE 3 The relationship between EEG power and pain: (a) Plots of the relationship between pain intensity and EEG power in the theta,
alpha and beta bands at each of the 27 channels, on a surface representation of the head. (b) Plots of the relationship between pain
duration and EEG power in the theta, alpha, and beta bands at each of the 27 channels, on a surface representation of the head. (c) Plots of
the correlation between pain intensity and beta power in electrodes FC6 and CP6, and the correlation between pain duration and alpha
power in electrode CP5
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found no significant thalamic GABA difference between chronic pain
and control subjects (mean6 SEM GABA:Cr: chronic pain: 0.1860.01,
controls: 0.1760.01, p5 .27) (Figure 4a,b). Additionally, there was no
significant relationship between thalamic GABA and on-going pain inten-
sity (r5 .14, p5 .62) or pain duration (Spearman’s rho5 .05, p5 .85).
3.3.1 | Thalamic GABA concentration and its association
with power
Although there was no difference in thalamic GABA content between
control and chronic pain subjects, we found that the relationship between
thalamic GABA and cortical power was remarkably different between the
two groups (Figure 4c). In controls, there was no significant relationship
between thalamic GABA and overall theta power (r5 .1, p5 .70), alpha
power (r52.01, p5 .98), or beta power (r52.05, p5 .84). In contrast,
chronic pain subjects displayed significant positive relationships between
thalamic GABA and overall theta power (r5 .61, p5 .02), alpha power
(r5 .52, p5 .04), and beta power (r5 .68, p5 .006). Furthermore, the
relationships between thalamic GABA and overall theta and beta power
were significantly different between control and chronic pain groups
(all p< .05, two-tailed, Fisher r-to-z transformation).
FIGURE 4 Thalamic GABA concentration: (a) Axial MR-image representing the voxel placement in the thalamus contralateral to the side of on-
going chronic pain in the pain subjects, together with a diagram depicting the chemical shift axis. Note GABA concentration was measured at
3.01 parts per million (ppm). (b) Distribution of GABA:Cr ratios for chronic pain (grey circles) and control (black squares) subjects, demonstrating
the lack of difference between groups. Plots of the correlations between pain intensity and pain duration with thalamic GABA concentration,
demonstrating a lack of correlation with these measures. (c) Plots demonstrating the correlation between EEG power and thalamic GABA concen-
tration in both chronic pain and control subjects in each of the theta, alpha, and beta ranges. Note the moderate to strong correlations in all
bands in the pain subjects, while no such relationship exists in the control group. Glx, glutamate; NAA, N-Acetylaspartic acid
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3.3.2 | Spatial distribution of relationships between
thalamic GABA and power
In addition to the overall differences between groups in the relation-
ship between thalamic GABA and EEG power, there were striking dif-
ferences in the spatial distributions of the relationships. In control
subjects, at none of the EEG electrodes was there a significant relation-
ship between thalamic GABA and theta, alpha or beta power (Figure
5a). In contrast, in chronic pain subjects, multiple electrodes showed
positive correlations between thalamic GABA and theta, alpha, or beta
power (Figure 5b). Within the theta range, significant correlations
between power and thalamic GABA occurred in the frontal (FP1
r5 .66, FP2 r5 .59, F3, r5 .61, FZ r5 .61, F4 r5 .57, F8 r5 .62, FC1
r5 .57), sensorimotor (FC6 r5 .61, CZ r5 .55), temporal (T3 r5 .67),
parietal (CP1 r5 .78), and occipital cortices (O1 r5 .72)(all p<0.05;
Figure 5c). More restricted significant correlations occurred between
thalamic GABA and alpha power (F8 r5 .57, T3 r5 .60, CP5 r5 .55,
CP1 r5 .73, O1 r5 .54) and thalamic GABA and beta power (F7
r5 .62, F3 r5 .57, F8 r5 .58, T3 r5 .66, CZ r5 .66, CP5, r5 .78,
CP1 r5 .86, O1 r5 .76). At no EEG electrode was there a significant
negative relationship between thalamic GABA and power.
FIGURE 5 Spatial distribution of thalamic GABA versus power: (a) Plots of the relationship between thalamic GABA and EEG power in
control subjects, and (b) chronic pain subjects, mapped onto a surface representation of the head, in theta, alpha, and beta bands. Note the
lack of relationship in control subjects in all bands, and the relationship between GABA and power in pain subjects in all three frequency
bands. (c) Plots of the correlation between thalamic GABA and theta power in EEG electrodes CP1, FC6, and FP1; note the striking
difference in this relationship between groups
1952 | DI PIETRO ET AL.
143
4 | DISCUSSION
Consistent with our hypothesis, we found that chronic orofacial neuro-
pathic pain was associated with significantly increased cortical power,
particularly in theta and alpha frequency bands, compared to healthy
controls. Furthermore, the region encompassing the sensorimotor
cortex displayed a strong positive correlation between power and
on-going pain intensity. Although we found no significant difference in
thalamic GABA concentration between the two groups, which was in
contrast to our previous findings and our hypothesis, there was a strik-
ing difference in the relationship between thalamic GABA and cortical
power between pain subjects and controls. In the chronic pain group,
significant positive linear relationships occurred between thalamic
GABA and power, particularly in regions of the sensorimotor, frontal,
and parietal association cortices. That is, the greater the thalamic
GABA concentration, the greater the resting cortical power. In striking
contrast, we detected no significant relationships between thalamic
GABA and theta, alpha, or beta power in any region in the control
group.
Consistent with much of the literature, the thalamocortical dys-
rhythmia that occurred here in individuals with orofacial neuropathic
pain was characterized by a significant enhancement of activity in the
theta and alpha ranges and a significant increase in power at the domi-
nant spectral power peak. The enhanced power in pain subjects relative
to controls was most marked between 8 and 10 Hz. These changes
are consistent with many previous studies demonstrating thalamocorti-
cal dysrhythmia in chronic neuropathic pain (Sarnthein et al., 2006;
Schulman et al., 2005; Stern et al., 2006; Walton & Llinas, 2010). Some
studies demonstrated reduced or absent power in the alpha band (Jen-
sen et al., 2013; Llinas et al., 1999) and enhanced power in the beta
band in pain subjects (Stern et al., 2006), however these samples dif-
fered from ours and none comprised exclusively orofacial neuropathic
pain. That we found a distinct increase in power at 8 Hz is similar to
that found in neuropathic pain in the past (Sarnthein et al., 2006; Schul-
man et al., 2005). Interestingly though, in their neuropathic pain investi-
gation, Schulman et al. (2005) termed this 7–9 Hz range the “high theta
range.” There are indeed differences across the literature with regard
to the grouping of frequencies, and different definitions of frequency
bands would go some of the way to explaining some of the apparent,
slight discrepancies across the EEG literature.
The thalamus plays a key role in the generation and maintenance
of brain rhythms (Buzsaki, 2006; Hughes & Crunelli, 2005). It is thought
that increases in low-frequency cortical power are due to a shift in tha-
lamic neuron activity from a state dominated by tonic firing to one in
which there is an increase in low-threshold spike burst firing (Hughes &
Crunelli, 2005). This theory is supported by the finding that neuro-
pathic pain is associated with an increase in burst firing in the ventro-
caudal (Vc) thalamus and an associated increase in theta power (Lenz
et al., 1989). Low-threshold calcium bursts occur when thalamocortical
relay cells are in a state of hyperpolarisation; there is evidence that the
TRN is capable of entraining this ‘burst firing mode’ (Golshani, Liu, &
Jones, 2001), and it is argued that the TRN serves to maintain the low
frequency thalamocortical oscillations (4–10 Hz) (Buzsaki, 1991;
Jones, 2010). Given this, we were surprised we found no difference in
thalamic GABA concentration between pain subjects and control sub-
jects. Indeed, one would predict that neuropathic pain would be associ-
ated with increased TRN GABAergic output, which is contrary to the
results of our previous studies in which we found reduced thalamic
GABA content and reduced TRN blood flow in individuals with neuro-
pathic pain (Gustin et al., 2014; Henderson et al., 2013). Although we
found remarkable differences in the relationships between thalamic
GABA and cortical power between subject groups, and a relationship in
pain subjects suggestive of increased TRN GABAergic output, we can-
not draw the conclusion that the TRN is solely responsible for the
altered cortical rhythm. Indeed, we found no evidence of a difference
in GABA content between groups, which raises the possibility of other
mechanisms, for instance intracortical and corticothalamic projections,
which include influences on both thalamic relay and possibly TRN neu-
rons, and possibly affecting the hyperpolarization of thalamocortical
relay cells.
Why thalamic GABA was reduced in our previous study but not in
the present one is not known, though it is unlikely due to technical dif-
ferences since similar collection and analysis techniques were used. It is
possible that differences in thalamic GABA results from differences in
patient characteristics and while pain duration and intensity were simi-
lar across studies, medication regimens were not (Henderson et al.,
2013). In our previous investigation, 10 of the 23 pain subjects were
not taking any medication compared with only 2 of 20 in this investiga-
tion. Furthermore, in our previous study, those taking medication were
on relatively standard treatment regimens such as gabapentin and ami-
triptyline. In direct contrast, in this study, in addition to these standard
medications, 8 of the 20 pain subjects were taking palmitoylethanola-
mide (PEA), which has been reported to target the peroxisome
proliferator-activated receptor alpha as well as cannabinoid-like G-
coupled receptors (Godlewski, Offertaler, Wagner, & Kunos, 2009; Lo
Verme et al., 2005). While we do not have a sample large enough to
explore the effects of PEA on thalamic GABA and brain activity, there is
some evidence to suggest PEA may reduce neuropathic pain and thus
this could have affected the results of this study (Keppel Hesselink &
Kopsky, 2015). The effects of medications on thalamic GABA and rest-
ing brain activity require further detailed and directed investigations.
Although we found no reduction in thalamic GABA in this study,
our finding of significant positive relationships between thalamic GABA
and cortical power in individuals with neuropathic pain, but not con-
trols, is consistent with the idea that increased GABAergic inhibition of
specific thalamic nuclei such as Vc by the TRN results in increased tha-
lamocortical power. Furthermore, this is consistent with our previous
study in which we reported significant positive relationships between
thalamic GABA and resting Vc-S1 connectivity strength in neuropathic
pain subjects but not in controls (Henderson et al., 2013). The lack of
relationship between Vc-S1 connectivity strength and thalamic GABA
in controls is congruous with the lack of significant relationships
between thalamic GABA and power at any of the 27 electrode loca-
tions in controls in the current study. However, this was surprising
given the proposed role of the TRN and its GABAergic output in
setting cortical rhythms. This, together with the lack of difference in
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thalamic GABA content between groups found here, leads us to ques-
tion somewhat the importance of the role of the TRN in setting cortical
rhythms particularly in individuals with chronic neuropathic pain.
While there are variations in the spatial distribution, or topography,
of the enhanced EEG/MEG power in pain groups across the literature,
most studies report enhanced low frequency power in somatosensory
regions in patients relative to controls (Stern et al., 2006; Walton,
Dubois, & Llinas, 2010). Our findings demonstrate the presence of
more widespread activation in the patient group. Indeed, low-
frequency brain rhythms (<10 Hz) show long-range cortical coherence
and can span the entire cortex, whereas higher frequency oscillations
(>30 Hz) tend to be associated with more restricted cortical activity
(Contreras & Llinas, 2001). Furthermore, electrical stimulation immedi-
ately below the cortical surface at low frequencies activates a signifi-
cantly greater cortical area than that produced by higher frequency
stimulation, a difference thought to result from lateral inhibition (Llinas,
Urbano, Leznik, Ramírez, & van Marle, 2005). This is consistent with
our finding of increased low frequency power over a relatively large
region of the cerebral cortex in individuals with neuropathic pain. Inter-
estingly, however, only a restricted part of this power increase was cor-
related to on-going pain intensity, namely the sensorimotor and
parietal association cortices. While we did not extend our analyses
here to investigation of rhythms in the gamma band (>30 Hz), interest-
ing questions remain as to whether the patches of lower and higher
frequency cortical activity that we report on are evidence of the “edge
effect,” whereby GABAergic inhibition of lateral cortical areas is dimin-
ished in disease states (Llinas et al., 2005).
We have previously shown that orofacial neuropathic pain is asso-
ciated with increased infra-slow oscillations in the ascending pain path-
way, including in the spinal trigeminal nucleus, Vc, TRN, and S1, and
we have provided anatomical evidence that these changes may result
from chronic astrocyte activation and changes in oscillatory gliotrans-
mission (Alshelh et al., 2016). It is possible that following nerve injury,
altered Vc thalamus infra-slow oscillatory activity, in addition to altered
GABAergic influences of TRN outputs to the Vc thalamus, results in
increased low frequency (theta and alpha) thalamocortical rhythm in
Vc-S1 recurrent loops. Increased low frequency oscillations in this rela-
tively restricted thalamocortical network could then feasibly evoke
increased oscillatory changes over a relatively wide area of the cerebral
cortex, which in turn feeds back to the thalamus and so on, driving a
loop of altered activity. All that said however, in this study, we were
not able to demonstrate the altered GABAergic influence of the TRN—
and so, while feasible, this prospect is somewhat speculative. It is also
important to consider the alternative sources of thalamic GABAergic
inhibition. Extrathalamic inhibitory structures, such as the zona incerta
(Bartho, Freund, & Acsady, 2002), the anterior pretectal nucleus (Bokor
et al., 2005), the basal ganglia (Bodor, Giber, Rovo, Ulbert, & Acsady,
2008), and the pontine reticular formation (Giber et al., 2015) also tar-
get the thalamus. Furthermore the thalamus contains a proportion of
local GABAergic interneurons (Jones & Hendry, 1989; Smith, Seguela,
& Parent, 1987), although the TRN contains exclusively GABAergic
cells (Houser, Vaughn, Barber, & Roberts, 1980; Smith et al., 1987). It is
possible that mechanisms other than the circuit with the TRN could be
responsible for the findings we report on; however, we think it less
likely to be these sources than the TRN. As well as our previous finding
of decreased cerebral blood flow in the TRN in neuropathic pain (Hen-
derson et al., 2013), extrathalamic inhibitory nuclei do not exhibit
recurrent circuits with the thalamus (i.e., they have no thalamic inputs),
nor do they directly innervate the primary somatosensory thalamus
(Bartho et al., 2002; Bokor et al., 2005; Halassa & Acsady, 2016).
Several limitations influence the interpretation of the results. First,
while it is common for EEG and MEG studies to discount the spectral
data at and below 2 Hz (Llinas et al., 1999; Sarnthein et al., 2006), we
omitted spectral data below 4 Hz because of high noise levels, and
thus we may have excluded some interesting differences within the
delta range. Furthermore, we did not collect MRS and EEG data con-
currently, due to practical constraints and inherent technical difficulties.
Whilst it is possible that this may have altered the relationships
between thalamic GABA and cortical power, we collected MRS and
EEG data on the same day, directly after one another and at a similar
time of day for all participants. Last, because the voxel size in MRS is
large, it is possible we may have collected chemical spectra from other
thalamic nuclei as well as the TRN. However, we are confident we
acquired spectra in the TRN in all participants, and the GABAergic con-
tent of the TRN is indeed well documented.
The results of this study raise important questions about mecha-
nisms of altered resting brain rhythm in chronic neuropathic pain. Given
its GABAergic output, it follows that the TRN is an integral part of thala-
mocortical circuitry; however, we found no direct evidence of altered
thalamic GABA concentration in the pain state here, and the relationship
between GABA concentration and cortical rhythms is not fully under-
stood. While the thalamus has long been suggested to play a key role in
the maintenance of pain, this too has not been fully elucidated. That we
found evidence of an association between GABA concentration in the
TRN and thalamocortical rhythm in pain subjects, but no such associa-
tion in controls, is intriguing and offers a new avenue for investigation
into the mechanisms possibly underpinning chronic neuropathic pain.
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